Essec\Faculty\Model\Profile {#2216
#_id: "B00072308"
#_source: array:40 [
"bid" => "B00072308"
"academId" => "1987"
"slug" => "de-pouvourville-gerard"
"fullName" => "Gérard DE POUVOURVILLE"
"lastName" => "DE POUVOURVILLE"
"firstName" => "Gérard"
"title" => array:2 [
"fr" => "Professeur émérite"
"en" => "Emeritus Professor"
]
"email" => "gdepouvourville@free.fr"
"status" => "ACTIF"
"campus" => "Campus de Cergy"
"departments" => []
"phone" => "+33 (0)1 34 43 30 10"
"sites" => []
"facNumber" => "1987"
"externalCvUrl" => "https://faculty.essec.edu/en/cv/de-pouvourville-gerard/pdf"
"googleScholarUrl" => "https://scholar.google.com/citations?user=w_ysIu8AAAAJ"
"facOrcId" => "https://orcid.org/0000-0002-5941-6823"
"career" => array:24 [
0 => Essec\Faculty\Model\CareerItem {#2311
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2019-04-01"
"endDate" => null
"isInternalPosition" => true
"type" => array:2 [
"fr" => "Positions académiques principales"
"en" => "Full-time academic appointments"
]
"label" => array:2 [
"fr" => "Professeur émérite"
"en" => "Emeritus Professor"
]
"institution" => array:2 [
"fr" => "ESSEC Business School"
"en" => "ESSEC Business School"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
1 => Essec\Faculty\Model\CareerItem {#2312
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2006-01-01"
"endDate" => "2006-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Responsable d’équipe de recherche, CERMES, INSERM U750, CNRS UMR 8169"
"en" => "Research teams manager, CERMES, INSERM U750, CNRS UMR 8169"
]
"institution" => array:2 [
"fr" => "Institut national de la santé et de la recherche médicale (INSERM)"
"en" => "Institut national de la santé et de la recherche médicale (INSERM)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
2 => Essec\Faculty\Model\CareerItem {#2313
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2003-01-01"
"endDate" => "2006-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Responsable du programme de recherche « Epidémiologie, Santé Publique, Economie de la Santé et Sciences Humaines et Sociales », Direction de la Recherche"
"en" => "Head of the Research Program « Epidémiologie, Santé Publique, Economie de la Santé et Sciences Humaines et Sociales », at the Direction de la Recherche"
]
"institution" => array:2 [
"fr" => "Institut Gustave Roussy"
"en" => "Institut Gustave Roussy"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
3 => Essec\Faculty\Model\CareerItem {#2314
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2000-01-01"
"endDate" => "2005-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Directeur du Centre de Recherche en Economie et Gestion Appliquées à la Santé, INSERM U537, CNRS UMR 8052."
"en" => "Head of the Centre de Recherche en Economie et Gestion Appliquées à la Santé, INSERM U537, CNRS UMR 8052."
]
"institution" => array:2 [
"fr" => "Institut national de la santé et de la recherche médicale (INSERM)"
"en" => "Institut national de la santé et de la recherche médicale (INSERM)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
4 => Essec\Faculty\Model\CareerItem {#2315
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1993-01-01"
"endDate" => "2000-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Directeur scientifique du Groupe Information Médicale et Aide à la Gestion des Etablissements (IMAGE); mis à disposition par le CNRS."
"en" => "Scientific Director of Groupe Information Médicale et Aide à la Gestion des Etablissements (IMAGE); by the CNRS."
]
"institution" => array:2 [
"fr" => "École Nationale de la Santé Publique"
"en" => "École Nationale de la Santé Publique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
5 => Essec\Faculty\Model\CareerItem {#2316
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1989-01-01"
"endDate" => "1993-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Directeur de recherche, 2ème classe, Centre de Recherche en Gestion"
"en" => "Research Director, 2nd class, Centre de Recherche en Gestion"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
6 => Essec\Faculty\Model\CareerItem {#2317
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1989-01-01"
"endDate" => "1992-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Chercheur Associé, Groupe IMAGE"
"en" => "Research fellow, Groupe IMAGE"
]
"institution" => array:2 [
"fr" => "École Nationale de la Santé Publique"
"en" => "École Nationale de la Santé Publique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
7 => Essec\Faculty\Model\CareerItem {#2318
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1981-01-01"
"endDate" => "1989-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Chargé de recherche CNRS, Centre de Recherche en Gestion"
"en" => "Research fellow, CNRS, Centre de Recherche en Gestion"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
8 => Essec\Faculty\Model\CareerItem {#2319
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1984-01-01"
"endDate" => "1984-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Chercheur invité, Leonard Davis Institute for Health Economics"
"en" => "Guest Researcher, Leonard Davis Institute for Health Economics"
]
"institution" => array:2 [
"fr" => "Université de Pennsylvanie"
"en" => "Université de Pennsylvanie"
]
"country" => array:2 [
"fr" => "États-Unis"
"en" => "United States of America"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
9 => Essec\Faculty\Model\CareerItem {#2320
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1986-01-01"
"endDate" => "1986-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Chercheur invité au Groupe de Recherche Interdisciplinaires en Santé (GRIS). Expert invité auprès de la Commission d'Enquête sur les Services Sociaux et de Santé, Gouvernement du Québec."
"en" => "Invited Researcher at Groupe de Recherche Interdisciplinaires en Santé (GRIS). Expert invited at the Commission d'Enquête sur les Services Sociaux et de Santé, Gouvernement du Québec."
]
"institution" => array:2 [
"fr" => "Université de Montréal"
"en" => "Université de Montréal"
]
"country" => array:2 [
"fr" => "Canada"
"en" => "Canada"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
10 => Essec\Faculty\Model\CareerItem {#2321
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1978-01-01"
"endDate" => "1981-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Attaché de recherche, Centre de Recherche en Gestion"
"en" => "Researcher, Centre de Recherche en Gestion"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
11 => Essec\Faculty\Model\CareerItem {#2322
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1973-01-01"
"endDate" => "1978-08-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Doctorant, Centre de Recherche en Gestion"
"en" => "Doctorate, Centre de Recherche en Gestion"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
12 => Essec\Faculty\Model\CareerItem {#2323
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2000-01-01"
"endDate" => "2006-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other Academic Appointments"
"fr" => "Autres positions académiques"
]
"label" => array:2 [
"fr" => "Responsable de l'Option Recherche "Economie de la Santé", M2 de Santé Publique. Enseignements et encadrement de mémoire."
"en" => "Track Head, "Economie de la Santé", Master 2 Santé Publique. Teaching and Dissertation mentoring"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
13 => Essec\Faculty\Model\CareerItem {#2324
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2000-01-01"
"endDate" => "2006-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other Academic Appointments"
"fr" => "Autres positions académiques"
]
"label" => array:2 [
"fr" => "Responsable des enseignements d’économie et de gestion, Master de Santé Publique, M1"
"en" => "Supervisor of Economics and Management courses, Master Santé Publique, M1"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
14 => Essec\Faculty\Model\CareerItem {#2325
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2004-01-01"
"endDate" => "2006-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other Academic Appointments"
"fr" => "Autres positions académiques"
]
"label" => array:2 [
"fr" => "Chargé de cours, Module « Préparation à la vie professionnelle », DCEM2, Faculté de Médecine de Bicêtre"
"en" => "Lecturer, Module « Préparation à la vie professionnelle », DCEM2, Faculté de Médecine de Bicêtre"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
15 => Essec\Faculty\Model\CareerItem {#2326
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2000-01-01"
"endDate" => "2006-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other Academic Appointments"
"fr" => "Autres positions académiques"
]
"label" => array:2 [
"fr" => "Chargé de cours, en collaboration avec Monique Kerleau, "Approche économique et théorie des organisations appliquées au système de soins", DESS Economie et Gestion des systèmes de santé"
"en" => "Lecturer, with Monique Kerleau, "Approche économique et théorie des organisations appliquées au système de soins", DESS Economie et Gestion des systèmes de santé"
]
"institution" => array:2 [
"fr" => "Université Paris 1 Panthéon-Sorbonne"
"en" => "Université Paris 1 Panthéon-Sorbonne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
16 => Essec\Faculty\Model\CareerItem {#2327
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1994-01-01"
"endDate" => "1999-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other Academic Appointments"
"fr" => "Autres positions académiques"
]
"label" => array:2 [
"fr" => "Chargé de cours, Faculté de Médecine Saint-Louis-Lariboisière; enseignant au DEA "Système de soins hospitaliers et Société" (Directeur: Dominique Bertrand). Séminaire "Evaluation des coûts à l'hôpital", séminaire (en collaboration avec Alain Fontaine) "Préparation du mémoire de DEA"."
"en" => "Lecturer, Faculté de Médecine Saint-Louis-Lariboisière; teacher for the DEA "Système de soins hospitaliers et Société" (Director: Dominique Bertrand). Seminar "Evaluation des coûts à l'hôpital", seminar (with Alain Fontaine) "Préparation du mémoire de DEA"."
]
"institution" => array:2 [
"fr" => "Université Paris Cité"
"en" => "Université Paris Cité"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
17 => Essec\Faculty\Model\CareerItem {#2328
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1986-01-01"
"endDate" => "1993-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other Academic Appointments"
"fr" => "Autres positions académiques"
]
"label" => array:2 [
"fr" => "Chargé de cours; DEA 103 "Méthodes Scientifiques de Gestion" (Professeur Bernard Roy)"
"en" => "Lecturer; DEA 103 "Méthodes Scientifiques de Gestion" (Professor Bernard Roy)"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
18 => Essec\Faculty\Model\CareerItem {#2329
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1998-01-01"
"endDate" => "2001-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other Academic Appointments"
"fr" => "Autres positions académiques"
]
"label" => array:2 [
"fr" => "Professeur associé, Université de Lausanne"
"en" => "Associate Professor, Université de Lausanne"
]
"institution" => array:2 [
"fr" => "HEC Lausanne"
"en" => "HEC Lausanne"
]
"country" => array:2 [
"fr" => "Suisse"
"en" => "Switzerland"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
19 => Essec\Faculty\Model\CareerItem {#2330
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1979-01-01"
"endDate" => "1980-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other Academic Appointments"
"fr" => "Autres positions académiques"
]
"label" => array:2 [
"fr" => "Maître de Conférence à temps partiel, Institut Auguste Comte pour l'Etude des Sciences de l'Action."
"en" => "Part-time lecturer, Institut Auguste Comte pour l'Etude des Sciences de l'Action."
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
20 => Essec\Faculty\Model\CareerItem {#2331
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1976-01-01"
"endDate" => "1977-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other Academic Appointments"
"fr" => "Autres positions académiques"
]
"label" => array:2 [
"fr" => "Chargé de cours en économie"
"en" => "Economics classes lecturer"
]
"institution" => array:2 [
"fr" => "École Nationale du Génie Rural et des Eaux et Forêts (ENGREF)"
"en" => "École Nationale du Génie Rural et des Eaux et Forêts (ENGREF)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
21 => Essec\Faculty\Model\CareerItem {#2332
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "1973-01-01"
"endDate" => "1977-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other Academic Appointments"
"fr" => "Autres positions académiques"
]
"label" => array:2 [
"fr" => "Chargé de cours en économie. Responsable de l'organisation des stages de fins d'études en économie et gestion."
"en" => "Economics class lecturer. In charge of the organization of final internships in Economics and Management."
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
22 => Essec\Faculty\Model\CareerItem {#2333
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2000-01-01"
"endDate" => "2006-12-31"
"isInternalPosition" => true
"type" => array:2 [
"en" => "Other appointments"
"fr" => "Autres positions"
]
"label" => array:2 [
"fr" => "Directeur des Etudes Médico-Economiques, poste à mi-temps."
"en" => "Head of the Etudes Médico-Economiques, part-time role"
]
"institution" => array:2 [
"fr" => "Institut Gustave Roussy"
"en" => "Institut Gustave Roussy"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
23 => Essec\Faculty\Model\CareerItem {#2334
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2007-01-01"
"endDate" => "2019-03-31"
"isInternalPosition" => true
"type" => array:2 [
"fr" => "Positions académiques principales"
"en" => "Full-time academic appointments"
]
"label" => array:2 [
"fr" => "Professeur"
"en" => "Professor"
]
"institution" => array:2 [
"fr" => "ESSEC Business School"
"en" => "ESSEC Business School"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
]
"diplomes" => array:3 [
0 => Essec\Faculty\Model\Diplome {#2218
#_index: null
#_id: null
#_source: array:6 [
"diplome" => "DIPLOMA"
"type" => array:2 [
"fr" => "Diplômes"
"en" => "Diplomas"
]
"year" => "1978"
"label" => array:2 [
"en" => "Doctorate in Economics and Business Administration"
"fr" => "Doctorat en Economie et Administration des entreprises"
]
"institution" => array:2 [
"fr" => "Université d'Aix-Marseille"
"en" => "Université d'Aix-Marseille"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
1 => Essec\Faculty\Model\Diplome {#2220
#_index: null
#_id: null
#_source: array:6 [
"diplome" => "DIPLOMA"
"type" => array:2 [
"fr" => "Diplômes"
"en" => "Diplomas"
]
"year" => "1974"
"label" => array:2 [
"en" => "Diplôme d'Etudes Supérieures in Economics"
"fr" => "Diplôme d'Etudes Supérieures en Sciences Economiques"
]
"institution" => array:2 [
"fr" => "Université Paris 1 Panthéon-Sorbonne"
"en" => "Université Paris 1 Panthéon-Sorbonne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
2 => Essec\Faculty\Model\Diplome {#2217
#_index: null
#_id: null
#_source: array:6 [
"diplome" => "DIPLOMA"
"type" => array:2 [
"fr" => "Diplômes"
"en" => "Diplomas"
]
"year" => "1970"
"label" => array:2 [
"en" => "Graduate"
"fr" => "Diplômé"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
]
"bio" => array:2 [
"fr" => null
"en" => null
]
"department" => array:2 [
"fr" => "Economie"
"en" => "Economics"
]
"site" => array:2 [
"fr" => ""
"en" => ""
]
"industrrySectors" => array:2 [
"fr" => null
"en" => null
]
"researchFields" => array:2 [
"fr" => "management hospitalier - politiques de santé - Economie de la santé"
"en" => "hospital management - health policy - Health Economics"
]
"teachingFields" => array:2 [
"fr" => "Marketing et analyses des données - Santé et médecine - Management"
"en" => "Marketing and Data Analytics - Health and Medicine - Management"
]
"distinctions" => []
"teaching" => array:56 [
0 => Essec\Faculty\Model\TeachingItem {#2306
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => null
"program" => null
"label" => array:2 [
"fr" => "Entre ordre et désordre: la fabrique des réseaux régionaux de cancérologie (1990-2010)"
"en" => "Entre ordre et désordre: la fabrique des réseaux régionaux de cancérologie (1990-2010)"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "EHESS - École des hautes études en sciences sociales"
"en" => "EHESS - École des hautes études en sciences sociales"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
1 => Essec\Faculty\Model\TeachingItem {#2285
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2020"
"program" => null
"label" => array:2 [
"fr" => "Les facteurs d'incertitude dans les évaluations économiques des vaccins en France"
"en" => "Les facteurs d'incertitude dans les évaluations économiques des vaccins en France"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
2 => Essec\Faculty\Model\TeachingItem {#2300
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2019"
"program" => null
"label" => array:2 [
"fr" => "Aspects juridiques et économiques de l'accès au marché des médicaments innovants"
"en" => "Aspects juridiques et économiques de l'accès au marché des médicaments innovants"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris Descartes (Paris V)"
"en" => "Université Paris Descartes (Paris V)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
3 => Essec\Faculty\Model\TeachingItem {#2255
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2007"
"endDate" => "2019"
"program" => "Grande Ecole - Master in Management"
"label" => array:2 [
"fr" => "Systèmes de santé- Markerting des produits de santé"
"en" => "Health care Systems- Health product mrketing"
]
"type" => array:2 [
"fr" => "Economie"
"en" => "Economics"
]
"institution" => array:2 [
"fr" => "ESSEC Business School"
"en" => "ESSEC Business School"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
4 => Essec\Faculty\Model\TeachingItem {#2298
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2018"
"program" => null
"label" => array:2 [
"fr" => "Méthodologie et apport des évaluations économiques dans l'évaluation et la diffusion des innovations thérapeutiques à l'hôpital"
"en" => "Méthodologie et apport des évaluations économiques dans l'évaluation et la diffusion des innovations thérapeutiques à l'hôpital"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
5 => Essec\Faculty\Model\TeachingItem {#2258
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2014"
"endDate" => "2018"
"program" => null
"label" => array:2 [
"fr" => "Msc in Management of Health Industries"
"en" => "Msc in Management of Health Industries"
]
"type" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"institution" => array:2 [
"fr" => "ESSEC Business School"
"en" => "ESSEC Business School"
]
"country" => array:2 [
"fr" => "Singapour"
"en" => "Singapore"
]
]
+lang: "en"
}
6 => Essec\Faculty\Model\TeachingItem {#2299
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2017"
"program" => null
"label" => array:2 [
"fr" => "L'évaluation économique des soins hopitaliers en cancérologie: de la décision de remboursement à la régulation de l'offre de soins"
"en" => "L'évaluation économique des soins hopitaliers en cancérologie: de la décision de remboursement à la régulation de l'offre de soins"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
7 => Essec\Faculty\Model\TeachingItem {#2257
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2013"
"endDate" => "2017"
"program" => "Management Général"
"label" => array:2 [
"fr" => "Management général hospitalier"
"en" => "Hospital Management program"
]
"type" => array:2 [
"fr" => "Autre discipline"
"en" => "Other Discipline"
]
"institution" => array:2 [
"fr" => "ESSEC Business School"
"en" => "ESSEC Business School"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
8 => Essec\Faculty\Model\TeachingItem {#2296
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2016"
"program" => null
"label" => array:2 [
"fr" => "Des modalités de fixation aux déterminants du prix des médicaments innovants: le cas des anticancéreux dans les pays de l'OCDE"
"en" => "Des modalités de fixation aux déterminants du prix des médicaments innovants: le cas des anticancéreux dans les pays de l'OCDE"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
9 => Essec\Faculty\Model\TeachingItem {#2292
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2016"
"program" => null
"label" => array:2 [
"fr" => "The role of information in decisionmaking: an application to seasonal influenza vaccination policy"
"en" => "The role of information in decisionmaking: an application to seasonal influenza vaccination policy"
]
"type" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Lyon 2"
"en" => "Université Lyon 2"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
10 => Essec\Faculty\Model\TeachingItem {#2290
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2016"
"program" => null
"label" => array:2 [
"fr" => "Hospitalisations des patients en Bourgogne et dans neuf autres régions métropolitaines: analyse territoriale des flux interrégionaux à partir de la base national PMSI MCO"
"en" => "Hospitalisations des patients en Bourgogne et dans neuf autres régions métropolitaines: analyse territoriale des flux interrégionaux à partir de la base national PMSI MCO"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université de Bourgogne"
"en" => "Université de Bourgogne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
11 => Essec\Faculty\Model\TeachingItem {#2289
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2016"
"program" => null
"label" => array:2 [
"fr" => "Evaluation des technologies en santé: organisation institutionnelle et stratégies des firmes pharmaceutiques"
"en" => "Evaluation des technologies en santé: organisation institutionnelle et stratégies des firmes pharmaceutiques"
]
"type" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
12 => Essec\Faculty\Model\TeachingItem {#2288
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2016"
"program" => null
"label" => array:2 [
"fr" => "Réguler le marché de ville du médicament: trois essais de microéconomie appliquée"
"en" => "Réguler le marché de ville du médicament: trois essais de microéconomie appliquée"
]
"type" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Paris Est Créteil"
"en" => "Université Paris Est Créteil"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
13 => Essec\Faculty\Model\TeachingItem {#2287
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2016"
"program" => null
"label" => array:2 [
"fr" => "De l'éducation sanitaire à la promotion de la santé: Enjeux et organisation des savoirs au coeur de l'action publique sanitaire internationale"
"en" => "De l'éducation sanitaire à la promotion de la santé: Enjeux et organisation des savoirs au coeur de l'action publique sanitaire internationale"
]
"type" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
14 => Essec\Faculty\Model\TeachingItem {#2301
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2015"
"program" => null
"label" => array:2 [
"fr" => "Troubles mictionnels chez l'homme et incontinence urinaire. Influence des paramètres génétiques sur le vieillissement vésico-prostatique"
"en" => "Troubles mictionnels chez l'homme et incontinence urinaire. Influence des paramètres génétiques sur le vieillissement vésico-prostatique"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Pierre et Marie Curie (UPMC)"
"en" => "Université Pierre et Marie Curie (UPMC)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
15 => Essec\Faculty\Model\TeachingItem {#2294
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2015"
"program" => null
"label" => array:2 [
"fr" => "Vers un cadre d'analyse intégré de la performance des systèmes de santé"
"en" => "Vers un cadre d'analyse intégré de la performance des systèmes de santé"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris 1 Panthéon-Sorbonne"
"en" => "Université Paris 1 Panthéon-Sorbonne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
16 => Essec\Faculty\Model\TeachingItem {#2256
#_index: null
#_id: null
#_source: array:7 [
"startDate" => "2012"
"endDate" => "2015"
"program" => null
"label" => array:2 [
"fr" => "HealthTechnology assessmentin Asia Pacific"
"en" => "Heattl Technology assessmentin Asia Pacific"
]
"type" => array:2 [
"fr" => "Economie"
"en" => "Economics"
]
"institution" => array:2 [
"fr" => "ESSEC Business School"
"en" => "ESSEC Business School"
]
"country" => array:2 [
"fr" => "Singapour"
"en" => "Singapore"
]
]
+lang: "en"
}
17 => Essec\Faculty\Model\TeachingItem {#2302
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2014"
"program" => null
"label" => array:2 [
"fr" => "Médicaments biosimilaires: quels enjeux économiques et politiques?"
"en" => "Médicaments biosimilaires: quels enjeux économiques et politiques?"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
18 => Essec\Faculty\Model\TeachingItem {#2303
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2013"
"program" => null
"label" => array:2 [
"fr" => "Prix, concurrence et régulation: soutien à l'innovation et prix des médicaments à l'hôpital"
"en" => "Prix, concurrence et régulation: soutien à l'innovation et prix des médicaments à l'hôpital"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
19 => Essec\Faculty\Model\TeachingItem {#2291
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2012"
"program" => null
"label" => array:2 [
"fr" => "Analyse de la qualité de l'offre de soins de médecine générale du point de vue des patients"
"en" => "Analyse de la qualité de l'offre de soins de médecine générale du point de vue des patients"
]
"type" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
20 => Essec\Faculty\Model\TeachingItem {#2310
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2012"
"program" => null
"label" => array:2 [
"fr" => "Autorité et performance dans les réseaux: l'exemple de la production de soins dans les centres de référence maladies rares"
"en" => "Autorité et performance dans les réseaux: l'exemple de la production de soins dans les centres de référence maladies rares"
]
"type" => array:2 [
"fr" => "Président de jury"
"en" => "Thesis jury president"
]
"institution" => array:2 [
"fr" => "Université Paris 1 Panthéon-Sorbonne"
"en" => "Université Paris 1 Panthéon-Sorbonne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
21 => Essec\Faculty\Model\TeachingItem {#2304
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2011"
"program" => null
"label" => array:2 [
"fr" => "L'économie de la médecine libérale"
"en" => "L'économie de la médecine libérale"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
22 => Essec\Faculty\Model\TeachingItem {#2293
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2010"
"program" => null
"label" => array:2 [
"fr" => "Essais sur l'offre de travail en médecine générale: du rôle des incitations et des motivations"
"en" => "Essais sur l'offre de travail en médecine générale: du rôle des incitations et des motivations"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université d'Aix-Marseille"
"en" => "Université d'Aix-Marseille"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
23 => Essec\Faculty\Model\TeachingItem {#2305
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2010"
"program" => null
"label" => array:2 [
"fr" => "Efficacité de la norme dans la régulation économique des pratiques médicales"
"en" => "Efficacité de la norme dans la régulation économique des pratiques médicales"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
24 => Essec\Faculty\Model\TeachingItem {#2269
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2010"
"program" => null
"label" => array:2 [
"fr" => "Mesure des utilités attachés aux états de santé"
"en" => "Mesure des utilités attachés aux états de santé"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
25 => Essec\Faculty\Model\TeachingItem {#2271
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2009"
"program" => null
"label" => array:2 [
"fr" => "Adhésion aux traitements de l'ostéoporose: impact sur le risque fracturaire"
"en" => "Adhésion aux traitements de l'ostéoporose: impact sur le risque fracturaire"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
26 => Essec\Faculty\Model\TeachingItem {#2276
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2009"
"program" => null
"label" => array:2 [
"fr" => "Déterminants socio-géographiques de la prise en charge et de la survie des patients atteints d'un cancer digestif en France"
"en" => "Déterminants socio-géographiques de la prise en charge et de la survie des patients atteints d'un cancer digestif en France"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
27 => Essec\Faculty\Model\TeachingItem {#2297
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2008"
"program" => null
"label" => array:2 [
"fr" => "De la régulation des systèmes de santé à l'évaluation des résultats"
"en" => "De la régulation des systèmes de santé à l'évaluation des résultats"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université d'Aix-Marseille"
"en" => "Université d'Aix-Marseille"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
28 => Essec\Faculty\Model\TeachingItem {#2295
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2008"
"program" => null
"label" => array:2 [
"fr" => "Le décideur public face à la société en microéconomie de la santé"
"en" => "Le décideur public face à la société en microéconomie de la santé"
]
"type" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Pierre et Marie Curie (UPMC)"
"en" => "Université Pierre et Marie Curie (UPMC)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
29 => Essec\Faculty\Model\TeachingItem {#2270
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2008"
"program" => null
"label" => array:2 [
"fr" => "Optimisation de la prise en charge globale des patients atteints d'un cancer différencié de la thyroïde"
"en" => "Optimisation de la prise en charge globale des patients atteints d'un cancer différencié de la thyroïde"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
30 => Essec\Faculty\Model\TeachingItem {#2278
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2007"
"program" => null
"label" => array:2 [
"fr" => "La prise en charge du grand âge en perte d'autonomie en France et en Europe."
"en" => "La prise en charge du grand âge en perte d'autonomie en France et en Europe."
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
31 => Essec\Faculty\Model\TeachingItem {#2268
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2007"
"program" => null
"label" => array:2 [
"fr" => "La production de recherche dans les établissements publics de santé: impact sur les coûts"
"en" => "La production de recherche dans les établissements publics de santé: impact sur les coûts"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
32 => Essec\Faculty\Model\TeachingItem {#2273
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2007"
"program" => null
"label" => array:2 [
"fr" => "Santé Périnatale et territoire urbain:analyse géographique des inégalités sociales de santé en Seine-Saint-Denis"
"en" => "Santé Périnatale et territoire urbain:analyse géographique des inégalités sociales de santé en Seine-Saint-Denis"
]
"type" => array:2 [
"fr" => "Co-directeur de thèse"
"en" => "Thesis co-director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
33 => Essec\Faculty\Model\TeachingItem {#2272
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2007"
"program" => null
"label" => array:2 [
"fr" => "La gestion des réseaux de distribution: le cas de l'assurance dommage en France"
"en" => "La gestion des réseaux de distribution: le cas de l'assurance dommage en France"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
34 => Essec\Faculty\Model\TeachingItem {#2277
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2007"
"program" => null
"label" => array:2 [
"fr" => "Les équipes hospitalières de soins palliatifs dans le processus de rationalisation des soins."
"en" => "Les équipes hospitalières de soins palliatifs dans le processus de rationalisation des soins."
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
35 => Essec\Faculty\Model\TeachingItem {#2308
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2004"
"program" => null
"label" => array:2 [
"fr" => "Approches économiques de l'organisation du dépistage du cancer colorectal en France"
"en" => "Approches économiques de l'organisation du dépistage du cancer colorectal en France"
]
"type" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université de Caen Normandie"
"en" => "Université de Caen Normandie"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
36 => Essec\Faculty\Model\TeachingItem {#2265
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2003"
"program" => null
"label" => array:2 [
"fr" => "La formation du prix des médicaments en Europe"
"en" => "La formation du prix des médicaments en Europe"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris 1 Panthéon-Sorbonne"
"en" => "Université Paris 1 Panthéon-Sorbonne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
37 => Essec\Faculty\Model\TeachingItem {#2266
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2003"
"program" => null
"label" => array:2 [
"fr" => "Processus de choix de projets dans l'industrie pharmaceutique"
"en" => "Processus de choix de projets dans l'industrie pharmaceutique"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
38 => Essec\Faculty\Model\TeachingItem {#2279
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2003"
"program" => null
"label" => array:2 [
"fr" => "Elaboration d'un modèle prévisionnel médicalisé pour renforcer le contrôle de gestion dans les hôpitaux des Armées"
"en" => "Elaboration d'un modèle prévisionnel médicalisé pour renforcer le contrôle de gestion dans les hôpitaux des Armées"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris Diderot (Paris VII)"
"en" => "Université Paris Diderot (Paris VII)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
39 => Essec\Faculty\Model\TeachingItem {#2280
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2003"
"program" => null
"label" => array:2 [
"fr" => "Mécanismes incitatifs et changements dans les systèmes de santé. Application à l'amélioration de la qualité et à l'évaluation"
"en" => "Mécanismes incitatifs et changements dans les systèmes de santé. Application à l'amélioration de la qualité et à l'évaluation"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris Diderot (Paris VII)"
"en" => "Université Paris Diderot (Paris VII)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
40 => Essec\Faculty\Model\TeachingItem {#2274
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2002"
"program" => null
"label" => array:2 [
"fr" => "Eléments pour la mesure de la performance d'un réseau de soins"
"en" => "Eléments pour la mesure de la performance d'un réseau de soins"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris Diderot (Paris VII)"
"en" => "Université Paris Diderot (Paris VII)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
41 => Essec\Faculty\Model\TeachingItem {#2275
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "2001"
"program" => null
"label" => array:2 [
"fr" => "Le coût de la recherche dans les hôpitaux universitaires"
"en" => "Le coût de la recherche dans les hôpitaux universitaires"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris Diderot (Paris VII)"
"en" => "Université Paris Diderot (Paris VII)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
42 => Essec\Faculty\Model\TeachingItem {#2267
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1999"
"program" => null
"label" => array:2 [
"fr" => "L'hôpital et son projet d'établissement"
"en" => "L'hôpital et son projet d'établissement"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
43 => Essec\Faculty\Model\TeachingItem {#2281
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1999"
"program" => null
"label" => array:2 [
"fr" => "Régulation des soins par la qualité: un modèle pour la périnatalité"
"en" => "Régulation des soins par la qualité: un modèle pour la périnatalité"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris Diderot (Paris VII)"
"en" => "Université Paris Diderot (Paris VII)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
44 => Essec\Faculty\Model\TeachingItem {#2264
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1999"
"program" => null
"label" => array:2 [
"fr" => "Maladie d'Alzheimer et évaluation économique"
"en" => "Maladie d'Alzheimer et évaluation économique"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
45 => Essec\Faculty\Model\TeachingItem {#2307
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1998"
"program" => null
"label" => array:2 [
"fr" => "Soigner ou prendre de soins des toxicomanes: anatomie d'une croyance collective. Analyse historique du champ de la toxicomanie en France de 1970 à 1995 ou l'histoire de la domination d'un paradigme."
"en" => "Soigner ou prendre de soins des toxicomanes: anatomie d'une croyance collective. Analyse historique du champ de la toxicomanie en France de 1970 à 1995 ou l'histoire de la domination d'un paradigme."
]
"type" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Institut d'Etudes Politiques"
"en" => "Institut d'Etudes Politiques"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
46 => Essec\Faculty\Model\TeachingItem {#2282
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1998"
"program" => null
"label" => array:2 [
"fr" => "L'informatique comme instrument du changement organisationnel"
"en" => "L'informatique comme instrument du changement organisationnel"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
47 => Essec\Faculty\Model\TeachingItem {#2286
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1997"
"program" => null
"label" => array:2 [
"fr" => "Elaboration d'un outil d'évaluation de la performance hospitalière: implications pour une politique d'allocation des ressources en santé"
"en" => "Elaboration d'un outil d'évaluation de la performance hospitalière: implications pour une politique d'allocation des ressources en santé"
]
"type" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Toulouse III Paul Sabatier"
"en" => "Université Toulouse III Paul Sabatier"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
48 => Essec\Faculty\Model\TeachingItem {#2309
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1997"
"program" => null
"label" => array:2 [
"fr" => "Qualité de vie et évaluation économique: des fondements théoriques à la mise en pratique"
"en" => "Qualité de vie et évaluation économique: des fondements théoriques à la mise en pratique"
]
"type" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université de Bourgogne"
"en" => "Université de Bourgogne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
49 => Essec\Faculty\Model\TeachingItem {#2263
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1996"
"program" => null
"label" => array:2 [
"fr" => "Gérer la singularité à grande échelle"
"en" => "Gérer la singularité à grande échelle"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
50 => Essec\Faculty\Model\TeachingItem {#2283
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1995"
"program" => null
"label" => array:2 [
"fr" => "Deux composantes essentielles de l'évaluation des soins à l'hôpital : continuité et accessibilité. Le cas de l'urgence pédiatrique à l'hôpital Robert Debré à Paris"
"en" => "Deux composantes essentielles de l'évaluation des soins à l'hôpital : continuité et accessibilité. Le cas de l'urgence pédiatrique à l'hôpital Robert Debré à Paris"
]
"type" => array:2 [
"fr" => "Co-directeur de thèse"
"en" => "Thesis co-director"
]
"institution" => array:2 [
"fr" => "IUT Sceaux - Université Paris Sud"
"en" => "IUT Sceaux - Université Paris Sud"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
51 => Essec\Faculty\Model\TeachingItem {#2262
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1994"
"program" => null
"label" => array:2 [
"fr" => "Formation des trajectoires d'offre de soins"
"en" => "Formation des trajectoires d'offre de soins"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
52 => Essec\Faculty\Model\TeachingItem {#2284
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1994"
"program" => null
"label" => array:2 [
"fr" => "Analyse de la diffusion de la cholecystectomie en France"
"en" => "Analyse de la diffusion de la cholecystectomie en France"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université d'Aix-Marseille"
"en" => "Université d'Aix-Marseille"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
53 => Essec\Faculty\Model\TeachingItem {#2260
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1992"
"program" => null
"label" => array:2 [
"fr" => "Construction d'usages et transformation des pratiques autour d'instruments de gestion agricole informatisés"
"en" => "Construction d'usages et transformation des pratiques autour d'instruments de gestion agricole informatisés"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
54 => Essec\Faculty\Model\TeachingItem {#2259
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1992"
"program" => null
"label" => array:2 [
"fr" => "Servir et gérer dans le domaine socio-sanitaire: comment les professionnels de la prise en charge apprennent-ils à rendre des comptes?"
"en" => "Servir et gérer dans le domaine socio-sanitaire: comment les professionnels de la prise en charge apprennent-ils à rendre des comptes?"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
55 => Essec\Faculty\Model\TeachingItem {#2261
#_index: null
#_id: null
#_source: array:7 [
"startDate" => null
"endDate" => "1988"
"program" => null
"label" => array:2 [
"fr" => "Introduction et diffusion d'une innovation médicale en France: le processus décisionnel"
"en" => "Introduction et diffusion d'une innovation médicale en France: le processus décisionnel"
]
"type" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
}
]
"otherActivities" => array:36 [
0 => Essec\Faculty\Model\ExtraActivity {#2221
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "2000-01-01"
"endDate" => "2005-05-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Président du Collège des Economistes de la Santé, membre du Conseil d’Administration ; à ce titre, responsable scientifique de l’organisation de 2 colloques nationaux et de deux colloques internationaux ; promoteur de la base documentaire « Connaissance et Décision en Economie de la Santé », créateur du réseau européen (16 pays) de bases de données documentaires en économie de la santé « EURONHEED » ; co-responsable de la rédaction des « Recommandations pour l’évaluation économique des stratégies de santé »."
"en" => "President of the Collège des Economistes de la Santé, member of the Conseil d’Administration , hence scientific supervisor of the organization of two international symposia ; promoter of the basis of the documentary « Connaissance et Décision en Economie de la Santé », creator of the European network (16 countries) of documentary databases in Health Economics "EURONHEED" ; co-supervisor of the writing of « Recommandations pour l’évaluation économique des stratégies de santé »."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
1 => Essec\Faculty\Model\ExtraActivity {#2215
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1950-01-18"
"endDate" => null
"year" => null
"uuid" => "204"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Membre d'une association académique"
"en" => "Member of an academic association"
]
"label" => array:2 [
"fr" => "Membre de l'International Health Economics Association (IHEA)"
"en" => "Member of the International Health Economics Association (IHEA)"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
2 => Essec\Faculty\Model\ExtraActivity {#2219
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1950-01-18"
"endDate" => null
"year" => null
"uuid" => "203"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Rôle d’expert ou évaluateur dans une organisation de recherche"
"en" => "Role as an expert or appraisor in a research organization"
]
"label" => array:2 [
"fr" => "Membre du Conseil Scientifique de la Mission Innovation, Recherche et Expérimentation (MIRE), DREES, Ministère de la Santé"
"en" => "Member of the Scientific Council of Mission Innovation, Recherche et Expérimentation (MIRE), DREES, Ministère de la Santé"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
3 => Essec\Faculty\Model\ExtraActivity {#2222
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1995-01-01"
"endDate" => null
"year" => null
"uuid" => "203"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Rôle d’expert ou évaluateur dans une organisation de recherche"
"en" => "Role as an expert or appraisor in a research organization"
]
"label" => array:2 [
"fr" => "Membre du Conseil Scientifique de l’Institut de Recherche et de Documentation en Economie de la Santé (IRDES), Caisse Nationale d'Assurance Maladie"
"en" => "Member of the Scientific Council of l’Institut de Recherche et de Documentation en Economie de la Santé (IRDES), Caisse Nationale d'Assurance Maladie"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
4 => Essec\Faculty\Model\ExtraActivity {#2223
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1950-01-18"
"endDate" => null
"year" => null
"uuid" => "203"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Rôle d’expert ou évaluateur dans une organisation de recherche"
"en" => "Role as an expert or appraisor in a research organization"
]
"label" => array:2 [
"fr" => "Membre du Comité de Pilotage des opérations de recherche de la Haute Autorité de Santé"
"en" => "Member of the Steering Committee on research operations of Haute Autorité de Santé"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
5 => Essec\Faculty\Model\ExtraActivity {#2224
#_index: null
#_id: null
#_source: array:9 [
"startDate" => null
"endDate" => null
"year" => null
"uuid" => "104"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Reviewer pour un journal"
"en" => "Reviewer for a journal"
]
"label" => array:2 [
"fr" => "Relecteur pour European Journal of Health Economics; Gérer et Comprendre; Health Economics; International Journal of Technology Assessment in Health Care; Pharmacoeconomics; Politiques et Management Public; Revue Française de Gestion; Social Science and Medicine"
"en" => "Reviewer for European Journal of Health Economics; Gérer et Comprendre; Health Economics; International Journal of Technology Assessment in Health Care; Pharmacoeconomics; Politiques et Management Public; Revue Française de Gestion; Social Science and Medicine"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
6 => Essec\Faculty\Model\ExtraActivity {#2225
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1950-01-18"
"endDate" => null
"year" => null
"uuid" => "501"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Membre d'une association professionnelle, d'un groupe d'experts ou d'un conseil d'administration"
"en" => "Member of a professional association, of an expert group or of a board of directors"
]
"label" => array:2 [
"fr" => "Membre de la Commission des Comptes de la Santé"
"en" => "Member of theCommission des Comptes de la Santé"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
7 => Essec\Faculty\Model\ExtraActivity {#2226
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1950-01-18"
"endDate" => null
"year" => null
"uuid" => "502"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Consulting"
"en" => "Consulting"
]
"label" => array:2 [
"fr" => "Missionné par le Ministre de la Santé et le Ministre Délégué à la Recherche sur le développement de la recherche en médecine générale en France."
"en" => "For the Ministre de la Santé and the Ministre Délégué à la Recherche, about the development of general medicine research in France."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
8 => Essec\Faculty\Model\ExtraActivity {#2227
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1950-01-18"
"endDate" => null
"year" => null
"uuid" => "501"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Membre d'une association professionnelle, d'un groupe d'experts ou d'un conseil d'administration"
"en" => "Member of a professional association, of an expert group or of a board of directors"
]
"label" => array:2 [
"fr" => "Expert scientifique auprès de la Mission Tarification à l’Activité, Ministère de la Santé- Participation au groupe de travail sur le financement des Missions d’Intérêt Général et d’Aide à la Contractualisation"
"en" => "Scientific expert for the Mission Tarification à l’Activité, Ministère de la Santé- Participation in the working group on the topic : Financement des Missions d’Intérêt Général et d’Aide à la Contractualisation"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
9 => Essec\Faculty\Model\ExtraActivity {#2228
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1950-01-18"
"endDate" => null
"year" => null
"uuid" => "502"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Consulting"
"en" => "Consulting"
]
"label" => array:2 [
"fr" => "Consultant, Centre Hospitalier Régional Universitaire de Lille, évaluation des Missions d’Intérêt Général et d’Aide à la Contractualisation, dans le cadre de la Tarification à l’Activité."
"en" => "Consultant, Centre Hospitalier Régional Universitaire de Lille, evaluation of the Missions d’Intérêt Général et d’Aide à la Contractualisation, as part of the Tarification à l’Activité."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
10 => Essec\Faculty\Model\ExtraActivity {#2229
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1950-01-18"
"endDate" => null
"year" => null
"uuid" => "501"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Membre d'une association professionnelle, d'un groupe d'experts ou d'un conseil d'administration"
"en" => "Member of a professional association, of an expert group or of a board of directors"
]
"label" => array:2 [
"fr" => "Expert invité, Ministère de la Santé et du Bien-être, Province d’Alberta, Canada."
"en" => "Invited Expert, Ministère de la Santé et du Bien-être, Province d’Alberta, Canada."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => "Canada"
"en" => "Canada"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
11 => Essec\Faculty\Model\ExtraActivity {#2230
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1950-01-18"
"endDate" => null
"year" => null
"uuid" => "501"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Membre d'une association professionnelle, d'un groupe d'experts ou d'un conseil d'administration"
"en" => "Member of a professional association, of an expert group or of a board of directors"
]
"label" => array:2 [
"fr" => "Membre du Global Health Outcome Board, Groupe Glaxo-Smith-Kline"
"en" => "Member of the Global Health Outcome Board, Groupe Glaxo-Smith-Kline"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
12 => Essec\Faculty\Model\ExtraActivity {#2231
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1950-01-18"
"endDate" => null
"year" => null
"uuid" => "502"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Consulting"
"en" => "Consulting"
]
"label" => array:2 [
"fr" => "Consultant auprès des laboratoires: MSD, Sanofi-Aventis, Astra-Zeneca, Pfizer, Servier, Procter& Gamble, BMS, Bayer SA."
"en" => "Consultant for the laboratories: MSD, Sanofi-Aventis, Astra-Zeneca, Pfizer, Servier, Procter& Gamble, BMS, Bayer SA."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
13 => Essec\Faculty\Model\ExtraActivity {#2232
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1982-01-01"
"endDate" => "1996-12-31"
"year" => null
"uuid" => "502"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Consulting"
"en" => "Consulting"
]
"label" => array:2 [
"fr" => "Consultant auprès de la Direction des Hôpitaux, Ministère de la Santé; conception des systèmes d’information médicale à l’hôpital ; en charge de l'élaboration d'une méthode de budgétisation fondée sur l'activité médicale des établissements ; participation à l’élaboration de l’Etude Nationale des Coûts."
"en" => "Consultant for the Direction des Hôpitaux, Ministère de la Santé; conception of medical information systems for hospitals, in charge of the development of a budgetization method based on the medical activity of the establishments ; participation in the writing of Etude Nationale des Coûts."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
14 => Essec\Faculty\Model\ExtraActivity {#2233
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1989-01-01"
"endDate" => "1998-12-31"
"year" => null
"uuid" => "201"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Organisation d'une conférence ou d'un séminaire"
"en" => "Organization of a conference or a seminar"
]
"label" => array:2 [
"fr" => "Organisation et co-organisation de 8 colloques et séminaires de recherche, dont 3 en tant que membre du comité scientifique de mini-colloques INSERM"
"en" => "Organization and co-organization of 8 symposia and research seminars, 3 of them as a member of the scientific committee of "mini-symposia" INSERM"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
15 => Essec\Faculty\Model\ExtraActivity {#2234
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1992-01-01"
"endDate" => null
"year" => null
"uuid" => "501"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Membre d'une association professionnelle, d'un groupe d'experts ou d'un conseil d'administration"
"en" => "Member of a professional association, of an expert group or of a board of directors"
]
"label" => array:2 [
"fr" => "Membre du Groupe de Prospective Santé 2010, Commissariat Général au Plan ; rédacteur du scénario de régionalisation de la régulation du système de soins (Rapport Santé 2010, sous la direction de Raymond Soubie). ; à ce titre, rédacteur de la synthèse présentant un projet de création d’Agences Régionales de Santé."
"en" => "Member of the Groupe de Prospective Santé 2010, Commissariat Général au Plan ; writer of the health system regulation regionalization scenario (Rapport Santé 2010, under the supervision of Raymond Soubie) ; to this end writer of a synthesis presenting a creation project of Health Regional Agencies."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
16 => Essec\Faculty\Model\ExtraActivity {#2235
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1983-01-01"
"endDate" => "1984-12-31"
"year" => null
"uuid" => "502"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Consulting"
"en" => "Consulting"
]
"label" => array:2 [
"fr" => "Consultant auprès de la Direction Générale de la Santé, Ministère de la Santé; expertise auprès de la Commission Nationale d'Anesthésiologie, sur la régulation de la démographie de la spécialité."
"en" => "Consultant for Direction Générale de la Santé, Ministère de la Santé; expert for the Commission Nationale d'Anesthésiologie about specialty demography regulation."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
17 => Essec\Faculty\Model\ExtraActivity {#2236
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1974-01-01"
"endDate" => "1974-12-31"
"year" => null
"uuid" => "502"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Consulting"
"en" => "Consulting"
]
"label" => array:2 [
"fr" => "Consultant pour l'OCDE, sur le projet "Politiques pour l'innovation dans le secteur des services"."
"en" => "Consultant for OECD, on the project "Politiques pour l'innovation dans le secteur des services"."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
18 => Essec\Faculty\Model\ExtraActivity {#2237
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "2001-01-01"
"endDate" => "2006-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Membre du Comité Directeur de l'IFR "Epidémiologie, Santé Publique, Sciences Sociales""
"en" => "Member of the Comité Directeur of IFR "Epidémiologie, Santé Publique, Sciences Sociales""
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
19 => Essec\Faculty\Model\ExtraActivity {#2238
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "2000-01-01"
"endDate" => "2006-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Coordinateur du Comité d'Interface INSERM/Médecine Générale"
"en" => "Coordinator of the Comité d'Interface INSERM/Médecine Générale"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
20 => Essec\Faculty\Model\ExtraActivity {#2239
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "2000-01-01"
"endDate" => "2006-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Membre du Comité Scientifique Sciences Humaines et Sociales, Institut National du Cancer."
"en" => "Member of the Comité Scientifique Sciences Humaines et Sociales, Institut National du Cancer."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
21 => Essec\Faculty\Model\ExtraActivity {#2240
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "2002-01-01"
"endDate" => "2005-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Membre nommé du Conseil d’Administration de l’INSERM"
"en" => "Designated member of the board of directors of INSERM"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
22 => Essec\Faculty\Model\ExtraActivity {#2241
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1995-01-01"
"endDate" => "2000-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Membre élu du Comité National, section 37 « Economie et Société »"
"en" => "Elected member of the Comité National, section 37 « Economie et Société »"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
23 => Essec\Faculty\Model\ExtraActivity {#2242
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1990-01-01"
"endDate" => "1995-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Membre nommé du Conseil Scientifique de l'INSERM"
"en" => "Designated member of the Scientific Council of INSERM"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
24 => Essec\Faculty\Model\ExtraActivity {#2243
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1995-01-01"
"endDate" => "1999-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Membre du Conseil Scientifique de l'Ecole Nationale de la Santé Publique"
"en" => "Member of the Scientific Council of Ecole Nationale de la Santé Publique"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
25 => Essec\Faculty\Model\ExtraActivity {#2244
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1998-01-01"
"endDate" => "1998-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Membre de la mission d'évaluation scientifique de l'Agence Nationale de Recherche sur le SIDA, Ministère de la Recherche et de la Technologie."
"en" => "Member of the scientific evaluation mission of Agence Nationale de Recherche sur le SIDA, Ministère de la Recherche et de la Technologie."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
26 => Essec\Faculty\Model\ExtraActivity {#2245
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1998-01-01"
"endDate" => "2000-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Membre du Conseil Scientifique de l'Institut Paoli Calmettes"
"en" => "Member of the Scientific Council of Institut Paoli Calmettes"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
27 => Essec\Faculty\Model\ExtraActivity {#2246
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1995-01-01"
"endDate" => "1998-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Membre du Conseil Scientifique de l'Institut d'Etude des Politiques de Santé, Paris V."
"en" => "Member of the Scientific Council of Institut d'Etude des Politiques de Santé, Paris V."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
28 => Essec\Faculty\Model\ExtraActivity {#2247
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1996-01-01"
"endDate" => "1998-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Responsable scientifique du programme de coopération scientifique France-Québec " Economie de la Santé "."
"en" => "Scientific supervisor of the France-Québec scientific cooperation program" Economie de la Santé "."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
29 => Essec\Faculty\Model\ExtraActivity {#2248
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1997-01-01"
"endDate" => "2000-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Membre du Conseil Scientifique de l'Institut Universitaire de Santé Publique de l'Ile de France"
"en" => "Member of the Scientific Council of Institut Universitaire de Santé Publique of Ile de France"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
30 => Essec\Faculty\Model\ExtraActivity {#2249
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "1992-01-01"
"endDate" => "1994-12-31"
"year" => null
"uuid" => "202"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Fonction dans une association académique"
"en" => "Function in an academic association"
]
"label" => array:2 [
"fr" => "Président du Comité Scientifique de l'appel d'offres "Evaluation Economique des Stratégies Préventives et Thérapeutiques", Ministère de la Recherche"
"en" => "Scientific Committee President of the invitation to tender "Evaluation Economique des Stratégies Préventives et Thérapeutiques", Ministère de la Recherche"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
31 => Essec\Faculty\Model\ExtraActivity {#2250
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "2004-01-01"
"endDate" => "2004-12-31"
"year" => null
"uuid" => "501"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Membre d'une association professionnelle, d'un groupe d'experts ou d'un conseil d'administration"
"en" => "Member of a professional association, of an expert group or of a board of directors"
]
"label" => array:2 [
"fr" => "Membre du Comité d’Experts, Tarification à l’Activité, Ministère de la Santé"
"en" => "Member of the Comité d’Experts, Tarification à l’Activité, Ministère de la Santé"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
32 => Essec\Faculty\Model\ExtraActivity {#2251
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "2004-01-01"
"endDate" => "2004-12-31"
"year" => null
"uuid" => "502"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Consulting"
"en" => "Consulting"
]
"label" => array:2 [
"fr" => "Consultant auprès du Centre Hospitalier de Lagny-Marne-la-Vallée: mise en place de la contractualisation interne"
"en" => "Consultant for Centre Hospitalier de Lagny-Marne-la-Vallée: implementation of intern contractualization"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
33 => Essec\Faculty\Model\ExtraActivity {#2252
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "2003-01-01"
"endDate" => "2003-12-31"
"year" => null
"uuid" => "502"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Consulting"
"en" => "Consulting"
]
"label" => array:2 [
"fr" => "Expert auprès de la Commission Royale pour la réforme du système de santé canadien (Commission Romanow)"
"en" => "Expert for the Royal Commission for the reform of the Canadian Health System (Romanow Commission)"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
34 => Essec\Faculty\Model\ExtraActivity {#2253
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "2001-01-01"
"endDate" => "2003-12-31"
"year" => null
"uuid" => "502"
"type" => array:2 [
"fr" => "Activités professionnelles"
"en" => "Professional activities"
]
"subType" => array:2 [
"fr" => "Consulting"
"en" => "Consulting"
]
"label" => array:2 [
"fr" => "Vice-Président du Comité d'Orientation, Observatoire des Prescriptions et de la Consommation des Médicaments, Ministère de la Solidarité Nationale, de l'Emploi et de la Santé."
"en" => "Vice-President of the Comité d'Orientation, Observatoire des Prescriptions et de la Consommation des Médicaments, Ministère de la Solidarité Nationale, de l'Emploi et de la Santé."
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
35 => Essec\Faculty\Model\ExtraActivity {#2254
#_index: null
#_id: null
#_source: array:9 [
"startDate" => "2016-01-01"
"endDate" => "2018-03-01"
"year" => "2016"
"uuid" => "103"
"type" => array:2 [
"fr" => "Activités de recherche"
"en" => "Research activities"
]
"subType" => array:2 [
"fr" => "Membre d'un comité de lecture"
"en" => "Editorial Board Membership"
]
"label" => array:2 [
"fr" => "Membre du comité de lecture - Gérer et Comprendre"
"en" => "Editorial board membership - Gérer et Comprendre"
]
"institution" => array:2 [
"fr" => null
"en" => null
]
"country" => array:2 [
"fr" => null
"en" => null
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
]
"theses" => array:52 [
0 => Essec\Faculty\Model\These {#2335
#_index: null
#_id: null
#_source: array:9 [
"year" => "1992"
"startDate" => null
"endDate" => "1992"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Servir et gérer dans le domaine socio-sanitaire: comment les professionnels de la prise en charge apprennent-ils à rendre des comptes?"
"en" => "Servir et gérer dans le domaine socio-sanitaire: comment les professionnels de la prise en charge apprennent-ils à rendre des comptes?"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
1 => Essec\Faculty\Model\These {#2336
#_index: null
#_id: null
#_source: array:9 [
"year" => "1992"
"startDate" => null
"endDate" => "1992"
"student" => ""
"firstJob" => "INRA"
"label" => array:2 [
"fr" => "Construction d'usages et transformation des pratiques autour d'instruments de gestion agricole informatisés"
"en" => "Construction d'usages et transformation des pratiques autour d'instruments de gestion agricole informatisés"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
2 => Essec\Faculty\Model\These {#2337
#_index: null
#_id: null
#_source: array:9 [
"year" => "1988"
"startDate" => null
"endDate" => "1988"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Introduction et diffusion d'une innovation médicale en France: le processus décisionnel"
"en" => "Introduction et diffusion d'une innovation médicale en France: le processus décisionnel"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
3 => Essec\Faculty\Model\These {#2338
#_index: null
#_id: null
#_source: array:9 [
"year" => "1994"
"startDate" => null
"endDate" => "1994"
"student" => ""
"firstJob" => "Université de Grenoble"
"label" => array:2 [
"fr" => "Formation des trajectoires d'offre de soins"
"en" => "Formation des trajectoires d'offre de soins"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
4 => Essec\Faculty\Model\These {#2339
#_index: null
#_id: null
#_source: array:9 [
"year" => "1996"
"startDate" => null
"endDate" => "1996"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Gérer la singularité à grande échelle"
"en" => "Gérer la singularité à grande échelle"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
5 => Essec\Faculty\Model\These {#2340
#_index: null
#_id: null
#_source: array:9 [
"year" => "1999"
"startDate" => null
"endDate" => "1999"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Maladie d'Alzheimer et évaluation économique"
"en" => "Maladie d'Alzheimer et évaluation économique"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
6 => Essec\Faculty\Model\These {#2341
#_index: null
#_id: null
#_source: array:9 [
"year" => "2003"
"startDate" => null
"endDate" => "2003"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "La formation du prix des médicaments en Europe"
"en" => "La formation du prix des médicaments en Europe"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris 1 Panthéon-Sorbonne"
"en" => "Université Paris 1 Panthéon-Sorbonne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
7 => Essec\Faculty\Model\These {#2342
#_index: null
#_id: null
#_source: array:9 [
"year" => "2003"
"startDate" => null
"endDate" => "2003"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Processus de choix de projets dans l'industrie pharmaceutique"
"en" => "Processus de choix de projets dans l'industrie pharmaceutique"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
8 => Essec\Faculty\Model\These {#2343
#_index: null
#_id: null
#_source: array:9 [
"year" => "1999"
"startDate" => null
"endDate" => "1999"
"student" => ""
"firstJob" => "Conseil en entreprise"
"label" => array:2 [
"fr" => "L'hôpital et son projet d'établissement"
"en" => "L'hôpital et son projet d'établissement"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
9 => Essec\Faculty\Model\These {#2344
#_index: null
#_id: null
#_source: array:9 [
"year" => "2007"
"startDate" => null
"endDate" => "2007"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "La production de recherche dans les établissements publics de santé: impact sur les coûts"
"en" => "La production de recherche dans les établissements publics de santé: impact sur les coûts"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
10 => Essec\Faculty\Model\These {#2345
#_index: null
#_id: null
#_source: array:9 [
"year" => "2009"
"startDate" => null
"endDate" => "2009"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Adhésion aux traitements de l'ostéoporose: impact sur le risque fracturaire"
"en" => "Adhésion aux traitements de l'ostéoporose: impact sur le risque fracturaire"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
11 => Essec\Faculty\Model\These {#2346
#_index: null
#_id: null
#_source: array:9 [
"year" => "2007"
"startDate" => null
"endDate" => "2007"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "La gestion des réseaux de distribution: le cas de l'assurance dommage en France"
"en" => "La gestion des réseaux de distribution: le cas de l'assurance dommage en France"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
12 => Essec\Faculty\Model\These {#2347
#_index: null
#_id: null
#_source: array:9 [
"year" => "2007"
"startDate" => null
"endDate" => "2007"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Santé Périnatale et territoire urbain:analyse géographique des inégalités sociales de santé en Seine-Saint-Denis"
"en" => "Santé Périnatale et territoire urbain:analyse géographique des inégalités sociales de santé en Seine-Saint-Denis"
]
"role" => array:2 [
"fr" => "Co-directeur de thèse"
"en" => "Thesis co-director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
13 => Essec\Faculty\Model\These {#2348
#_index: null
#_id: null
#_source: array:9 [
"year" => "2002"
"startDate" => null
"endDate" => "2002"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Eléments pour la mesure de la performance d'un réseau de soins"
"en" => "Eléments pour la mesure de la performance d'un réseau de soins"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris Diderot (Paris VII)"
"en" => "Université Paris Diderot (Paris VII)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
14 => Essec\Faculty\Model\These {#2349
#_index: null
#_id: null
#_source: array:9 [
"year" => "2001"
"startDate" => null
"endDate" => "2001"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Le coût de la recherche dans les hôpitaux universitaires"
"en" => "Le coût de la recherche dans les hôpitaux universitaires"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris Diderot (Paris VII)"
"en" => "Université Paris Diderot (Paris VII)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
15 => Essec\Faculty\Model\These {#2350
#_index: null
#_id: null
#_source: array:9 [
"year" => "2007"
"startDate" => null
"endDate" => "2007"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Les équipes hospitalières de soins palliatifs dans le processus de rationalisation des soins."
"en" => "Les équipes hospitalières de soins palliatifs dans le processus de rationalisation des soins."
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
16 => Essec\Faculty\Model\These {#2351
#_index: null
#_id: null
#_source: array:9 [
"year" => "2007"
"startDate" => null
"endDate" => "2007"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "La prise en charge du grand âge en perte d'autonomie en France et en Europe."
"en" => "La prise en charge du grand âge en perte d'autonomie en France et en Europe."
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
17 => Essec\Faculty\Model\These {#2352
#_index: null
#_id: null
#_source: array:9 [
"year" => "2003"
"startDate" => null
"endDate" => "2003"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Elaboration d'un modèle prévisionnel médicalisé pour renforcer le contrôle de gestion dans les hôpitaux des Armées"
"en" => "Elaboration d'un modèle prévisionnel médicalisé pour renforcer le contrôle de gestion dans les hôpitaux des Armées"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris Diderot (Paris VII)"
"en" => "Université Paris Diderot (Paris VII)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
18 => Essec\Faculty\Model\These {#2353
#_index: null
#_id: null
#_source: array:9 [
"year" => "2003"
"startDate" => null
"endDate" => "2003"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Mécanismes incitatifs et changements dans les systèmes de santé. Application à l'amélioration de la qualité et à l'évaluation"
"en" => "Mécanismes incitatifs et changements dans les systèmes de santé. Application à l'amélioration de la qualité et à l'évaluation"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris Diderot (Paris VII)"
"en" => "Université Paris Diderot (Paris VII)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
19 => Essec\Faculty\Model\These {#2354
#_index: null
#_id: null
#_source: array:9 [
"year" => "1999"
"startDate" => null
"endDate" => "1999"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Régulation des soins par la qualité: un modèle pour la périnatalité"
"en" => "Régulation des soins par la qualité: un modèle pour la périnatalité"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris Diderot (Paris VII)"
"en" => "Université Paris Diderot (Paris VII)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
20 => Essec\Faculty\Model\These {#2355
#_index: null
#_id: null
#_source: array:9 [
"year" => "1998"
"startDate" => null
"endDate" => "1998"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "L'informatique comme instrument du changement organisationnel"
"en" => "L'informatique comme instrument du changement organisationnel"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "École Polytechnique"
"en" => "École Polytechnique"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
21 => Essec\Faculty\Model\These {#2356
#_index: null
#_id: null
#_source: array:9 [
"year" => "1995"
"startDate" => null
"endDate" => "1995"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Deux composantes essentielles de l'évaluation des soins à l'hôpital : continuité et accessibilité. Le cas de l'urgence pédiatrique à l'hôpital Robert Debré à Paris"
"en" => "Deux composantes essentielles de l'évaluation des soins à l'hôpital : continuité et accessibilité. Le cas de l'urgence pédiatrique à l'hôpital Robert Debré à Paris"
]
"role" => array:2 [
"fr" => "Co-directeur de thèse"
"en" => "Thesis co-director"
]
"institution" => array:2 [
"fr" => "IUT Sceaux - Université Paris Sud"
"en" => "IUT Sceaux - Université Paris Sud"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
22 => Essec\Faculty\Model\These {#2357
#_index: null
#_id: null
#_source: array:9 [
"year" => "1994"
"startDate" => null
"endDate" => "1994"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Analyse de la diffusion de la cholecystectomie en France"
"en" => "Analyse de la diffusion de la cholecystectomie en France"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université d'Aix-Marseille"
"en" => "Université d'Aix-Marseille"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
23 => Essec\Faculty\Model\These {#2358
#_index: null
#_id: null
#_source: array:9 [
"year" => "2020"
"startDate" => null
"endDate" => "2020"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Les facteurs d'incertitude dans les évaluations économiques des vaccins en France"
"en" => "Les facteurs d'incertitude dans les évaluations économiques des vaccins en France"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
24 => Essec\Faculty\Model\These {#2359
#_index: null
#_id: null
#_source: array:9 [
"year" => "1997"
"startDate" => null
"endDate" => "1997"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Elaboration d'un outil d'évaluation de la performance hospitalière: implications pour une politique d'allocation des ressources en santé"
"en" => "Elaboration d'un outil d'évaluation de la performance hospitalière: implications pour une politique d'allocation des ressources en santé"
]
"role" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Toulouse III Paul Sabatier"
"en" => "Université Toulouse III Paul Sabatier"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
25 => Essec\Faculty\Model\These {#2360
#_index: null
#_id: null
#_source: array:9 [
"year" => "2016"
"startDate" => null
"endDate" => "2016"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "De l'éducation sanitaire à la promotion de la santé: Enjeux et organisation des savoirs au coeur de l'action publique sanitaire internationale"
"en" => "De l'éducation sanitaire à la promotion de la santé: Enjeux et organisation des savoirs au coeur de l'action publique sanitaire internationale"
]
"role" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
26 => Essec\Faculty\Model\These {#2361
#_index: null
#_id: null
#_source: array:9 [
"year" => "2016"
"startDate" => null
"endDate" => "2016"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Réguler le marché de ville du médicament: trois essais de microéconomie appliquée"
"en" => "Réguler le marché de ville du médicament: trois essais de microéconomie appliquée"
]
"role" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Paris Est Créteil"
"en" => "Université Paris Est Créteil"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
27 => Essec\Faculty\Model\These {#2362
#_index: null
#_id: null
#_source: array:9 [
"year" => "2016"
"startDate" => null
"endDate" => "2016"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Evaluation des technologies en santé: organisation institutionnelle et stratégies des firmes pharmaceutiques"
"en" => "Evaluation des technologies en santé: organisation institutionnelle et stratégies des firmes pharmaceutiques"
]
"role" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
28 => Essec\Faculty\Model\These {#2363
#_index: null
#_id: null
#_source: array:9 [
"year" => "2016"
"startDate" => null
"endDate" => "2016"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Hospitalisations des patients en Bourgogne et dans neuf autres régions métropolitaines: analyse territoriale des flux interrégionaux à partir de la base national PMSI MCO"
"en" => "Hospitalisations des patients en Bourgogne et dans neuf autres régions métropolitaines: analyse territoriale des flux interrégionaux à partir de la base national PMSI MCO"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université de Bourgogne"
"en" => "Université de Bourgogne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
29 => Essec\Faculty\Model\These {#2364
#_index: null
#_id: null
#_source: array:9 [
"year" => "2012"
"startDate" => null
"endDate" => "2012"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Analyse de la qualité de l'offre de soins de médecine générale du point de vue des patients"
"en" => "Analyse de la qualité de l'offre de soins de médecine générale du point de vue des patients"
]
"role" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
30 => Essec\Faculty\Model\These {#2365
#_index: null
#_id: null
#_source: array:9 [
"year" => "2016"
"startDate" => null
"endDate" => "2016"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "The role of information in decisionmaking: an application to seasonal influenza vaccination policy"
"en" => "The role of information in decisionmaking: an application to seasonal influenza vaccination policy"
]
"role" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université Lyon 2"
"en" => "Université Lyon 2"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
31 => Essec\Faculty\Model\These {#2366
#_index: null
#_id: null
#_source: array:9 [
"year" => "2010"
"startDate" => null
"endDate" => "2010"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Essais sur l'offre de travail en médecine générale: du rôle des incitations et des motivations"
"en" => "Essais sur l'offre de travail en médecine générale: du rôle des incitations et des motivations"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université d'Aix-Marseille"
"en" => "Université d'Aix-Marseille"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
32 => Essec\Faculty\Model\These {#2367
#_index: null
#_id: null
#_source: array:9 [
"year" => "2015"
"startDate" => null
"endDate" => "2015"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Vers un cadre d'analyse intégré de la performance des systèmes de santé"
"en" => "Vers un cadre d'analyse intégré de la performance des systèmes de santé"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris 1 Panthéon-Sorbonne"
"en" => "Université Paris 1 Panthéon-Sorbonne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
33 => Essec\Faculty\Model\These {#2368
#_index: null
#_id: null
#_source: array:9 [
"year" => "2008"
"startDate" => null
"endDate" => "2008"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Le décideur public face à la société en microéconomie de la santé"
"en" => "Le décideur public face à la société en microéconomie de la santé"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Pierre et Marie Curie (UPMC)"
"en" => "Université Pierre et Marie Curie (UPMC)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
34 => Essec\Faculty\Model\These {#2369
#_index: null
#_id: null
#_source: array:9 [
"year" => "2016"
"startDate" => null
"endDate" => "2016"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Des modalités de fixation aux déterminants du prix des médicaments innovants: le cas des anticancéreux dans les pays de l'OCDE"
"en" => "Des modalités de fixation aux déterminants du prix des médicaments innovants: le cas des anticancéreux dans les pays de l'OCDE"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
35 => Essec\Faculty\Model\These {#2370
#_index: null
#_id: null
#_source: array:9 [
"year" => "2008"
"startDate" => null
"endDate" => "2008"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "De la régulation des systèmes de santé à l'évaluation des résultats"
"en" => "De la régulation des systèmes de santé à l'évaluation des résultats"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université d'Aix-Marseille"
"en" => "Université d'Aix-Marseille"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
36 => Essec\Faculty\Model\These {#2371
#_index: null
#_id: null
#_source: array:9 [
"year" => "2018"
"startDate" => null
"endDate" => "2018"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Méthodologie et apport des évaluations économiques dans l'évaluation et la diffusion des innovations thérapeutiques à l'hôpital"
"en" => "Méthodologie et apport des évaluations économiques dans l'évaluation et la diffusion des innovations thérapeutiques à l'hôpital"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
37 => Essec\Faculty\Model\These {#2372
#_index: null
#_id: null
#_source: array:9 [
"year" => "2019"
"startDate" => null
"endDate" => "2019"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Aspects juridiques et économiques de l'accès au marché des médicaments innovants"
"en" => "Aspects juridiques et économiques de l'accès au marché des médicaments innovants"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris Descartes (Paris V)"
"en" => "Université Paris Descartes (Paris V)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
38 => Essec\Faculty\Model\These {#2373
#_index: null
#_id: null
#_source: array:9 [
"year" => "2015"
"startDate" => null
"endDate" => "2015"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Troubles mictionnels chez l'homme et incontinence urinaire. Influence des paramètres génétiques sur le vieillissement vésico-prostatique"
"en" => "Troubles mictionnels chez l'homme et incontinence urinaire. Influence des paramètres génétiques sur le vieillissement vésico-prostatique"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Pierre et Marie Curie (UPMC)"
"en" => "Université Pierre et Marie Curie (UPMC)"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
39 => Essec\Faculty\Model\These {#2374
#_index: null
#_id: null
#_source: array:9 [
"year" => "2014"
"startDate" => null
"endDate" => "2014"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Médicaments biosimilaires: quels enjeux économiques et politiques?"
"en" => "Médicaments biosimilaires: quels enjeux économiques et politiques?"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
40 => Essec\Faculty\Model\These {#2375
#_index: null
#_id: null
#_source: array:9 [
"year" => "2013"
"startDate" => null
"endDate" => "2013"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Prix, concurrence et régulation: soutien à l'innovation et prix des médicaments à l'hôpital"
"en" => "Prix, concurrence et régulation: soutien à l'innovation et prix des médicaments à l'hôpital"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
41 => Essec\Faculty\Model\These {#2376
#_index: null
#_id: null
#_source: array:9 [
"year" => "2011"
"startDate" => null
"endDate" => "2011"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "L'économie de la médecine libérale"
"en" => "L'économie de la médecine libérale"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
42 => Essec\Faculty\Model\These {#2377
#_index: null
#_id: null
#_source: array:9 [
"year" => "2010"
"startDate" => null
"endDate" => "2010"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Efficacité de la norme dans la régulation économique des pratiques médicales"
"en" => "Efficacité de la norme dans la régulation économique des pratiques médicales"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
43 => Essec\Faculty\Model\These {#2378
#_index: null
#_id: null
#_source: array:9 [
"year" => null
"startDate" => null
"endDate" => null
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Entre ordre et désordre: la fabrique des réseaux régionaux de cancérologie (1990-2010)"
"en" => "Entre ordre et désordre: la fabrique des réseaux réginoaux de cancérologie (1990-2010)"
]
"role" => array:2 [
"fr" => "Rapporteur"
"en" => "Thesis referee"
]
"institution" => array:2 [
"fr" => "EHESS - École des hautes études en sciences sociales"
"en" => "EHESS - École des hautes études en sciences sociales"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
44 => Essec\Faculty\Model\These {#2379
#_index: null
#_id: null
#_source: array:9 [
"year" => "1998"
"startDate" => null
"endDate" => "1998"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Soigner ou prendre de soins des toxicomanes: anatomie d'une croyance collective. Analyse historique du champ de la toxicomanie en France de 1970 à 1995 ou l'histoire de la domination d'un paradigme."
"en" => "Soigner ou prendre de soins des toxicomanes: anatomie d'une croyance collective. Analyse historique du champ de la toxicomanie en France de 1970 à 1995 ou l'histoire de la domination d'un paradigme."
]
"role" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Institut d'Etudes Politiques"
"en" => "Institut d'Etudes Politiques"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
45 => Essec\Faculty\Model\These {#2380
#_index: null
#_id: null
#_source: array:9 [
"year" => "2004"
"startDate" => null
"endDate" => "2004"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Approches économiques de l'organisation du dépistage du cancer colorectal en France"
"en" => "Approches économiques de l'organisation du dépistage du cancer colorectal en France"
]
"role" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université de Caen Normandie"
"en" => "Université de Caen Normandie"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
46 => Essec\Faculty\Model\These {#2381
#_index: null
#_id: null
#_source: array:9 [
"year" => "1997"
"startDate" => null
"endDate" => "1997"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Qualité de vie et évaluation économique: des fondements théoriques à la mise en pratique"
"en" => "Qualité de vie et évaluation économique: des fondements théoriques à la mise en pratique"
]
"role" => array:2 [
"fr" => "Membre de jury"
"en" => "Thesis jury member"
]
"institution" => array:2 [
"fr" => "Université de Bourgogne"
"en" => "Université de Bourgogne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
47 => Essec\Faculty\Model\These {#2382
#_index: null
#_id: null
#_source: array:9 [
"year" => "2012"
"startDate" => null
"endDate" => "2012"
"student" => ""
"firstJob" => ""
"label" => array:2 [
"fr" => "Autorité et performance dans les réseaux: l'exemple de la production de soins dans les centres de référence maladies rares"
"en" => "Autorité et performance dans les réseaux: l'exemple de la production de soins dans les centres de référence maladies rares"
]
"role" => array:2 [
"fr" => "Président de jury"
"en" => "Thesis jury president"
]
"institution" => array:2 [
"fr" => "Université Paris 1 Panthéon-Sorbonne"
"en" => "Université Paris 1 Panthéon-Sorbonne"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
48 => Essec\Faculty\Model\These {#2383
#_index: null
#_id: null
#_source: array:9 [
"year" => "2017"
"startDate" => null
"endDate" => "2017"
"student" => "BONASTRE J."
"firstJob" => ""
"label" => array:2 [
"fr" => "L'évaluation économique des soins hopitaliers en cancérologie: de la décision de remboursement à la régulation de l'offre de soins"
"en" => "L'évaluation économique des soins hopitaliers en cancérologie: de la décision de remboursement à la régulation de l'offre de soins"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
49 => Essec\Faculty\Model\These {#2384
#_index: null
#_id: null
#_source: array:9 [
"year" => "2008"
"startDate" => null
"endDate" => "2008"
"student" => "BORGET-VANDERVERREN I."
"firstJob" => ""
"label" => array:2 [
"fr" => "Optimisation de la prise en charge globale des patients atteints d'un cancer différencié de la thyroïde"
"en" => "Optimisation de la prise en charge globale des patients atteints d'un cancer différencié de la thyroïde"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
50 => Essec\Faculty\Model\These {#2385
#_index: null
#_id: null
#_source: array:9 [
"year" => "2010"
"startDate" => null
"endDate" => "2010"
"student" => "CHEVALIER J."
"firstJob" => ""
"label" => array:2 [
"fr" => "Mesure des utilités attachés aux états de santé"
"en" => "Mesure des utilités attachés aux états de santé"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Dauphine, PSL"
"en" => "Université Paris-Dauphine, PSL"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
51 => Essec\Faculty\Model\These {#2386
#_index: null
#_id: null
#_source: array:9 [
"year" => "2009"
"startDate" => null
"endDate" => "2009"
"student" => "DEJARDIN O."
"firstJob" => ""
"label" => array:2 [
"fr" => "Déterminants socio-géographiques de la prise en charge et de la survie des patients atteints d'un cancer digestif en France"
"en" => "Déterminants socio-géographiques de la prise en charge et de la survie des patients atteints d'un cancer digestif en France"
]
"role" => array:2 [
"fr" => "Directeur de thèse"
"en" => "Thesis director"
]
"institution" => array:2 [
"fr" => "Université Paris-Saclay"
"en" => "Université Paris-Saclay"
]
"country" => array:2 [
"fr" => "France"
"en" => "France"
]
]
+lang: "en"
+"parent": Essec\Faculty\Model\Profile {#2216}
}
]
"indexedAt" => "2024-11-21T18:21:22.000Z"
"contributions" => array:122 [
0 => Essec\Faculty\Model\Contribution {#2388
#_index: "academ_contributions"
#_id: "2114"
#_source: array:18 [
"id" => "2114"
"slug" => "nutritional-lifestyle-and-environmental-factors-in-ocular-hypertension-and-primary-open-angle-glaucoma-an-exploratory-case-control-study"
"yearMonth" => "2013-09"
"year" => "2013"
"title" => "Nutritional, Lifestyle and Environmental Factors in Ocular Hypertension and Primary Open-Angle Glaucoma: An Exploratory Case-Control Study"
"description" => "RENARD, J.P., ROULAND, J.F., BRON, A., SELLEM, E., NORDMANN, J.P. et DE POUVOURVILLE, G. (2013). Nutritional, Lifestyle and Environmental Factors in Ocular Hypertension and Primary Open-Angle Glaucoma: An Exploratory Case-Control Study. <i>Acta Ophthalmologica</i>, 61(6), pp. 505-513."
"authors" => array:6 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "RENARD J. P."
]
2 => array:1 [
"name" => "ROULAND J. F."
]
3 => array:1 [
"name" => "BRON A."
]
4 => array:1 [
"name" => "SELLEM E."
]
5 => array:1 [
"name" => "NORDMANN J. P."
]
]
"ouvrage" => ""
"keywords" => array:6 [
0 => "environment"
1 => "epidemiology"
2 => "nutrition"
3 => "ocular hypertension"
4 => "open-angle glaucoma"
5 => "risk factors"
]
"updatedAt" => "2024-05-28 16:35:31"
"publicationUrl" => "https://pubmed.ncbi.nlm.nih.gov/22394398/"
"publicationInfo" => array:3 [
"pages" => "505-513"
"volume" => "61"
"number" => "6"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Etude cas-témoin pour identifier les facteurs de risque nutritionnels, de comportement et d'environnement prédictifs d'un glaucome à angle ouvert chez les patients avec hypertension intra-oculaire."
"en" => "A case-control study to identify nutritional, lifestyle, environmental factors predicative of open-angle glaucoma in patients with ocular hypertension."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
1 => Essec\Faculty\Model\Contribution {#2390
#_index: "academ_contributions"
#_id: "2202"
#_source: array:18 [
"id" => "2202"
"slug" => "patient-preference-for-chronic-obstructive-pulmonary-disease-copd-treatment-inhalers-a-discrete-choice-experiment-in-france"
"yearMonth" => "2019-02"
"year" => "2019"
"title" => "Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France"
"description" => "CHOUAID, C., GERMAIN, N., PUYOU DE POUVOURVILLE, G., ABALLEA, S., KORCHAGINA, D. et BALDWIN, M. (2019). Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. <i>Current Medical Research and Opinion</i>, 35(5), pp. 785-792."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "CHOUAID C."
]
2 => array:1 [
"name" => "GERMAIN N."
]
3 => array:1 [
"name" => "ABALLEA S."
]
4 => array:1 [
"name" => "KORCHAGINA D."
]
5 => array:1 [
"name" => "BALDWIN M."
]
]
"ouvrage" => ""
"keywords" => array:7 [
0 => "COPD"
1 => "Chronic obstructive pulmonary disease"
2 => "Convenience"
3 => "Discrete choice experiment"
4 => "Inhaler characteristics"
5 => "Inhaler device"
6 => "Patient preference"
]
"updatedAt" => "2023-05-31 12:07:04"
"publicationUrl" => "https://pubmed.ncbi.nlm.nih.gov/30681007/"
"publicationInfo" => array:3 [
"pages" => "785-792"
"volume" => "35"
"number" => "5"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Connaître les préférences des patients atteints de BPCO (broncho-pneumopathie chronique obstructuve) en matière d'inhalateurs peut permettre d'améliorer leur observance des traitements. Cette étude est fondée sur une expérience de choix discrets dont le but était d'identifier les caractéristiques préférés des patients en matière de formes et de fonction des inhalateurs."
"en" => "Understanding inhaler preferences may contribute to improving adherence in COPD patients and improving long-term outcomes. This study aims to identify and quantify preferences for convenience-related inhaler attributes in French moderate-to-severe COPD patients, with discretechoice experiment (DCE) methodology."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
2 => Essec\Faculty\Model\Contribution {#2392
#_index: "academ_contributions"
#_id: "2201"
#_source: array:18 [
"id" => "2201"
"slug" => "patient-characteristics-and-treatment-of-neovascular-age-related-macular-degeneration-in-france-the-lueur-1-observational-study"
"yearMonth" => "2011-04"
"year" => "2011"
"title" => "Patient Characteristics and Treatment of Neovascular Age-related Macular Degeneration in France: The LUEUR 1 Observational Study"
"description" => "COHEN, S.Y., SOUIED, E.H., WEBER, A.P., DUPEYRON, G., PUYOU DE POUVOURVILLE, G. et LIEVRE, M. (2011). Patient Characteristics and Treatment of Neovascular Age-related Macular Degeneration in France: The LUEUR 1 Observational Study. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i>, 249(4), pp. 521-527."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "COHEN S.-Y."
]
2 => array:1 [
"name" => "SOUIED E.H."
]
3 => array:1 [
"name" => "WEBER André Paul"
]
4 => array:1 [
"name" => "DUPEYRON G."
]
5 => array:1 [
"name" => "LIEVRE M."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://www.researchgate.net/publication/47701649_Patient_characteristics_and_treatment_of_neovascular_age-related_macular_degeneration_in_France_The_LUEUR1_observational_study"
"publicationInfo" => array:3 [
"pages" => "521-527"
"volume" => "249"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Age-related macular degeneration is the primary cause of blindness in developed countries. Current treatments of this degenerative disease mainly include laser, photodynamic therapy with verteporfin and administration of anti-vascular endothelial growth factors. The LUEUR (LUcentis® En Utilisation Réelle) study is composed of a cross-sectional part (LUEUR1), which examined the current management of wet AMD in France, and a follow-up part (LUEUR2), which will assess the development of patients treated for wet AMD over 4 years. Here we describe the results of LUEUR1. Patients with wet AMD were enrolled during a routine medical examination in LUEUR1, a cross-sectional, observational, prospective, multicentre study. Investigators recorded patient demographics, visual acuity, characteristics of wet AMD lesions, date of AMD diagnosis, comorbidities, previous treatments, treatments prescribed at inclusion, and low vision rehabilitation. A total of 72 investigators recruited 1,019 patients with wet AMD, corresponding to 1,405 eyes affected by the disease. The mean age of patients was 78.7 ± 7.3 years. Most were female (62.3%) and non-smokers (66.9%). The mean visual acuity was 49.12 ± 24.18 Early Treatment Diabetic Retinopathy Study letters. Most eyes showed occult (52.8%) and subfoveal (84.6%) choroidal neovascularisation. Bilateral wet AMD affected 37.9% of patients. The median time since diagnosis was 12 months. Ranibizumab-based therapy (67.3%) and photodynamic therapy (29.8%) were the most frequent previous treatments. Prior to inclusion, 5.6% of patients had low vision rehabilitation. When a treatment was prescribed on the day of inclusion, it was most often ranibizumab (89.0% of all treatments at inclusion). The results of this study illustrate the impact of anti-vascular endothelial growth factor therapies on the treatment of wet AMD in a real-life context. Specifically, ranibizumab-based therapy appears to have largely replaced laser photocoagulation and verteporfin-based photodynamic therapy."
"en" => "Age-related macular degeneration is the primary cause of blindness in developed countries. Current treatments of this degenerative disease mainly include laser, photodynamic therapy with verteporfin and administration of anti-vascular endothelial growth factors. The LUEUR (LUcentis® En Utilisation Réelle) study is composed of a cross-sectional part (LUEUR1), which examined the current management of wet AMD in France, and a follow-up part (LUEUR2), which will assess the development of patients treated for wet AMD over 4 years. Here we describe the results of LUEUR1. Patients with wet AMD were enrolled during a routine medical examination in LUEUR1, a cross-sectional, observational, prospective, multicentre study. Investigators recorded patient demographics, visual acuity, characteristics of wet AMD lesions, date of AMD diagnosis, comorbidities, previous treatments, treatments prescribed at inclusion, and low vision rehabilitation. A total of 72 investigators recruited 1,019 patients with wet AMD, corresponding to 1,405 eyes affected by the disease. The mean age of patients was 78.7 ± 7.3 years. Most were female (62.3%) and non-smokers (66.9%). The mean visual acuity was 49.12 ± 24.18 Early Treatment Diabetic Retinopathy Study letters. Most eyes showed occult (52.8%) and subfoveal (84.6%) choroidal neovascularisation. Bilateral wet AMD affected 37.9% of patients. The median time since diagnosis was 12 months. Ranibizumab-based therapy (67.3%) and photodynamic therapy (29.8%) were the most frequent previous treatments. Prior to inclusion, 5.6% of patients had low vision rehabilitation. When a treatment was prescribed on the day of inclusion, it was most often ranibizumab (89.0% of all treatments at inclusion). The results of this study illustrate the impact of anti-vascular endothelial growth factor therapies on the treatment of wet AMD in a real-life context. Specifically, ranibizumab-based therapy appears to have largely replaced laser photocoagulation and verteporfin-based photodynamic therapy."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
3 => Essec\Faculty\Model\Contribution {#2389
#_index: "academ_contributions"
#_id: "2215"
#_source: array:18 [
"id" => "2215"
"slug" => "performance-based-risk-sharing-arrangements-good-practices-for-design-implementation-and-evaluation-report-of-the-ispor-good-practices-for-performance-based-risk-sharing-arrangements-task-f"
"yearMonth" => "2013-07"
"year" => "2013"
"title" => "Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force"
"description" => "GARRISON, L.P., TOWSE, A., BRIGGS, A., PUYOU DE POUVOURVILLE, G., GRUEGER, J. et MOHR, P.E. (2013). Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force. <i>Value in Health</i>, 16(5), pp. 703-719."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "GARRISON L. P."
]
2 => array:1 [
"name" => "TOWSE A."
]
3 => array:1 [
"name" => "BRIGGS A."
]
4 => array:1 [
"name" => "GRUEGER J."
]
5 => array:1 [
"name" => "MOHR P. E."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://www.researchgate.net/publication/255957017_Performance-Based_Risk-Sharing_Arrangements-Good_Practices_for_Design_Implementation_and_Evaluation_Report_of_the_ISPOR_Good_Practices_for_Performance-Based_Risk-Sharing_Arrangements_Task_Force"
"publicationInfo" => array:3 [
"pages" => "703-719"
"volume" => "16"
"number" => "5"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "There is a significant and growing interest among both payers and producers of medical products for agreements that involve a “pay-for-performance” or “risk-sharing” element. These payment schemes— called “performance-based risk-sharing arrangements” (PBRSAs)— involve a plan by which the performance of the product is tracked in a defined patient population over a specified period of time and the amount or level of reimbursement is based on the health and cost outcomes achieved. There has always been considerable uncertainty at product launch about the ultimate real-world clinical and economic performance of new products, but this appears to have increased in recent years. PBRSAs represent one mechanism for reducing this uncertainty through greater investment in evidence collection while a technology is used within a health care system. The objective of this Task Force report was to set out the standards that should be applied to “good practices”—both research and operational—in the use of a PBRSA, encompassing questions around the desirability, design, implementation, and evaluation of such an arrangement. This report provides practical recommendations for the development and application of state-of-the-art methods to be used when considering, using, or reviewing PBRSAs. Key findings and recommendations include the following. Additional evidence collection is costly, and there are numerous barriers to establishing viable and cost-effective PBRSAs: negotiation, monitoring, and evaluation costs can be substantial. For good research practice in PBRSAs, it is critical to match the appropriate study and research design to the uncertainties being addressed. Good governance processes are also essential. The information generated as part of PBRSAs has public good aspects, bringing ethical and professional obligations, which need to be considered from a policy perspective. The societal desirability of a particular PBRSA is fundamentally an issue as to whether the cost of additional data collection is justified by the benefits of improved resource allocation decisions afforded by the additional evidence generated and the accompanying reduction in uncertainty. The ex post evaluation of a PBRSA should, however, be a multidimensional exercise that assesses many aspects, including not only the impact on long-term cost-effectiveness and whether appropriate evidence was generated but also process indicators, such as whether and how the evidence was used in coverage or reimbursement decisions, whether budget and time were appropriate, and whether the governance arrangements worked well. There is an important gap in the literature of structured ex post evaluation of PBRSAs. As an innovation in and of themselves, PBRSAs should also be evaluated from a long-run societal perspective in terms of their impact on dynamic efficiency (eliciting the optimal amount of innovation)."
"en" => "There is a significant and growing interest among both payers and producers of medical products for agreements that involve a “pay-for-performance” or “risk-sharing” element. These payment schemes— called “performance-based risk-sharing arrangements” (PBRSAs)— involve a plan by which the performance of the product is tracked in a defined patient population over a specified period of time and the amount or level of reimbursement is based on the health and cost outcomes achieved. There has always been considerable uncertainty at product launch about the ultimate real-world clinical and economic performance of new products, but this appears to have increased in recent years. PBRSAs represent one mechanism for reducing this uncertainty through greater investment in evidence collection while a technology is used within a health care system. The objective of this Task Force report was to set out the standards that should be applied to “good practices”—both research and operational—in the use of a PBRSA, encompassing questions around the desirability, design, implementation, and evaluation of such an arrangement. This report provides practical recommendations for the development and application of state-of-the-art methods to be used when considering, using, or reviewing PBRSAs. Key findings and recommendations include the following. Additional evidence collection is costly, and there are numerous barriers to establishing viable and cost-effective PBRSAs: negotiation, monitoring, and evaluation costs can be substantial. For good research practice in PBRSAs, it is critical to match the appropriate study and research design to the uncertainties being addressed. Good governance processes are also essential. The information generated as part of PBRSAs has public good aspects, bringing ethical and professional obligations, which need to be considered from a policy perspective. The societal desirability of a particular PBRSA is fundamentally an issue as to whether the cost of additional data collection is justified by the benefits of improved resource allocation decisions afforded by the additional evidence generated and the accompanying reduction in uncertainty. The ex post evaluation of a PBRSA should, however, be a multidimensional exercise that assesses many aspects, including not only the impact on long-term cost-effectiveness and whether appropriate evidence was generated but also process indicators, such as whether and how the evidence was used in coverage or reimbursement decisions, whether budget and time were appropriate, and whether the governance arrangements worked well. There is an important gap in the literature of structured ex post evaluation of PBRSAs. As an innovation in and of themselves, PBRSAs should also be evaluated from a long-run societal perspective in terms of their impact on dynamic efficiency (eliciting the optimal amount of innovation)."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
4 => Essec\Faculty\Model\Contribution {#2393
#_index: "academ_contributions"
#_id: "2341"
#_source: array:18 [
"id" => "2341"
"slug" => "quel-prix-payer-pour-un-benefice-en-sante"
"yearMonth" => "2016-04"
"year" => "2016"
"title" => "Quel prix payer pour un bénéfice en santé ?"
"description" => "PUYOU DE POUVOURVILLE, G. (2016). Quel prix payer pour un bénéfice en santé ? <i>SEP et Neurosciences</i>, (5), pp. 4-11."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-07-13 14:30:50"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "4-11"
"volume" => null
"number" => "5"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Les études d’évaluation économique des actions de soins ont fait une entrée officielle en France dans le processus de fixation de prix des médicaments et dispositifs médicaux en 2012. En présenter les concepts de base, les techniques et leurs limites, tel est le but ce cet article. L’analyse économique des traitements de la sclérose en plaques sera utilisée à titre illustratif."
"en" => "Cost-effectiveness analysis is now embedded in the French Pricing & Reimbursement process. This paper presents the basic concepts and methods of CEA, with an illustration for multiple sclerosis treatments."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
5 => Essec\Faculty\Model\Contribution {#2387
#_index: "academ_contributions"
#_id: "2361"
#_source: array:18 [
"id" => "2361"
"slug" => "quest-ce-que-la-recherche-en-medecine-generale"
"yearMonth" => "2007-06"
"year" => "2007"
"title" => "Qu'est-ce que la recherche en médecine générale ?"
"description" => "PUYOU DE POUVOURVILLE, G. (2007). Qu'est-ce que la recherche en médecine générale ? <i>La Revue du Practicien</i>, 57(11), pp. 1181-1185."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "1181-1185"
"volume" => "57"
"number" => "11"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'objectif de la recherche est de mener une réflexion épistémologique sur les spécificités de la recherche en médecine générale."
"en" => "The aim of the article is to perform an epistemological analysis of the specificities of general practice research."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
6 => Essec\Faculty\Model\Contribution {#2391
#_index: "academ_contributions"
#_id: "2363"
#_source: array:18 [
"id" => "2363"
"slug" => "quest-ce-quune-unite-de-soins-performante-du-point-de-vue-des-malades-relevant-de-soins-palliatifs-et-de-leurs-proches"
"yearMonth" => "2009-04"
"year" => "2009"
"title" => "Qu'est-ce qu'une unité de soins "performante", du point de vue des malades relevant de soins palliatifs et de leurs proches ?"
"description" => "TIBI-LEVY, Y. et PUYOU DE POUVOURVILLE, G. (2009). Qu'est-ce qu'une unité de soins "performante", du point de vue des malades relevant de soins palliatifs et de leurs proches ? <i>Médecine palliative</i>, 8(2), pp. 53-65."
"authors" => array:2 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "TIBI-LEVY Y."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "53-65"
"volume" => "8"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L’objectif de cette recherche est d’identifier les qualités ou les « attributs » que les équipes de soins palliatifsdoivent posséder pour être jugées « performantes » par les patients, comme par leurs proches."
"en" => "The objective of this research was to identify the qualities or ‘‘attributes’’ that palliative care units must possess to be considered by the patients and their families as ‘‘effective’’."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
7 => Essec\Faculty\Model\Contribution {#2394
#_index: "academ_contributions"
#_id: "2368"
#_source: array:18 [
"id" => "2368"
"slug" => "rapport-cout-efficacite-des-traitements-medicamenteux-et-interventionnels-dans-la-fibrillation-atriale"
"yearMonth" => "2016-02"
"year" => "2016"
"title" => "Rapport coût/efficacité des traitements médicamenteux et interventionnels dans la fibrillation atriale"
"description" => "COHEN, A. et PUYOU DE POUVOURVILLE, G. (2016). Rapport coût/efficacité des traitements médicamenteux et interventionnels dans la fibrillation atriale. <i>Archives of Cardiovascular Diseases Supplements</i>, 8(2), pp. 141-143."
"authors" => array:2 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "COHEN A."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-07-13 14:30:51"
"publicationUrl" => "https://doi.org/10.1016/S1878-6480(16)30328-7"
"publicationInfo" => array:3 [
"pages" => "141-143"
"volume" => "8"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => """
La fibrillation atriale (FA) est le trouble du rythme le plus fréquent touchant l'adulte âgé et est associée à une augmentation du risque de décès, d'accident ischémique cérébral (AIC), d'insuffisance cardiaque ainsi qu'à une réduction de la qualité de la vie. La charge de cette pathologie sur le patient, les soignants, et donc le retentissement sociétal, est importante. La FA est une maladie chronique augmentant de façon significative le coût de la prise en charge qui peut être lié aux modalités initiales de prise en charge, au traitement des complications, ainsi qu'à la baisse d'activité professionnelle. Cependant, le coût exact de la prise en charge de cette complication, terme évolutif des cardiopathies, est difficile à définir. De nouvelles approches de traitement interventionnel de la FA sont donc proposées, qu'il s'agisse d'une ablation par cathéter ou de l'occlusion de l'auricule gauche afin de réduire le risque thromboembolique chez les patients ayant une contre-indication au traitement anticoagulant, qui réduit de façon significative le risque thromboembolique. Ces approches invasives sont cependant coûteuses. \n
Cet article discute le coût de la prise en charge conventionnelle de la FA, contrôle du rythme vs contrôle de la fréquence cardiaque, ainsi que le coût de la prise en charge invasive, ablation vs traitement antiarythmique, occlusion vs traitement anticoagulant, et discutera en particulier les données comparatives évaluant le rapport coût/efficacité de ces différentes approches médicamenteuses ou interventionnelles souvent complémentaires et évolutives dans le temps.
"""
"en" => """
Atrial fibrillation (AF) is the most common arrhythmia encountered in adult and elderly population and is associated with increased risk of death, stroke, heart failure and reduced quality of life. \n
It places an enormous burden on the patients, caregivers and the society at large. As a chronic illness, AF accrues significant costs related to clinical presentation, complications and loss of productivity. The exact economic burden of AF is difficult to define. \n
Novel invasive approaches to AF aim to cure some patients (through catheter ablation) and/or induce a significant reduction in AF burden in others or to prevent complications such as thrombo-embolic events, but are very expensive (LAA occlusion, repeated catheter ablation). This review will address the cost of conventional (rhythm versus rate control) and invasive strategies in AF (ablation versus antiarrhythmic drugs, LAA occlusion) care and will review the evidence on the comparative cost effectiveness of these approaches.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
8 => Essec\Faculty\Model\Contribution {#2395
#_index: "academ_contributions"
#_id: "2381"
#_source: array:18 [
"id" => "2381"
"slug" => "recurrent-wheezing-in-infants"
"yearMonth" => "2016-04"
"year" => "2016"
"title" => "Recurrent Wheezing in Infants"
"description" => "BELHASSEN, M., DE BLIC, J., LAFOREST, L., LAIGLE, V., CHANUT-VOGEL, C. et DE POUVOURVILLE, G. (2016). Recurrent Wheezing in Infants. <i>Medicine</i>, 95(15)."
"authors" => array:6 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BELHASSEN M."
]
2 => array:1 [
"name" => "DE BLIC J."
]
3 => array:1 [
"name" => "LAFOREST L."
]
4 => array:1 [
"name" => "LAIGLE V."
]
5 => array:1 [
"name" => "CHANUT-VOGEL C."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-07-13 14:30:51"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => null
"volume" => "95"
"number" => "15"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Recurrent wheezing (RW) has a significant impact on infants, caregivers, and society, but morbidity and related medical resource utilization (MRU) have not been thoroughly explored. The burden of RW needs to be documented with population-based data. The objective was to assess the characteristics, medical management, and MRU of RW infants identified from national claims data. Infants aged from 6 to 24 months, receiving 2 dispensations of respiratory drugs within 3 months, and presenting a marker of poor control (index date), were selected. During the 6 months after index date, MRU was described in the cohort and among 3 subgroups with more severe RW, defined as 4 dispensations of respiratory drugs, 3 dispensations of oral corticosteroids (OCS), or 1 hospitalization for respiratory symptoms."
"en" => "Recurrent wheezing (RW) has a significant impact on infants, caregivers, and society, but morbidity and related medical resource utilization (MRU) have not been thoroughly explored. The burden of RW needs to be documented with population-based data. The objective was to assess the characteristics, medical management, and MRU of RW infants identified from national claims data. Infants aged from 6 to 24 months, receiving 2 dispensations of respiratory drugs within 3 months, and presenting a marker of poor control (index date), were selected. During the 6 months after index date, MRU was described in the cohort and among 3 subgroups with more severe RW, defined as 4 dispensations of respiratory drugs, 3 dispensations of oral corticosteroids (OCS), or 1 hospitalization for respiratory symptoms."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
9 => Essec\Faculty\Model\Contribution {#2396
#_index: "academ_contributions"
#_id: "2405"
#_source: array:18 [
"id" => "2405"
"slug" => "relationship-between-compliance-and-persistence-with-osteoporosis-medications-and-fracture-risk-in-primary-health-care-in-france-a-retroprospective-case-control-analysis"
"yearMonth" => "2008-12"
"year" => "2008"
"title" => "Relationship Between Compliance and Persistence with Osteoporosis Medications and Fracture Risk in Primary Health Care in France: A Retroprospective Case-control Analysis"
"description" => "COTTE, F.E., MERCIER, F. et PUYOU DE POUVOURVILLE, G. (2008). Relationship Between Compliance and Persistence with Osteoporosis Medications and Fracture Risk in Primary Health Care in France: A Retroprospective Case-control Analysis. <i>Clinical Therapeutics</i>, 30(12), pp. 2410-2422."
"authors" => array:3 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "COTTE F.-E."
]
2 => array:1 [
"name" => "MERCIER F."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "2410-2422"
"volume" => "30"
"number" => "12"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Cette étude a eu pour objectif d'établir le lien entre adhérence au traitement et risque fractuaire chez les patients ostéoporotiques, d'identifier des seuils optimaux de bonne observance et persistance."
"en" => "This study was conducted to investigate the association between adherence and osteoporotic fracture risk and to identify optimal thresholds for good compliance and persistence."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
10 => Essec\Faculty\Model\Contribution {#2397
#_index: "academ_contributions"
#_id: "2614"
#_source: array:18 [
"id" => "2614"
"slug" => "the-cost-of-treating-high-blood-pressure-in-general-practice-in-france"
"yearMonth" => "2008-08"
"year" => "2008"
"title" => "The Cost of Treating High Blood Pressure in General Practice in France"
"description" => "TIBI-LEVY, Y., PUYOU DE POUVOURVILLE, G., WESTERLOPPE, J. et BAMBERGER, M. (2008). The Cost of Treating High Blood Pressure in General Practice in France. <i>European Journal of Health Economics</i>, 9(3), pp. 229-236."
"authors" => array:4 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "TIBI-LEVY Y."
]
2 => array:1 [
"name" => "WESTERLOPPE J."
]
3 => array:1 [
"name" => "BAMBERGER M."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "229-236"
"volume" => "9"
"number" => "3"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "In this study, the cost of having high blood pressure treated by French general practitioners was estimated, using an analysis of the computerized records for 28,015 patients with either hypertension or history of hypertension over three years. Costs due to visits, drugs, and complementary tests were included. The average annual cost of treatment was 597 euros (SD 377 euros). The annual average cost of drugs was 447 euros, and antihypertensive drugs 258e. The average annual cost of patients who were controlled throughout the period was 537 euros, patients who were normalized cost 595 euros, and patients who deteriorated cost 612 euros."
"en" => "In this study, the cost of having high blood pressure treated by French general practitioners was estimated, using an analysis of the computerized records for 28,015 patients with either hypertension or history of hypertension over three years. Costs due to visits, drugs, and complementary tests were included. The average annual cost of treatment was 597 euros (SD 377 euros). The annual average cost of drugs was 447 euros, and antihypertensive drugs 258e. The average annual cost of patients who were controlled throughout the period was 537 euros, patients who were normalized cost 595 euros, and patients who deteriorated cost 612 euros."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
11 => Essec\Faculty\Model\Contribution {#2398
#_index: "academ_contributions"
#_id: "2645"
#_source: array:18 [
"id" => "2645"
"slug" => "the-efficiency-frontier-approach-to-economic-evaluation-of-health-care-interventions"
"yearMonth" => "2010-10"
"year" => "2010"
"title" => "The Efficiency Frontier Approach to Economic Evaluation of Health-Care Interventions"
"description" => "CARO, J.J., NORD, E., SIEBERT, U., MCGUIRE, A., MCGREGOR, M. et DE POUVOURVILLE, G. (2010). The Efficiency Frontier Approach to Economic Evaluation of Health-Care Interventions. <i>Health Economics</i>, 19(10), pp. 1117-1127."
"authors" => array:6 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "CARO J.J."
]
2 => array:1 [
"name" => "NORD E."
]
3 => array:1 [
"name" => "SIEBERT U."
]
4 => array:1 [
"name" => "MCGUIRE A."
]
5 => array:1 [
"name" => "MCGREGOR M."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://www.researchgate.net/publication/44699342_The_efficiency_frontier_approach_to_economic_evaluation_of_health-care_interventions"
"publicationInfo" => array:3 [
"pages" => "1117-1127"
"volume" => "19"
"number" => "10"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Background: IQWiG commissioned an international panel of experts to develop methods for the assessment of the relation of benefits to costs in the German statutory health-care system. Proposed methods: The panel recommended that IQWiG inform German decision makers of the net costs and value of additional benefits of an intervention in the context of relevant other interventions in that indication. To facilitate guidance regarding maximum reimbursement, this information is presented in an efficiency plot with costs on the horizontal axis and value of benefits on the vertical. The efficiency frontier links the interventions that are not dominated and provides guidance. A technology that places on the frontier or to the left is reasonably efficient, while one falling to the right requires further justification for reimbursement at that price. This information does not automatically give the maximum reimbursement, as other considerations may be relevant. Given that the estimates are for a specific indication, they do not address priority setting across the health-care system. Conclusion: This approach informs decision makers about efficiency of interventions, conforms to the mandate and is consistent with basic economic principles. Empirical testing of its feasibility and usefulness is required. Copyright"
"en" => "Background: IQWiG commissioned an international panel of experts to develop methods for the assessment of the relation of benefits to costs in the German statutory health-care system. Proposed methods: The panel recommended that IQWiG inform German decision makers of the net costs and value of additional benefits of an intervention in the context of relevant other interventions in that indication. To facilitate guidance regarding maximum reimbursement, this information is presented in an efficiency plot with costs on the horizontal axis and value of benefits on the vertical. The efficiency frontier links the interventions that are not dominated and provides guidance. A technology that places on the frontier or to the left is reasonably efficient, while one falling to the right requires further justification for reimbursement at that price. This information does not automatically give the maximum reimbursement, as other considerations may be relevant. Given that the estimates are for a specific indication, they do not address priority setting across the health-care system. Conclusion: This approach informs decision makers about efficiency of interventions, conforms to the mandate and is consistent with basic economic principles. Empirical testing of its feasibility and usefulness is required. Copyright"
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
12 => Essec\Faculty\Model\Contribution {#2399
#_index: "academ_contributions"
#_id: "2676"
#_source: array:18 [
"id" => "2676"
"slug" => "the-impact-of-research-on-hospital-costs-of-care-an-empirical-study"
"yearMonth" => "2011-01"
"year" => "2011"
"title" => "The Impact of Research on Hospital Costs of Care: An Empirical Study"
"description" => "BONASTRE, J., LE VAILLANT, M. et PUYOU DE POUVOURVILLE, G. (2011). The Impact of Research on Hospital Costs of Care: An Empirical Study. <i>Health Economics</i>, 20(1), pp. 73-84."
"authors" => array:3 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BONASTRE J."
]
2 => array:1 [
"name" => "LE VAILLANT M."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://www.researchgate.net/publication/41030440_The_impact_of_research_on_hospital_costs_of_care_An_empirical_study"
"publicationInfo" => array:3 [
"pages" => "73-84"
"volume" => "20"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "The goal of this study was to examine the impact of research activities on hospital costs and lengths of stay in French public hospitals. Our data consist of a random sample of 30000 inpatient stays in 38 hospitals that were extracted from the French Hospital Cost Survey database. Hospital characteristics were added using data from a French national survey and performing a bibliometric study. This is a retrospective study of hospitalizations. We used multilevel modeling. We considered separate models to explain the cost per day and the length of hospital stay (LOS). Research output was defined based on the quartiles of the distribution of the number of impact-weighted scientific publications produced in our sample of hospitals over a 6-year period. Research production was associated with a higher cost of care. The cost per day was 19% higher in hospitals in the 3rd quartile and 42% higher in hospitals in the 4th quartile compared to that in hospitals that were not involved in research activities. This result was sensitive to the type of care under consideration. The effect was stronger in oncology but not significant in routine care. Scientific production did not impact the LOS."
"en" => "The goal of this study was to examine the impact of research activities on hospital costs and lengths of stay in French public hospitals. Our data consist of a random sample of 30000 inpatient stays in 38 hospitals that were extracted from the French Hospital Cost Survey database. Hospital characteristics were added using data from a French national survey and performing a bibliometric study. This is a retrospective study of hospitalizations. We used multilevel modeling. We considered separate models to explain the cost per day and the length of hospital stay (LOS). Research output was defined based on the quartiles of the distribution of the number of impact-weighted scientific publications produced in our sample of hospitals over a 6-year period. Research production was associated with a higher cost of care. The cost per day was 19% higher in hospitals in the 3rd quartile and 42% higher in hospitals in the 4th quartile compared to that in hospitals that were not involved in research activities. This result was sensitive to the type of care under consideration. The effect was stronger in oncology but not significant in routine care. Scientific production did not impact the LOS."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
13 => Essec\Faculty\Model\Contribution {#2400
#_index: "academ_contributions"
#_id: "2779"
#_source: array:18 [
"id" => "2779"
"slug" => "two-year-vascular-hospitalisation-rates-and-associated-costs-in-patients-at-risk-of-atherothrombosis-in-france-and-germany-highest-burden-for-peripheral-arterial-disease"
"yearMonth" => "2012-02"
"year" => "2012"
"title" => "Two-Year Vascular Hospitalisation Rates and Associated Costs in Patients at Risk of Atherothrombosis in France and Germany: Highest Burden for Peripheral Arterial Disease"
"description" => "SMOLDEREN, K.G., WANG, K., PUYOU DE POUVOURVILLE, G., BRÜGGENJÜRGEN, B., RÖTHER, J. et ZEYMER, U. (2012). Two-Year Vascular Hospitalisation Rates and Associated Costs in Patients at Risk of Atherothrombosis in France and Germany: Highest Burden for Peripheral Arterial Disease. <i>European Journal of Vascular and Endovascular Surgery</i>, 43(2), pp. 198-207."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "SMOLDEREN K. G."
]
2 => array:1 [
"name" => "WANG K."
]
3 => array:1 [
"name" => "BRÜGGENJÜRGEN B."
]
4 => array:1 [
"name" => "RÖTHER J."
]
5 => array:1 [
"name" => "ZEYMER U."
]
]
"ouvrage" => ""
"keywords" => array:5 [
0 => "Costs"
1 => "Cerebrovascular disease"
2 => "Coronary disease"
3 => "Peripheral arterial disease"
4 => "Hospitalisation"
]
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://doi.org/10.1016/j.ejvs.2011.09.016"
"publicationInfo" => array:3 [
"pages" => "198-207"
"volume" => "43"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "The aim of this article is to obtain Western European perspectives on the economic burden of atherothrombosis in patients with multiple risk factors only (MRF), cerebrovascular disease (CVD), coronary artery disease (CAD), and in the under-evaluated group of patients with peripheral arterial disease (PAD), we examined vascular-related hospitalisation rates and associated costs in France and Germany."
"en" => "The aim of this article is to obtain Western European perspectives on the economic burden of atherothrombosis in patients with multiple risk factors only (MRF), cerebrovascular disease (CVD), coronary artery disease (CAD), and in the under-evaluated group of patients with peripheral arterial disease (PAD), we examined vascular-related hospitalisation rates and associated costs in France and Germany."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
14 => Essec\Faculty\Model\Contribution {#2401
#_index: "academ_contributions"
#_id: "2842"
#_source: array:18 [
"id" => "2842"
"slug" => "valuing-eq-5d-using-time-trade-off-in-france"
"yearMonth" => "2011-09"
"year" => "2011"
"title" => "Valuing EQ-5D using Time Trade-Off in France"
"description" => "CHEVALIER, J. et PUYOU DE POUVOURVILLE, G. (2011). Valuing EQ-5D using Time Trade-Off in France. <i>European Journal of Health Economics</i>, 14(1), pp. 57-66."
"authors" => array:2 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "CHEVALIER J."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://www.researchgate.net/publication/241110007_Valuing_EQ-5D_using_time_trade-off_in_France"
"publicationInfo" => array:3 [
"pages" => "57-66"
"volume" => "14"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Objectifs: Établir les valeurs d'utilité pour les états de santé décrits par le questionnaire EQ-5D, sur la base d'une enquête sur un échantillon représentatif de la population française, avec la méthode du Time Trade-Off."
"en" => "Objectifs: Établir les valeurs d'utilité pour les états de santé décrits par le questionnaire EQ-5D, sur la base d'une enquête sur un échantillon représentatif de la population française, avec la méthode du Time Trade-Off."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
15 => Essec\Faculty\Model\Contribution {#2402
#_index: "academ_contributions"
#_id: "8599"
#_source: array:18 [
"id" => "8599"
"slug" => "la-territorialisation-aux-mains-des-cpts-et-des-ght"
"yearMonth" => "2016-12"
"year" => "2016"
"title" => "La territorialisation aux mains des CPTS et des GHT"
"description" => "PUYOU DE POUVOURVILLE, G. 2016. <i>La territorialisation aux mains des CPTS et des GHT</i>. Décembre."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-09-24 10:33:27"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => null
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Interviews : Emission radio - TV - presse écrite"
"en" => "Interviews: radio - TV - press"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => null
"en" => null
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
16 => Essec\Faculty\Model\Contribution {#2403
#_index: "academ_contributions"
#_id: "894"
#_source: array:18 [
"id" => "894"
"slug" => "cout-de-la-prise-en-charge-des-accidents-vasculaires-cerebraux-en-france"
"yearMonth" => "2016-02"
"year" => "2016"
"title" => "Coût de la Prise en Charge des Accidents Vasculaires Cérébraux en France"
"description" => "PUYOU DE POUVOURVILLE, G. (2016). Coût de la Prise en Charge des Accidents Vasculaires Cérébraux en France. <i>Archives of Cardiovascular Diseases Supplements</i>, 8(2), pp. 161-168."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "Accidents cérébrovasculaires"
1 => "Coût"
2 => "France"
]
"updatedAt" => "2021-07-13 14:30:07"
"publicationUrl" => "https://www.sciencedirect.com/science/article/pii/S1878648016303305#:~:text=Selon%20les%20sources%20et%20la,%E2%82%AC%20(AVC%20h%C3%A9morragique%20s%C3%A9v%C3%A8re)."
"publicationInfo" => array:3 [
"pages" => "161-168"
"volume" => "8"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => """
Contexte. Les accidents vasculaires cérébraux (AVC) sont en France la première cause de handicap acquis chez l'adulte, la deuxième cause de démence et la troisième cause de mortalité. Malgré cela, le coût qu'ils induisent pour la collectivité est mal connu. \n
Objectifs. L'objectif de cette étude est de faire la synthèse des données françaises récentes publiées sur le coût de la prise en charge des AVC. \n
Méthode. Une revue et une analyse critique de la littérature publiée depuis 2000 sur des données françaises ont été réalisées. \n
Résultats. La dépense annuelle totale financée par la collectivité a été de 8,6 milliards d'euros en 2007. La dépense de soins au cours de la première année représentait environ un tiers de ce montant, les dépenses de soins pour les patients prévalents un autre tiers, et les dépenses médico-sociales le dernier tiers. Les dépenses post-AVC représenteraient 65 % du coût de prise en charge. Selon les sources et la nature de l'AVC, le coût des cas incidents sur 1 an variait entre 7 839 € (AVC ischémique peu sévère) et 41 437 € (AVC hémorragique sévère). Conclusion. Les AVC génèrent une dépense importante pour la collectivité, qui ne se résume pas à la prise en charge de l'évènement initial et qui va courir jusqu'au décès des patients. La prise en charge médico-sociale du handicap représente en particulier un poste important, qui reste mal connu dans le contexte français.
"""
"en" => """
Background. In France, stroke is the first cause of acquired disability for adults, the second cause of dementia and the third cause of death. Nonetheless, their economic burden for society is insufficiently documented. \n
Aims. The aim of the study was to synthetize existing published data on the cost of stroke in France. \n
Methods. A literature review of all studies published since 2000 and related to the cost of stroke in France was performed. \n
Results. Total annual expenditures funded by social security was Billion 8.7 € in 2007. Expenditures for the first year after the event was around one-third of this amount, whereas health care expenditures for patients beyond the first year and social services represented each another third. Depending on sources and nature of the initial event, the direct medical cost for the first year ranged between € 7,839 for a mild ischemic stroke to € 41,437 for a severe haemorrhagic stroke. Conclusion. The review confirms the important economic burden of stroke for the French society. This burden goes beyond the expenditures incurred for the initial event. In particular, the management of disability represents a substantial share, which is still unperfectly documented in the French context.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
17 => Essec\Faculty\Model\Contribution {#2404
#_index: "academ_contributions"
#_id: "1061"
#_source: array:18 [
"id" => "1061"
"slug" => "editorial-la-reforme-de-la-gouvernance-hospitaliere-mission-impossible"
"yearMonth" => "2007-04"
"year" => "2007"
"title" => "Editorial : La réforme de la gouvernance hospitalière : mission impossible?"
"description" => "PUYOU DE POUVOURVILLE, G. (2007). Editorial : La réforme de la gouvernance hospitalière : mission impossible? <i>La Presse Médicale</i>, 36(4), pp. 636-637."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-07-13 14:30:12"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "636-637"
"volume" => "36"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "La réfomre Hôpital 2007 prévoit une refonte majeure de la gouvernance des hôpitaux publis en France. Les obstacles à cette réforme sont étudiées."
"en" => "In 2007, a major reform has been immplemented in France to change the governance of public hospitals. The article identifies the main resistances to change."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
18 => Essec\Faculty\Model\Contribution {#2405
#_index: "academ_contributions"
#_id: "1062"
#_source: array:18 [
"id" => "1062"
"slug" => "editorial-a-french-approach-to-cost-effectiveness-analysis"
"yearMonth" => "2010-11"
"year" => "2010"
"title" => "Editorial: A French Approach to Cost-Effectiveness Analysis?"
"description" => "PUYOU DE POUVOURVILLE, G. (2010). Editorial: A French Approach to Cost-Effectiveness Analysis? <i>European Journal of Health Economics</i>, 11(6), pp. 521-523."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://link.springer.com/article/10.1007/s10198-010-0284-9"
"publicationInfo" => array:3 [
"pages" => "521-523"
"volume" => "11"
"number" => "6"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Comment les pouvoirs publics français envisagent-ils d'intégrer les études coût-efficacité dans les décisions de prix et de remboursement des innovations thérapeutiques ?"
"en" => "How do French HTA bodies and payers use cost-effectiveness analysis in pricing and reimbursement decisions?"
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
19 => Essec\Faculty\Model\Contribution {#2406
#_index: "academ_contributions"
#_id: "1063"
#_source: array:18 [
"id" => "1063"
"slug" => "editorial-has-to-be-nice"
"yearMonth" => "2013-02"
"year" => "2013"
"title" => "Editorial: HAS to be NICE?"
"description" => "PUYOU DE POUVOURVILLE, G. (2013). Editorial: HAS to be NICE? <i>European Journal of Health Economics</i>, 14, pp. 363-366."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "363-366"
"volume" => "14"
"number" => null
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Analyse de l'impact de l'introduction des études coût-efficacité dans les décisions de prix des médicaments et dispositifis médicaux. La France se rappoche-t-elle du moèle anglais?"
"en" => "Analyse de l'impact de l'introduction des études coût-efficacité dans les décisions de prix des médicaments et dispositifis médicaux. La France se rappoche-t-elle du moèle anglais?"
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
20 => Essec\Faculty\Model\Contribution {#2407
#_index: "academ_contributions"
#_id: "1064"
#_source: array:18 [
"id" => "1064"
"slug" => "editorial-paying-doctors-for-performance"
"yearMonth" => "2013-02"
"year" => "2013"
"title" => "Editorial: Paying Doctors for Performance"
"description" => "PUYOU DE POUVOURVILLE, G. (2013). Editorial: Paying Doctors for Performance. <i>European Journal of Health Economics</i>, 14(1), pp. 1-4."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => array:2 [
0 => "Médecins"
1 => "Rémunération à la performance"
]
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://link.springer.com/article/10.1007/s10198-012-0401-z"
"publicationInfo" => array:3 [
"pages" => "1-4"
"volume" => "14"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "In health economics textbooks, most discussions around incentives for doctors have focused on a comparison of the three most current payment schemes: fee-for-service, capitation, and salary. In general, the scope of analysis is restricted to primary care physicians versus specialist care and care delivered by doctors in hospitals. The story is well known: fee-for-service will incentivize doctors to provide excess care and increase expenditure, but compared to the other schemes it has a positive effect on productivity and quality, although it is not always very clear how quality is defined. Moreover, it is important to specify whether the level of fee is imposed by the payer, or if doctors have some latitude in setting their prices. Capitation will lead to a better control over overall expenditure, but eventually to the detriment of quality, as measured by the unit time per visit and the number of visits. The claim of better control over expenditures can be challenged if—to minimize their effort—GPs systematically refer cases to specialists. Finally, the discussion around salary must take into account the organizational incentives that will inevitably complement the remuneration provided by the employer of the physician."
"en" => "In health economics textbooks, most discussions around incentives for doctors have focused on a comparison of the three most current payment schemes: fee-for-service, capitation, and salary. In general, the scope of analysis is restricted to primary care physicians versus specialist care and care delivered by doctors in hospitals. The story is well known: fee-for-service will incentivize doctors to provide excess care and increase expenditure, but compared to the other schemes it has a positive effect on productivity and quality, although it is not always very clear how quality is defined. Moreover, it is important to specify whether the level of fee is imposed by the payer, or if doctors have some latitude in setting their prices. Capitation will lead to a better control over overall expenditure, but eventually to the detriment of quality, as measured by the unit time per visit and the number of visits. The claim of better control over expenditures can be challenged if—to minimize their effort—GPs systematically refer cases to specialists. Finally, the discussion around salary must take into account the organizational incentives that will inevitably complement the remuneration provided by the employer of the physician."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
21 => Essec\Faculty\Model\Contribution {#2408
#_index: "academ_contributions"
#_id: "1139"
#_source: array:18 [
"id" => "1139"
"slug" => "etude-polychrome-construction-dune-typologie-des-pathologies-chroniques-en-medecine-generale-pour-une-analyse-de-la-poly-prescription"
"yearMonth" => "2008-01"
"year" => "2008"
"title" => "Etude polychrome : construction d'une typologie des pathologies chroniques en médecine générale, pour une analyse de la poly-prescription"
"description" => "CLERC, P., LEBRETON, J., MOUSQUES, J., HEBBRECHT, G. et PUYOU DE POUVOURVILLE, G. (2008). Etude polychrome : construction d'une typologie des pathologies chroniques en médecine générale, pour une analyse de la poly-prescription. <i>Pratiques et Organisation des Soins</i>, 39(1), pp. 43-51."
"authors" => array:5 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "CLERC P."
]
2 => array:1 [
"name" => "LEBRETON J."
]
3 => array:1 [
"name" => "MOUSQUES J."
]
4 => array:1 [
"name" => "HEBBRECHT G."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "43-51"
"volume" => "39"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => """
Construction d’une typologie des pathologies\n
chroniques et de leurs combinaisons lors des rencontres\n
en médecine générale.
"""
"en" => """
Establish a typology of chronic diseases and their\n
combinations during general practitioner (GP) appointments.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
22 => Essec\Faculty\Model\Contribution {#2409
#_index: "academ_contributions"
#_id: "1140"
#_source: array:18 [
"id" => "1140"
"slug" => "etude-polychrome-une-methode-dexpertise-pour-optimiser-des-vignettes-de-polyprescription-en-medecine-generale"
"yearMonth" => "2009-07"
"year" => "2009"
"title" => "Etude polychrome : une méthode d'expertise pour optimiser des vignettes de polyprescription en médecine générale"
"description" => "CLERC, P., LE BRETON, J., MOUSQUES, J., HEBBRECHT, G. et PUYOU DE POUVOURVILLE, G. (2009). Etude polychrome : une méthode d'expertise pour optimiser des vignettes de polyprescription en médecine générale. <i>Pratiques et Organisation des Soins</i>, 40(3), pp. 165-174."
"authors" => array:5 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "CLERC P."
]
2 => array:1 [
"name" => "LE BRETON J."
]
3 => array:1 [
"name" => "MOUSQUES J."
]
4 => array:1 [
"name" => "HEBBRECHT G."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "165-174"
"volume" => "40"
"number" => "3"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Déterminer si un programme d’optimisation d’ordonnances de polyprescription par une équipe médicale multidisciplinaire permettrait d’améliorer la qualité des ordonnances en médecine générale."
"en" => "To determine whether a program of optimization polypharmacy regimens by a multidisciplinary medical team would improve medication regimens appropriateness in general practice."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
23 => Essec\Faculty\Model\Contribution {#2410
#_index: "academ_contributions"
#_id: "1151"
#_source: array:18 [
"id" => "1151"
"slug" => "evaluation-of-cost-savings-with-ferric-carboxymaltose-in-anemia-treatment-through-its-impact-on-erythropoiesis-stimulating-agents-and-blood-transfusion-french-healthcare-payer-perspective"
"yearMonth" => "2012-01"
"year" => "2012"
"title" => "Evaluation of Cost Savings with Ferric Carboxymaltose in Anemia Treatment Through Its Impact on Erythropoiesis-Stimulating Agents and Blood Transfusion: French Healthcare Payer Perspective"
"description" => "LUPORSI, E., MAHI, L., MORRE, C., WERNLI, J., PUYOU DE POUVOURVILLE, G. et BUGAT, R. (2012). Evaluation of Cost Savings with Ferric Carboxymaltose in Anemia Treatment Through Its Impact on Erythropoiesis-Stimulating Agents and Blood Transfusion: French Healthcare Payer Perspective. <i>Journal of Medical Economics</i>, 15(2), pp. 225-232."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "LUPORSI E."
]
2 => array:1 [
"name" => "MAHI L."
]
3 => array:1 [
"name" => "MORRE C."
]
4 => array:1 [
"name" => "WERNLI J."
]
5 => array:1 [
"name" => "BUGAT R."
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "Anemia"
1 => "Intravenous iron"
2 => "Erythropoiesis-stimulating agents"
]
"updatedAt" => "2021-07-13 14:30:14"
"publicationUrl" => "https://www.tandfonline.com/doi/abs/10.3111/13696998.2011.639823"
"publicationInfo" => array:3 [
"pages" => "225-232"
"volume" => "15"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "This article evaluates the economic impact of intravenous iron (in the form of intravenous iron preparation of ferric carboxymaltose) in three different clinical settings of iron deficiency anemia: chemotherapy-induced anemia in breast cancer, chemotherapy-induced anemia in digestive cancer, and perioperative anemia in knee and hip surgery."
"en" => "This article evaluates the economic impact of intravenous iron (in the form of intravenous iron preparation of ferric carboxymaltose) in three different clinical settings of iron deficiency anemia: chemotherapy-induced anemia in breast cancer, chemotherapy-induced anemia in digestive cancer, and perioperative anemia in knee and hip surgery."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
24 => Essec\Faculty\Model\Contribution {#2411
#_index: "academ_contributions"
#_id: "1300"
#_source: array:18 [
"id" => "1300"
"slug" => "guidelines-for-completing-the-euronheed-transferability-information-checklists"
"yearMonth" => "2009-05"
"year" => "2009"
"title" => "Guidelines for Completing the EURONHEED Transferability Information Checklists"
"description" => "NIXON, J., RICE, S., DRUMMOND, M., BOULENGER, S., ULMANN, P. et DE POUVOURVILLE, G. (2009). Guidelines for Completing the EURONHEED Transferability Information Checklists. <i>European Journal of Health Economics</i>, 10(2), pp. 157-165."
"authors" => array:6 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "NIXON J."
]
2 => array:1 [
"name" => "RICE S."
]
3 => array:1 [
"name" => "DRUMMOND M."
]
4 => array:1 [
"name" => "BOULENGER S."
]
5 => array:1 [
"name" => "ULMANN P."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "157-165"
"volume" => "10"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Développer une méthode standadisée pour évaluer le degré de transposition des résuktats des études coût-efficacité d'un pays à l'autre."
"en" => "Establish a checklist allowinfg to assess the transferability of cost-effectiveness studies inhealth care from one country to another."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
25 => Essec\Faculty\Model\Contribution {#2412
#_index: "academ_contributions"
#_id: "1306"
#_source: array:18 [
"id" => "1306"
"slug" => "health-related-quality-of-life-an-economists-perspective-viewpoint"
"yearMonth" => "2007-12"
"year" => "2007"
"title" => "Health-related Quality of Life - An Economist's Perspective (Viewpoint)"
"description" => "PUYOU DE POUVOURVILLE, G., BORGET, I. et SCHLUMBERGER, M. (2007). Health-related Quality of Life - An Economist's Perspective (Viewpoint). <i>Nature Reviews Endocrinology</i>, 3(12), pp. 2-3."
"authors" => array:3 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BORGET I."
]
2 => array:1 [
"name" => "SCHLUMBERGER M."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-07-13 14:30:19"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "2-3"
"volume" => "3"
"number" => "12"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "La mesure de la qualité de vie liée à des états de santé est devenue un standard dans l'évaluation des actoins de santé. L'article en présente les fondements économiques théoriques."
"en" => "Measuring health-related quality of life is now a standard in the assessment of new medical technologies. The article presents the underlying economic prionciples."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
26 => Essec\Faculty\Model\Contribution {#2413
#_index: "academ_contributions"
#_id: "1330"
#_source: array:18 [
"id" => "1330"
"slug" => "how-the-availability-of-recombinant-human-tsh-has-changed-the-management-of-patients-who-have-thyroid-cancer"
"yearMonth" => "2007-09"
"year" => "2007"
"title" => "How the Availability of Recombinant Human TSH Has Changed the Management of Patients Who Have Thyroid Cancer"
"description" => "SCHLUMBERGER, M., RICARD, M., PUYOU DE POUVOURVILLE, G. et PACINI, F. (2007). How the Availability of Recombinant Human TSH Has Changed the Management of Patients Who Have Thyroid Cancer. <i>Nature Reviews Endocrinology</i>, 3(9), pp. 641-650."
"authors" => array:4 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "SCHLUMBERGER M."
]
2 => array:1 [
"name" => "RICARD M."
]
3 => array:1 [
"name" => "PACINI F."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-07-13 14:30:20"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "641-650"
"volume" => "3"
"number" => "9"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "La TSH recombinante humaine a changé la prise en charge des patients atteints des cancers de la thyroîde en remplaçant la stimulation par servrage et en diminuant les épisodes d'hypothytroidie pendant le sevrage. L'article examine les conséquences cliniques et économiques de cette innovation."
"en" => "The paper analyzes the clinicaland economic impact of human recombinant TSH on the management of thyroid cancer patients."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
27 => Essec\Faculty\Model\Contribution {#2414
#_index: "academ_contributions"
#_id: "1416"
#_source: array:18 [
"id" => "1416"
"slug" => "iqwig-methods-a-response-to-two-critiques"
"yearMonth" => "2010-10"
"year" => "2010"
"title" => "IQWiG Methods – A Response to Two Critiques"
"description" => "CARO, J.J., NORD, E., MCGUIRE, A., MCGREGOR, D.H., PUYOU DE POUVOURVILLE, G. et ATELLA, V. (2010). IQWiG Methods – A Response to Two Critiques. <i>Health Economics</i>, 19(10), pp. 1137-1138."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "CARO J. J."
]
2 => array:1 [
"name" => "NORD E."
]
3 => array:1 [
"name" => "MCGUIRE A."
]
4 => array:1 [
"name" => "MCGREGOR D. H."
]
5 => array:1 [
"name" => "ATELLA V."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://www.researchgate.net/publication/46274415_IQWiG_methods_-_A_response_to_two_critiques"
"publicationInfo" => array:3 [
"pages" => "1137-1138"
"volume" => "19"
"number" => "10"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "The Journal asked researchers from York and Erasmus Universities to critique the paper in which wepresent the new IQWiG methods for setting a maximum reimbursement price for an intervention inGermany, and has also invited us to comment. This is, unfortunately, not likely to be productive as thecritiques simply restate the objections that were made (Institute for Quality and Efficiency in HealthCare (IQWiG), 13 October 2009), and responded to in detail (Institute for Quality and Efficiency inHealth Care (IQWiG), 16 January 2009), during the external review process. Brouwer and Ruttenwould have preferred that, despite all its faults, we had proposed the cost per QALY coupled with anassumed threshold and Sculpher and Claxton wish that the Panel had been given a broad mandate toaddress all extant issues in health economics. Both adhere closely to the belief that a normative priceexists and that cost-effectiveness calculations will reveal it and guide policymakers to decisions thatreflect societal values, respect the budget, identify the necessary trade-offs, and ensure consistency. Thisdespite abundant evidence to the contrary (see, for example: Birch and Gafni, 2006; McGregor, 2003;Nord et al., 1995) and the general failure of HTA agencies to achieve this after more than a decade oftrying. Neither commentary addresses the subject of our paper.The Panel was asked to outline a method for informing the German authorities who have to judgewhether a price demanded for an intervention in a given therapeutic area is reasonable. We maintainthat this was a clear, meaningful, and relevant mandate in the German health policy context and do notfind it fruitful to continue to discuss whether other ambitions would have been more appropriate orwhether the proposed method adheres to undefined ‘international standards’. Although some commonapproaches have developed, each country has its own procedures in accordance with its specific legaland cultural context. It seems self-evident, however, that whatever approach is taken, it is important fordecision makers to know what the existing efficiency is in a therapeutic area: what is being paid andwhat is obtained for that outlay; and that that should be a key input to decisions about price. Whetherthe benefits at that price are worth it to society is an entirely different question – one which remainsunresolved everywhere."
"en" => "The Journal asked researchers from York and Erasmus Universities to critique the paper in which wepresent the new IQWiG methods for setting a maximum reimbursement price for an intervention inGermany, and has also invited us to comment. This is, unfortunately, not likely to be productive as thecritiques simply restate the objections that were made (Institute for Quality and Efficiency in HealthCare (IQWiG), 13 October 2009), and responded to in detail (Institute for Quality and Efficiency inHealth Care (IQWiG), 16 January 2009), during the external review process. Brouwer and Ruttenwould have preferred that, despite all its faults, we had proposed the cost per QALY coupled with anassumed threshold and Sculpher and Claxton wish that the Panel had been given a broad mandate toaddress all extant issues in health economics. Both adhere closely to the belief that a normative priceexists and that cost-effectiveness calculations will reveal it and guide policymakers to decisions thatreflect societal values, respect the budget, identify the necessary trade-offs, and ensure consistency. Thisdespite abundant evidence to the contrary (see, for example: Birch and Gafni, 2006; McGregor, 2003;Nord et al., 1995) and the general failure of HTA agencies to achieve this after more than a decade oftrying. Neither commentary addresses the subject of our paper.The Panel was asked to outline a method for informing the German authorities who have to judgewhether a price demanded for an intervention in a given therapeutic area is reasonable. We maintainthat this was a clear, meaningful, and relevant mandate in the German health policy context and do notfind it fruitful to continue to discuss whether other ambitions would have been more appropriate orwhether the proposed method adheres to undefined ‘international standards’. Although some commonapproaches have developed, each country has its own procedures in accordance with its specific legaland cultural context. It seems self-evident, however, that whatever approach is taken, it is important fordecision makers to know what the existing efficiency is in a therapeutic area: what is being paid andwhat is obtained for that outlay; and that that should be a key input to decisions about price. Whetherthe benefits at that price are worth it to society is an entirely different question – one which remainsunresolved everywhere."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
28 => Essec\Faculty\Model\Contribution {#2415
#_index: "academ_contributions"
#_id: "1479"
#_source: array:18 [
"id" => "1479"
"slug" => "la-crise-didentite-des-medecins-face-au-nouveau-management-de-lhopital"
"yearMonth" => "2010-11"
"year" => "2010"
"title" => "La crise d'identité des médecins face au nouveau management de l'hôpital"
"description" => "PUYOU DE POUVOURVILLE, G. (2010). La crise d'identité des médecins face au nouveau management de l'hôpital. <i>Journal de l'Ecole de Paris du Management</i>, 6(86), pp. 22-29."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://www.cairn.info/revue-le-journal-de-l-ecole-de-paris-du-management-2010-6-page-22.htm"
"publicationInfo" => array:3 [
"pages" => "22-29"
"volume" => "6"
"number" => "86"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Le ministère de la Santé voulant que l’hôpital adopte des techniques de management d’entreprise, des médecins y sont chargés de diriger et gérer des pôles, avec des objectifs fixés et des budgets alloués. Nombre de médecins hospitaliers peinent à se situer dans ce nouveau contexte."
"en" => "Le ministère de la Santé voulant que l’hôpital adopte des techniques de management d’entreprise, des médecins y sont chargés de diriger et gérer des pôles, avec des objectifs fixés et des budgets alloués. Nombre de médecins hospitaliers peinent à se situer dans ce nouveau contexte."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
29 => Essec\Faculty\Model\Contribution {#2416
#_index: "academ_contributions"
#_id: "1577"
#_source: array:18 [
"id" => "1577"
"slug" => "la-tarification-a-lactivite-est-elle-compatible-avec-les-valeurs-des-professionnels-de-sante"
"yearMonth" => "2016-12"
"year" => "2016"
"title" => "La Tarification à l’Activité est-elle Compatible avec les Valeurs des Professionnels de Santé ?"
"description" => "PUYOU DE POUVOURVILLE, G. (2016). La Tarification à l’Activité est-elle Compatible avec les Valeurs des Professionnels de Santé ? <i>Médecine de l’Homme</i>, (15), pp. 11-25."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-09-24 10:33:27"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "11-25"
"volume" => null
"number" => "15"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "La Tarification à l’Activité (T2A) a introduit une dynamique entrepreneuriale au sein des établissements publics de santé. Cette réforme s’inscrit dans une tendance lourde de renforcement des outils de contrôle externe de l’activité hospitalière, dont elle est un des éléments. Après être revenu sur l’histoire longue de cette transformation, on rappelle quelles en sont les principales caractéristiques et on tente une analyse de ses avantages et ses inconvénients, en mon¬trant cependant que ses effets ne peuvent pas être dissociés des autres modalités de régulation du secteur hospitalier. On discute en conclusion la compatibilité de la T2A et les valeurs du corps médical et des professionnels de santé."
"en" => "La Tarification à l’Activité (T2A) a introduit une dynamique entrepreneuriale au sein des établissements publics de santé. Cette réforme s’inscrit dans une tendance lourde de renforcement des outils de contrôle externe de l’activité hospitalière, dont elle est un des éléments. Après être revenu sur l’histoire longue de cette transformation, on rappelle quelles en sont les principales caractéristiques et on tente une analyse de ses avantages et ses inconvénients, en mon¬trant cependant que ses effets ne peuvent pas être dissociés des autres modalités de régulation du secteur hospitalier. On discute en conclusion la compatibilité de la T2A et les valeurs du corps médical et des professionnels de santé."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
30 => Essec\Faculty\Model\Contribution {#2417
#_index: "academ_contributions"
#_id: "1618"
#_source: array:18 [
"id" => "1618"
"slug" => "lassurance-maladie-en-france-beveridge-et-bismarck-enfin-reconcilies"
"yearMonth" => "2011-11"
"year" => "2011"
"title" => "L'assurance maladie en France: Beveridge et Bismarck enfin reconciliés?"
"description" => "PUYOU DE POUVOURVILLE, G. (2011). L'assurance maladie en France: Beveridge et Bismarck enfin reconciliés? <i>Réalités Industrielles (série des "Annales des Mines")</i>, pp. 19-24."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://www.cairn.info/revue-realites-industrielles1-2011-4-page-19.htm"
"publicationInfo" => array:3 [
"pages" => "19-24"
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "La classification traditionnelle des systèmes de protection sociale renvoie à deux modèles principaux : le modèle dit de l’assurance sociale (ou bismarckien) et le modèle national (ou bévéridgien). Ces deux modèles se caractérisent par deux traits communs : l’universalité de la couverture offerte et, de par le caractère obligatoire de ces deux régimes, le principe d’un financement fondé sur la capacité contributive de l’assuré et non pas sur le niveau de risque estimé. A contrario, ces deux modèles se distinguent par l’assiette du financement (concentrée sur les seuls revenus du travail pour le régime de l’assurance sociale et sur l’ensemble des revenus pour le modèle national) et par le régime de gouvernance (gestion par des organismes placés sous tutelle publique pour le modèle d’assurance sociale et gestion par l’Etat pour le modèle national). Au gré de ses évolutions, le régime de protection sociale français (créé en 1945 par ordonnance) s’inscrit de plus en plus dans une logique bévéridgienne, avec un contrôle croissant de l’Etat sur la gestion paritaire instaurée après-guerre."
"en" => "Welfare systems are usually classified in two major categories : the social insurance (or Bismarckian) model and the national (or Beveridgian) model. These models share two characteristics : the universality of the coverage offered and, given that they are compulsory, the principle that funding is based on the insuree’s contributive ability and not on the estimated level of risk. However they differ owing to the underlying tax base : the first relies on earned income alone whereas the second draws taxes from all sources of income. They also differ with respect to governance : the social insurance model involves management by organizations under the oversight of public authorities whereas the national model entails state management. Created by order in 1945, the French welfare state has, as it evolved, increasingly shifted toward a Beveridgian rationale with the state exercising ever more control over the three-party system of management set up after World War II."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
31 => Essec\Faculty\Model\Contribution {#2418
#_index: "academ_contributions"
#_id: "1763"
#_source: array:18 [
"id" => "1763"
"slug" => "length-and-cost-of-hospital-stay-of-radioiodine-ablation-in-thyroid-cancer-patients-comparison-between-preparation-with-thyroid-hormone-withdrawal-and-thyrogen"
"yearMonth" => "2008-08"
"year" => "2008"
"title" => "Length and Cost of Hospital Stay of Radioiodine Ablation in Thyroid Cancer Patients: Comparison between Preparation with Thyroid Hormone Withdrawal and Thyrogen"
"description" => "BORGET, I., REMY, H., CHEVALIER, J., RICARD, M., ALLYN, M. et DE POUVOURVILLE, G. (2008). Length and Cost of Hospital Stay of Radioiodine Ablation in Thyroid Cancer Patients: Comparison between Preparation with Thyroid Hormone Withdrawal and Thyrogen. <i>European Journal of Nuclear Medicine and Molecular Imaging</i>, 35(8), pp. 1457-1463."
"authors" => array:6 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BORGET I."
]
2 => array:1 [
"name" => "REMY H."
]
3 => array:1 [
"name" => "CHEVALIER J."
]
4 => array:1 [
"name" => "RICARD M."
]
5 => array:1 [
"name" => "ALLYN M."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "1457-1463"
"volume" => "35"
"number" => "8"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'étude a montré l'impact sur la durée de séjour et le coût de l'utilisation du Thyrogène pour stimuler l'hormon,e thyroidienne au cours d'une abalation par exposition à l'iode radioactif."
"en" => """
Treatment of thyroid cancer consists of thyroidectomy\n
and radioiodine ablation following thyroid-stimulating\n
hormone (TSH) stimulation. Similar ablation rates were\n
obtained with either thyroid hormone withdrawal (THW) or\n
rhTSH. But with rhTSH, the elimination of radioiodine is\n
more rapid, thus reducing its whole-body retention and\n
potentially resulting in a shorter hospital stay. The aim of this study was to assess the financial impact of a reduced length of hospital stay with the use of rhTSH.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
32 => Essec\Faculty\Model\Contribution {#2419
#_index: "academ_contributions"
#_id: "1824"
#_source: array:18 [
"id" => "1824"
"slug" => "les-hopitaux-francais-face-au-paiement-prospectif-au-cas-la-mise-en-oeuvre-de-la-tarification-a-lactivite"
"yearMonth" => "2009-03"
"year" => "2009"
"title" => "Les hôpitaux français face au paiement prospectif au cas. La mise en œuvre de la tarification à l'activité"
"description" => "PUYOU DE POUVOURVILLE, G. (2009). Les hôpitaux français face au paiement prospectif au cas. La mise en œuvre de la tarification à l'activité. <i>Revue Economique</i>, 60(2), pp. 457-470."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "457-470"
"volume" => "60"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Depuis 2004, les établissements hospitaliers publics et privés sont assujettis à un mode de paiement prospectif au cas fondé sur une nomenclature de production importée des États-Unis, le Groupe homogène de malades. L’analyse comparative avec l’expérience nord-américaine montre que le modèle français, sous la forme actuelle de la tarification à l’activité (T2A), s’inscrit dans une contrainte budgétaire globale et que les mécanismes existants de planification de l’offre limite l’autonomie stratégique des établissements. Par ailleurs, le modèle associe des aspects prospectifs et rétrospectifs qui limitent l’incitation à la réduction des coûts. Au final, le modèle français s’apparente plus à un modèle de régulation administrée par les tarifs de l’activité et de la productivité des établissements qu’à un modèle de concurrence par comparaison mis en place aux États-Unis par le programme Medicare. Les conséquences de ce modèle, en termes d’allocation des ressources en France, sont analysées à la lumière d’une sélection de travaux théoriques et empiriques sur les incitations économiques induites par le paiement prospectif au cas."
"en" => "Since 2004, French public and private hospitals are submitted to a prospective per-case based payment system based on a drg like classification scheme. A comparative analysis with the Medicare prospective payment scheme shows that the implementation of the so-called Activity Based Payment Scheme (T2A) is embedded in a national expenditure cap and planning regulations which restrict the strategic autonomy of providers. Moreover, the system blends retrospective and prospective elements which limit the incentive to reduce unit costs. Altogether, the French model is closer to regulation with fixed rates under planning constraints than to the initial “yardstick competition model” that was implemented by Medicare in the usa. The consequences of the French model on resource allocation are then discussed using a selection of theoretical and empirical contributions on the incentive effects of prospective per case payment."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
33 => Essec\Faculty\Model\Contribution {#2420
#_index: "academ_contributions"
#_id: "2071"
#_source: array:18 [
"id" => "2071"
"slug" => "modeling-of-the-impact-on-health-outcomes-of-the-use-of-dabigatran-in-patients-with-atrial-fibrillation"
"yearMonth" => "2013-10"
"year" => "2013"
"title" => "Modeling of the Impact on Health Outcomes of the Use of Dabigatran in Patients with Atrial Fibrillation"
"description" => "CHEVALIER, J., GIROUD, M. et PUYOU DE POUVOURVILLE, G. (2013). Modeling of the Impact on Health Outcomes of the Use of Dabigatran in Patients with Atrial Fibrillation. <i>Cerebrovascular Diseases</i>, 35(4), pp. 320-326."
"authors" => array:3 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "CHEVALIER J."
]
2 => array:1 [
"name" => "GIROUD M."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://www.karger.com/Article/Abstract/347074"
"publicationInfo" => array:3 [
"pages" => "320-326"
"volume" => "35"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'étude a simulé le nombre d'évènements cérébro-vasculaires évités chez les patients souffrant de fibrillation auriculaire et sous traitement d'anticoagulation par les nouvelles classes de médicaments, comparées aux anti-vitamines K."
"en" => "The paper examines through modeling the number of events avoided with anticoagulation therapy with new drugs versus VKAs for patients with atrial fibrillation, in the French context."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
34 => Essec\Faculty\Model\Contribution {#2421
#_index: "academ_contributions"
#_id: "3483"
#_source: array:18 [
"id" => "3483"
"slug" => "conclusions-the-global-diffusion-of-casemix"
"yearMonth" => "2008-12"
"year" => "2008"
"title" => "Conclusions: The Global Diffusion of Casemix"
"description" => "D'AUNNO, T., KIMBERLY, J. et PUYOU DE POUVOURVILLE, G. (2008). Conclusions: The Global Diffusion of Casemix. Dans: <i>The Globalization of Managerial Innovation in Health Care</i>. 1st ed. Cambridge University Press, pp. 346-372."
"authors" => array:3 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "D'AUNNO T."
]
2 => array:1 [
"name" => "KIMBERLY J."
]
]
"ouvrage" => "The Globalization of Managerial Innovation in Health Care"
"keywords" => []
"updatedAt" => "2021-09-06 14:06:32"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "346-372"
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Chapitres"
"en" => "Book chapters"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Le chapitre présente une synthèse de 15 études de cas nationaux portant sur la diffusion des Diagnosis Related Groups en matière de gestion hospitalière. Il met l'accent sur le rôle du contexte national, les contraintes techniques inhérents à chaque pays, la pression financière, le rôle des différentes parties prenants, pour expliquer la diffusion de cette innovation."
"en" => "The conclusive chapter of this book points out to the main factors that have impacted the diffusion of Diagnosis Related Groups in 15 countries. Emphasis is put on national contexts, technical barriers, financial pressure and the role of the different stakeholders to explain variability in patterns of adoption."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
35 => Essec\Faculty\Model\Contribution {#2422
#_index: "academ_contributions"
#_id: "3781"
#_source: array:18 [
"id" => "3781"
"slug" => "la-distribution-du-medicament-en-france"
"yearMonth" => "2009-06"
"year" => "2009"
"title" => "La distribution du médicament en France"
"description" => "PUYOU DE POUVOURVILLE, G., CONTI, C. et BIBAULT, E. (2009). La distribution du médicament en France. Dans: <i>Traité d'économie et de gestion de la santé</i>. 1st ed. Presses de Sciences Po, pp. 427-434."
"authors" => array:3 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "CONTI C."
]
2 => array:1 [
"name" => "BIBAULT E."
]
]
"ouvrage" => "Traité d'économie et de gestion de la santé"
"keywords" => []
"updatedAt" => "2021-09-06 14:06:32"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "427-434"
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Chapitres"
"en" => "Book chapters"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Le chapitre présente les canaux de distribution des médicaments en France et analyse les tendances d'évolution."
"en" => "The chapter focuses on the distribution channels of drugs in France and proposes a prospective analysis of future trends."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
36 => Essec\Faculty\Model\Contribution {#2423
#_index: "academ_contributions"
#_id: "3860"
#_source: array:18 [
"id" => "3860"
"slug" => "le-financement-des-hopitaux"
"yearMonth" => "2009-06"
"year" => "2009"
"title" => "Le financement des hôpitaux"
"description" => "PUYOU DE POUVOURVILLE, G. (2009). Le financement des hôpitaux. Dans: <i>Traité d'économie et de gestion de la santé</i>. 1st ed. Presses de Sciences Po, pp. 269-274."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => "Traité d'économie et de gestion de la santé"
"keywords" => []
"updatedAt" => "2021-09-06 14:06:32"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "269-274"
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Chapitres"
"en" => "Book chapters"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Le chapitre présente les principes d'un financement efficient des établissements hospitaliers et discute les principaux modes utilisés dans les pays développés à la lumière de ces principes."
"en" => "The chapter proposes guiding principles of efficient funding of hospitals, and discusses the characteristics of existing models in developed countries."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
37 => Essec\Faculty\Model\Contribution {#2424
#_index: "academ_contributions"
#_id: "3890"
#_source: array:18 [
"id" => "3890"
"slug" => "leconomie-de-la-sante-perimetre-et-questions-de-recherche"
"yearMonth" => "2009-06"
"year" => "2009"
"title" => "L'économie de la santé : périmètre et questions de recherche"
"description" => "PUYOU DE POUVOURVILLE, G. (2009). L'économie de la santé : périmètre et questions de recherche. Dans: <i>Traité d'économie et de gestion de la santé</i>. 1st ed. Presses de Sciences Po, pp. 15-24."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => "Traité d'économie et de gestion de la santé"
"keywords" => []
"updatedAt" => "2021-09-06 14:06:32"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "15-24"
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Chapitres"
"en" => "Book chapters"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Le chapitre présente une perspective globale des travaux de recherche en économie de la santé et dégage des pistes de recherche pour le futur."
"en" => "The chapter is an overall introduction to research questions in health economics and proposes future research issues."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
38 => Essec\Faculty\Model\Contribution {#2425
#_index: "academ_contributions"
#_id: "3910"
#_source: array:18 [
"id" => "3910"
"slug" => "les-consequences-economiques-des-droits-des-malades"
"yearMonth" => "2007-06"
"year" => "2007"
"title" => "Les conséquences économiques des droits des malades"
"description" => "PUYOU DE POUVOURVILLE, G. (2007). Les conséquences économiques des droits des malades. Dans: <i>Les droits des malades et des usagers du système de santé, une législature plus tard</i>. 1st ed. Presses de Sciences Po, pp. 53-58."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => "Les droits des malades et des usagers du système de santé, une législature plus tard"
"keywords" => []
"updatedAt" => "2021-09-06 14:06:32"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "53-58"
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Chapitres"
"en" => "Book chapters"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Une part importante de la loi du 4 mars 2002 sur les droits des patients a été consacrée au droit à l'accès à l'information des patients par les professionnels de santé, au recueil de leur consentement éclairé et donc à l'exercice de leur liberté de choix face aux alternatives proposés. L'objectif de la présentation a été de présenter le point de vue de l'économiste sur les dispositions de la loi."
"en" => "Une part importante de la loi du 4 mars 2002 sur les droits des patients a été consacrée au droit à l'accès à l'information des patients par les professionnels de santé, au recueil de leur consentement éclairé et donc à l'exercice de leur liberté de choix face aux alternatives proposés. L'objectif de la présentation a été de présenter le point de vue de l'économiste sur les dispositions de la loi."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
39 => Essec\Faculty\Model\Contribution {#2426
#_index: "academ_contributions"
#_id: "3964"
#_source: array:18 [
"id" => "3964"
"slug" => "lindustrie-pharmaceutique-en-france"
"yearMonth" => "2009-06"
"year" => "2009"
"title" => "L'industrie pharmaceutique en France"
"description" => "PUYOU DE POUVOURVILLE, G., BRAS, P.L. et TABUTEAU, D. (2009). L'industrie pharmaceutique en France. Dans: <i>Traité d'économie et de gestion de la santé</i>. 1st ed. Presses de Sciences Po, pp. 415-426."
"authors" => array:3 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BRAS P.-L."
]
2 => array:1 [
"name" => "TABUTEAU D."
]
]
"ouvrage" => "Traité d'économie et de gestion de la santé"
"keywords" => []
"updatedAt" => "2021-09-06 14:06:32"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "415-426"
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Chapitres"
"en" => "Book chapters"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Le chapitre présente la dynamique industrielle et économique de l'industrie pharmaceutique en France."
"en" => "This chapter deals with the dynamics of the drug industry in France."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
40 => Essec\Faculty\Model\Contribution {#2427
#_index: "academ_contributions"
#_id: "3977"
#_source: array:18 [
"id" => "3977"
"slug" => "lorganisation-des-soins"
"yearMonth" => "2009-06"
"year" => "2009"
"title" => "L'organisation des soins"
"description" => "PUYOU DE POUVOURVILLE, G. (2009). L'organisation des soins. Dans: <i>Traité d'économie et de gestion de la santé</i>. 1st ed. Presses de Sciences Po, pp. 401-406."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => "Traité d'économie et de gestion de la santé"
"keywords" => []
"updatedAt" => "2021-09-06 14:06:32"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "401-406"
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Chapitres"
"en" => "Book chapters"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Le chapitre analyse les caractéristiques structurels des services de santé en montrant quels modes de coordination économiques sont requis pour un fonctionnement optimal des services."
"en" => "The chapter analyses the main structural characteristics of health care delivery and the required economic coordination modes to achieve the efficiency of services."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
41 => Essec\Faculty\Model\Contribution {#2428
#_index: "academ_contributions"
#_id: "525"
#_source: array:18 [
"id" => "525"
"slug" => "a-comparative-analysis-of-two-contrasting-european-approaches-for-rewarding-the-value-added-by-drugs-for-cancer-england-versus-france"
"yearMonth" => "2014-05"
"year" => "2014"
"title" => "A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France"
"description" => "DRUMMOND, M., PUYOU DE POUVOURVILLE, G., JONES, E., HAIG, J., SABA, G. et CAWSTON, H. (2014). A Comparative Analysis of Two Contrasting European Approaches for Rewarding the Value Added by Drugs for Cancer: England Versus France. <i>Pharmacoeconomics</i>, 32(5), pp. 509-520."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "DRUMMOND M."
]
2 => array:1 [
"name" => "JONES E."
]
3 => array:1 [
"name" => "HAIG J."
]
4 => array:1 [
"name" => "SABA G."
]
5 => array:1 [
"name" => "CAWSTON H."
]
]
"ouvrage" => ""
"keywords" => array:5 [
0 => "National Health Service"
1 => "Incremental Cost"
2 => "Evidence Review Group"
3 => "Technology Appraisal"
4 => "Appraisal Committee"
]
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://link.springer.com/article/10.1007%2Fs40273-014-0144-z"
"publicationInfo" => array:3 [
"pages" => "509-520"
"volume" => "32"
"number" => "5"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Within Europe, contrasting approaches have emerged for rewarding the value added by new drugs. In Ireland, The Netherlands, Sweden and the UK, the price of, and access to, a new drug has to be justified by the health gain it delivers compared with current therapy, typically expressed in quality-adjusted life-years (QALYs) gained. By contrast, in France and Germany, the assessment of added benefit is expressed on an ordinal scale, based on an assessment of the clinical outcomes as compared with existing care. This assessment then influences price negotiations. The objective of this paper is to assess the pros and cons of each approach, both in terms of the assessments they produce and the efficiency and practical feasibility of the process."
"en" => "Within Europe, contrasting approaches have emerged for rewarding the value added by new drugs. In Ireland, The Netherlands, Sweden and the UK, the price of, and access to, a new drug has to be justified by the health gain it delivers compared with current therapy, typically expressed in quality-adjusted life-years (QALYs) gained. By contrast, in France and Germany, the assessment of added benefit is expressed on an ordinal scale, based on an assessment of the clinical outcomes as compared with existing care. This assessment then influences price negotiations. The objective of this paper is to assess the pros and cons of each approach, both in terms of the assessments they produce and the efficiency and practical feasibility of the process."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
42 => Essec\Faculty\Model\Contribution {#2429
#_index: "academ_contributions"
#_id: "549"
#_source: array:18 [
"id" => "549"
"slug" => "a-markov-model-simulation-of-the-impact-of-treatment-persistence-in-postmenopausal-osteoporosis"
"yearMonth" => "2009-01"
"year" => "2009"
"title" => "A Markov Model Simulation of the Impact of Treatment Persistence in Postmenopausal Osteoporosis"
"description" => "COTTE, F.E., FAUTREL, B. et PUYOU DE POUVOURVILLE, G. (2009). A Markov Model Simulation of the Impact of Treatment Persistence in Postmenopausal Osteoporosis. <i>Medical Decision Making</i>, 29(1), pp. 125-139."
"authors" => array:3 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "COTTE F.-E."
]
2 => array:1 [
"name" => "FAUTREL B."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "125-139"
"volume" => "29"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'ostéoporose est une maladie fréquente du squelette qui fragilise les os et augmente le risque de fracture. Les biphosphonates ont démontré leur efficacité dans la prévention fracturaire, mais cette efficacité est limitée par la mauvaise observance au traitement des patients. Unmodèle a été développé pour estimer le gain d'efficacité lié à la disponibilité dun traitement favorisant l'observance."
"en" => "Osteoporosis is a common disorder of the skeleton that increases bone fragility and the risk of fracture. Bisphosphonates have become the reference treatment for postmenopausal osteoporosis because of their proven efficacy in reducing fracture rates. The effectiveness of bisphosphonates is, however, limited by poor treatment adherence and persistence with treatment. A model has been designed to simulate the impact of improving persistence rates on treatment effectiveness."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
43 => Essec\Faculty\Model\Contribution {#2430
#_index: "academ_contributions"
#_id: "1178"
#_source: array:18 [
"id" => "1178"
"slug" => "exploitation-seconde-de-la-base-de-letude-nationale-de-couts-enc"
"yearMonth" => "2009-09"
"year" => "2009"
"title" => "Exploitation seconde de la base de l'Etude nationale de coûts (ENC)"
"description" => "PUYOU DE POUVOURVILLE, G. (2009). Exploitation seconde de la base de l'Etude nationale de coûts (ENC). <i>Dossiers Solidarité et santé</i>, (9), pp. 2-6."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "2-6"
"volume" => null
"number" => "9"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => null
"en" => null
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
44 => Essec\Faculty\Model\Contribution {#2431
#_index: "academ_contributions"
#_id: "595"
#_source: array:18 [
"id" => "595"
"slug" => "access-to-care-socioeconomic-deprivation-and-colon-cancer-survival"
"yearMonth" => "2008-05"
"year" => "2008"
"title" => "Access to Care, Socioeconomic Deprivation and Colon Cancer Survival"
"description" => "DEJARDIN, O., BOUVIER, A.M., FAIVRE, J., BOUTREUX, S., PUYOU DE POUVOURVILLE, G. et LAUNOY, G. (2008). Access to Care, Socioeconomic Deprivation and Colon Cancer Survival. <i>Alimentary Pharmacology & Therapeutics</i>, 27(10), pp. 940-949."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "DEJARDIN O."
]
2 => array:1 [
"name" => "BOUVIER A.M."
]
3 => array:1 [
"name" => "FAIVRE J."
]
4 => array:1 [
"name" => "BOUTREUX S."
]
5 => array:1 [
"name" => "LAUNOY G."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-07-13 14:29:58"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "940-949"
"volume" => "27"
"number" => "10"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'influence des facteurs socio-économiques sur la survie des patients cancéreux a été établie par de nombreuses études, le pronostic étant systématique plus péjoratif pour les patients à statut précaire. L'étude a aznalysé l'impact de la distance d'accès ax soins et de la précarité sur la survie des cancers du colon en France."
"en" => "The influence of socioeconomic environment on cancer survival has been established in numerous studies in the EU and the US, prognosis being constantly poorer for the most underprivileged patients. The aim was to investigate the influence of distance to care centre and deprivation on colon cancer survival in France."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
45 => Essec\Faculty\Model\Contribution {#2432
#_index: "academ_contributions"
#_id: "596"
#_source: array:18 [
"id" => "596"
"slug" => "access-to-innovation-is-there-a-difference-in-the-use-of-expensive-anticancer-drugs-between-french-hospitals"
"yearMonth" => "2014-06"
"year" => "2014"
"title" => "Access to Innovation: Is there a Difference in the Use of Expensive Anticancer Drugs Between French Hospitals?"
"description" => "BONASTRE, J., CHEVALIER, J., VAN DER LAANC, C., DELIBESC, M. et PUYOU DE POUVOURVILLE, G. (2014). Access to Innovation: Is there a Difference in the Use of Expensive Anticancer Drugs Between French Hospitals? <i>Health Policy</i>, 116(2&3), pp. 162-169."
"authors" => array:5 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BONASTRE Julia"
]
2 => array:1 [
"name" => "CHEVALIER Julie"
]
3 => array:1 [
"name" => "VAN DER LAANC Chantal"
]
4 => array:1 [
"name" => "DELIBESC Michel"
]
]
"ouvrage" => ""
"keywords" => array:4 [
0 => "Hospitals"
1 => "Patient access"
2 => "Innovation"
3 => "Anticancer drugs"
]
"updatedAt" => "2021-02-09 11:31:52"
"publicationUrl" => "https://www.sciencedirect.com/science/article/abs/pii/S0168851013003035"
"publicationInfo" => array:3 [
"pages" => "162-169"
"volume" => "116"
"number" => "2&3"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "In DRG-based hospital payment systems, expensive drugs are often funded separately. In France, specific expensive drugs (including a large proportion of anticancer drugs) are fully reimbursed up to national reimbursement tariffs to ensure equity of access. Our objective was to analyze the use of expensive anticancer drugs in public and private hospitals, and between regions. We had access to sales per anticancer drug and per hospital in the year2008. We used a multilevel model to study the variation in the mean expenditure of expensive anticancer drugs per course of chemotherapy and per hospital. The mean expenditure per course of chemotherapy was D 922 [95% CI: 890–954]. At the hospital level, specialization in chemotherapies for breast cancers was associated with a higher expenditure of anticancer drugs per course for those hospitals with the highest proportion of cancers at this site. There were no differences in the use of expensive drugs between the private and the public hospital sector after controlling for case mix. There were no differences between the mean expenditures per region. The absence of disparities in the use of expensive anti-cancer drugs between hospitals and regions may indicate that exempting chemotherapies from DRG-based payments and providing additional reimbursement for these drugs has been successful at ensuring equal access to care."
"en" => "In DRG-based hospital payment systems, expensive drugs are often funded separately. In France, specific expensive drugs (including a large proportion of anticancer drugs) are fully reimbursed up to national reimbursement tariffs to ensure equity of access. Our objective was to analyze the use of expensive anticancer drugs in public and private hospitals, and between regions. We had access to sales per anticancer drug and per hospital in the year2008. We used a multilevel model to study the variation in the mean expenditure of expensive anticancer drugs per course of chemotherapy and per hospital. The mean expenditure per course of chemotherapy was D 922 [95% CI: 890–954]. At the hospital level, specialization in chemotherapies for breast cancers was associated with a higher expenditure of anticancer drugs per course for those hospitals with the highest proportion of cancers at this site. There were no differences in the use of expensive drugs between the private and the public hospital sector after controlling for case mix. There were no differences between the mean expenditures per region. The absence of disparities in the use of expensive anti-cancer drugs between hospitals and regions may indicate that exempting chemotherapies from DRG-based payments and providing additional reimbursement for these drugs has been successful at ensuring equal access to care."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
46 => Essec\Faculty\Model\Contribution {#2433
#_index: "academ_contributions"
#_id: "657"
#_source: array:18 [
"id" => "657"
"slug" => "anticoagulants-daction-directe-une-revue-de-la-litterature-des-etudes-cout-efficacite-en-europe"
"yearMonth" => "2016-02"
"year" => "2016"
"title" => "Anticoagulants d'action directe: une revue de la littérature des études coût/efficacité en Europe"
"description" => "PUYOU DE POUVOURVILLE, G. (2016). Anticoagulants d'action directe: une revue de la littérature des études coût/efficacité en Europe. <i>Archives of Cardiovascular Diseases Supplements</i>, 8(2), pp. 180-191."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => array:4 [
0 => "Cost-effectiveness"
1 => "Atrial fibrillation"
2 => "Oral anticoagulants"
3 => "International comparison"
]
"updatedAt" => "2021-07-13 14:30:00"
"publicationUrl" => "https://www.sciencedirect.com/science/article/pii/S1878648016303330"
"publicationInfo" => array:3 [
"pages" => "180-191"
"volume" => "8"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => """
Contexte. Les résultats des études coût/efficacité des innovations thérapeutiques sont devenus un critère de référence dans la plupart des pays développés. Lorsque de nouveaux traitements proposent des alternatives à des traitements de référence éprouvés mais très peu coûteux, les payeurs anticipent un impact budgétaire important et cherchent à connaître la valeur supplémentaire apportée par ceux-ci. \n
Objectif. L’objectif de cette étude a été de présenter les différents modèles élaborés autour des trois premiers anticoagulants oraux directs (AOD), le dabigatran, le rivaroxaban et l’apixaban, ainsi que leurs résultats dans l’indication de prévention des accidents vasculaires cérébraux (AVC) pour les patients souffrant de fibrillation atriale (FA). Le périmètre de l’étude a été limité aux pays européens et au Canada, tous pays disposant d’un système de couverture universelle des dépenses de soins. \n
Méthode. À partir d’une revue de la littérature, les caractéristiques générales des études et leurs principaux résultats ont été présentés et comparés. \n
Résultats. Dix-neuf études ont été sélectionnées, couvrant onze pays européens et le Canada, comparant chacune des molécules aux antivitamines K (AVK) et entre elles. Toutes les études ont calculé un ratio de coût par QALY. La majorité des résultats (34/46) se situe au-dessous de 20 000 € par Quality-Adjusted Life Year (QALY). L’apixaban et le dabigatran à la dose de 150 mg bid présentaient les ratios les plus favorables. \n
Conclusion. Les nouveaux traitements présentent des ratios coût/efficacité acceptables en Europe et au Canada, au regard des standards habituels. Au-delà des différences intrinsèques entre les différents systèmes de santé, la diversité des résultats témoigne cependant d’une nécessaire standardisation des études à des fins de comparabilité.
"""
"en" => """
Background. The cost-effectiveness analysis of therapeutic innovations has become a reference for decision makers in developed countries. When new treatments are available as alternatives to existing well established and cheap treatments, payers anticipate a major budget impact and will assess the extra benefit for society for extra Euros spent. \n
Aims. This study aimed at presenting the different published results of cost-effectiveness analyses performed for the three first new oral anticoagulants, dabigatran, rivaroxaban and apixaban, for the prevention of strokes for patients with atrial fibrillation. The study covered European countries and Canada, which all propose universal coverage for healthcare expenditures. \n
Methods. A literature review was performed. The general characteristics and main results of selected studies were presented and compared. Results. Nineteen studies were selected, covering 11 European countries and Canada. All studies have performed the estimation of a cost per QALY. The majority of the results (34/46) were under €20,000 per QALY. Apixaban and dabigatran 150mg bid presented with the most favourable results. \n
Conclusion. New oral anticoagulants appear to have an acceptable cost-effectiveness ratio for European countries and Canada considering usual standards. Nevertheless, beyond intrinsic differences between healthcare systems, the observed variability of results strongly suggest a need for a standardisation of models used across countries.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
47 => Essec\Faculty\Model\Contribution {#2434
#_index: "academ_contributions"
#_id: "680"
#_source: array:18 [
"id" => "680"
"slug" => "assessment-of-the-cost-of-fine-needle-aspiration-cytology-as-a-diagnostic-tool-in-patients-with-thyroid-nodules"
"yearMonth" => "2008-05"
"year" => "2008"
"title" => "Assessment of the Cost of Fine-needle Aspiration Cytology as a Diagnostic Tool in Patients with Thyroid Nodules"
"description" => "BORGET, I., VIELH, P., LEBOULLEUX, S., ALLYN, M., IACOBELLI, S. et DE POUVOURVILLE, G. (2008). Assessment of the Cost of Fine-needle Aspiration Cytology as a Diagnostic Tool in Patients with Thyroid Nodules. <i>American Journal of Clinical Pathology</i>, 129(5), pp. 763-771."
"authors" => array:6 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BORGET I."
]
2 => array:1 [
"name" => "VIELH P."
]
3 => array:1 [
"name" => "LEBOULLEUX S."
]
4 => array:1 [
"name" => "ALLYN M."
]
5 => array:1 [
"name" => "IACOBELLI S."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "763-771"
"volume" => "129"
"number" => "5"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Le prélèvement cytologique par aiguille fine est l'outil diagnostique de référence pour lesp atien,ts avec nodules thyroidiens. L'avantage du diagnostic est d'éviter des interventions chirurgicales; l'étude a visé à évaluerl e co^put complet de cette technique de diagnostic, en prenant en compte sa valeur prédictive."
"en" => "Fine-needle aspiration cytology (FNAC) is the reference diagnostic tool in patients with thyroid nodules. Because the true diagnosis is based on histopathologic findings, the final diagnosis of nodules not operated on is postponed, impacting the cost. We aimed to determine the cost of FNAC by taking account of diagnostic mistakes, failures, and follow-up of patients who did not have surgery."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
48 => Essec\Faculty\Model\Contribution {#2435
#_index: "academ_contributions"
#_id: "755"
#_source: array:18 [
"id" => "755"
"slug" => "capeco-cost-evaluation-of-community-acquired-pneumonia-managed-in-primary-care"
"yearMonth" => "2016-04"
"year" => "2016"
"title" => "CAPECO: Cost Evaluation of Community Acquired Pneumonia Managed in Primary Care"
"description" => "PERSONNE, V., CHEVALIER, J., BUFFEL DU VAURE, C., PARTOUCHE, H., GILBERG, S. et DE POUVOURVILLE, G. (2016). CAPECO: Cost Evaluation of Community Acquired Pneumonia Managed in Primary Care. <i>Vaccine</i>, 19(34), pp. 2275-2280."
"authors" => array:6 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "PERSONNE V."
]
2 => array:1 [
"name" => "CHEVALIER J."
]
3 => array:1 [
"name" => "BUFFEL DU VAURE C."
]
4 => array:1 [
"name" => "PARTOUCHE H."
]
5 => array:1 [
"name" => "GILBERG S."
]
]
"ouvrage" => ""
"keywords" => array:6 [
0 => "Costs"
1 => "Community acquired pneumonia"
2 => "Pneumonia"
3 => "Disease burden"
4 => "Primary care"
5 => "Incidence"
]
"updatedAt" => "2021-07-13 14:30:03"
"publicationUrl" => "https://www.sciencedirect.com/science/article/pii/S0264410X16003030?via%3Dihub"
"publicationInfo" => array:3 [
"pages" => "2275-2280"
"volume" => "19"
"number" => "34"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'objectif de l'article est l'estimation rétrospective du coût de la prise en charge de la pneumonie communautaire en milieu ambulatoire en Franc, à partir des données d'une enquête prospective en médecine générale en France."
"en" => """
Background: Estimating the economic burden of community acquired pneumonia (CAP) managed in ambulatory setting is needed in France since no data are available.\n
Method: A retrospective study (CAPECO) was conducted based on a prospective French study describing patients with suspected CAP managed in primary care (CAPA). The aim of the CAPECO study was to estimate and explain medical costs of a disease episode in CAP patients only followed in ambulatory care and in hospitalised patients. Primary endpoints were the direct medical costs, impact on productivity and costs of incident CAP over one year. Secondary endpoint was to describe predictive factors of costs, hospital admission and stay length.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
49 => Essec\Faculty\Model\Contribution {#2436
#_index: "academ_contributions"
#_id: "811"
#_source: array:18 [
"id" => "811"
"slug" => "comment-ameliorer-le-suivi-des-avk-et-pour-quel-cout"
"yearMonth" => "2016-01"
"year" => "2016"
"title" => "Comment Améliorer le Suivi des AVK et pour quel Coût?"
"description" => "PUYOU DE POUVOURVILLE, G. (2016). Comment Améliorer le Suivi des AVK et pour quel Coût? <i>Archives of Cardiovascular Diseases Supplements</i>, 8(2), pp. 169-173."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "VKA"
1 => "Time to Target"
2 => "Cost"
]
"updatedAt" => "2021-07-13 14:30:05"
"publicationUrl" => "https://www.sciencedirect.com/science/article/pii/S1878648016303317"
"publicationInfo" => array:3 [
"pages" => "169-173"
"volume" => "8"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => """
Contexte : Dans l'analyse de l'efficience des anticoagulants oraux directs (AOD), l'estimation du coût complet de traitement par les antivitamines K (AVK) est un paramètre clé des modèles, puisqu'il sert de base au calcul du différentiel de coût des traitements. On sait également qu'en France, ce suivi n'est pas optimal. Or, ce coût exact est mal connu, ainsi que son efficacité, mesurée en temps passé à la cible. De ce fait, l'efficacité en vie réelle des AVK peut être moindre que celle observée dans les essais cliniques comparateurs. \n
Objectifs : On a estimé quel serait l'investissement à réaliser en France et selon quel modèle d'organisation pour améliorer le suivi des AVK et, partant, leur efficacité préventive. On a estimé ensuite quelle serait la perte d'efficacité théorique AVK si le temps passé à la cible était de 50 %, taux rapporté dans le contexte français. \n
Méthode : Dans les deux cas, la méthode utilisée est la construction d'un modèle hypothétique plausible et de données de la littérature. \n
Résultats : En organisant un suivi systématique fondé sur l'association des médecins généralistes, des infirmières libérales et des laboratoires d'analyse, le coût supplémentaire à consentir pour atteindre un temps passé à la cible proche de celui observé dans les essais cliniques des AOD serait de 48 € ou de 103 € par an selon le modèle choisi, soit un coût supérieur à celui estimé sans optimisation de traitement de 17 à 39 %. La perte d'efficacité des AVK avec un temps moyen passé à la cible de 50 % a été estimée à 16,7 %, en termes de nombre d'accidents vasculaires cérébraux (AVC) évités par an. \n
Conclusion : Dans le calcul de l'efficience des AOD, il importe de prendre en compte, non le coût observé du suivi sous AVK, sous-optimal en France, mais l'investissement qu'il faut consentir pour obtenir un temps passé à la cible thérapeutique similaire à celui des essais cliniques. À défaut, il faut corriger le taux observé dans les essais cliniques pour les patients sous AVK de la perte d'efficacité liée à un suivi sous-optimal.
"""
"en" => """
Background: When assessing the cost-effectiveness ratio of New Oral Anticoagulants vs VKA, the total cost of managing patients with VKA is a key parameter of the result, since it determines the cost-differential between the two treatments which will apply to all patients who are treated. In France, the management of patients with VKA is not optimal, with many publications estimating that average time to target is 50%. The actual cost of managing patients with VKAs is not well known, as well as its effectiveness in terms of Time to Target. \n
Objectives: To calculate what extra cost would be need in France for patients with VKA to reach the Time to Target observed in the clinical trials comparing them to NOAC; to estimate the loss of preventive effectiveness associated to an under-optimal management leading to a Time to Target of 50%. \n
Methods: Two hypothetical models were designed, based on plausible assumptions and literature review. \n
Results: Based on a strengthened coordination between general practitioners, laboratories and nurses, the extra cost per year needed to reach Time to Target similar to what was observed in the clinical trials of NOAC, would be €48 or €103 per year, according to the different organisational solutions. This extra cost would represent a relative increase of 17% to 39% relative to present sub-optimal management. If real life Time to Target was 50%, then this would represent a relative loss of preventive effectiveness of 16.7% of VKA compared to what was observed in clinical trials. \n
Conclusion: When estimating the cost-effectiveness of NOAC compared to VKA, one should consider the extra cost to be invested to reach a level of quality of the management of VKA similar as to what was observed in trials. If not, then one should consider modelling a lower effectiveness of VKA.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
50 => Essec\Faculty\Model\Contribution {#2437
#_index: "academ_contributions"
#_id: "889"
#_source: array:18 [
"id" => "889"
"slug" => "cost-of-non-persistence-with-oral-biphosphonates-in-post-menopausal-osteoporosis-treatment-in-france"
"yearMonth" => "2011-06"
"year" => "2011"
"title" => "Cost of Non-Persistence with Oral Biphosphonates in Post-Menopausal Osteoporosis Treatment in France"
"description" => "COTTE, F.E. et PUYOU DE POUVOURVILLE, G. (2011). Cost of Non-Persistence with Oral Biphosphonates in Post-Menopausal Osteoporosis Treatment in France. <i>BMC Health Services Research</i>, 151(11), pp. 1-10."
"authors" => array:2 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "COTTE F.-E."
]
]
"ouvrage" => ""
"keywords" => array:6 [
0 => "Osteoporosis"
1 => "Bisphosphonate"
2 => "Adherence"
3 => "Persistence"
4 => "Cost"
5 => "Modelling study"
]
"updatedAt" => "2021-02-02 16:16:18"
"publicationUrl" => "https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-11-151"
"publicationInfo" => array:3 [
"pages" => "1-10"
"volume" => "151"
"number" => "11"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Pendant la dernière décennie, les biphosphonates sont devenus le traitement de référence de l'ostéoporose. Cependant, de nombreuses études montrent que la persistance sous traitement est faible et diminue leur efficacité préventive. L'étude a estimé l'impact de cette faible persistance sur le coût de prise en charge de l'ostéoporose en France."
"en" => "During the last decade, oral biphosphonates (BP) became the most widely prescribed pharmacologic class for post-menopausal osteoporosis. However, many surveys revealed the important issue of poor persistence with those drugs resulting in a failure of treatment to reduce fracture risk sufficiently. Using a published Markov model, this study analyses the economic impact of non-persistence with biphosphonates in the context of the introduction of generics in France."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
51 => Essec\Faculty\Model\Contribution {#2438
#_index: "academ_contributions"
#_id: "890"
#_source: array:18 [
"id" => "890"
"slug" => "cost-effectiveness-analysis-of-aldosterone-blockade-with-eplerenone-in-patients-with-heart-failure-after-acute-myocardial-infarction-in-the-french-context-the-ephesus-study"
"yearMonth" => "2008-09"
"year" => "2008"
"title" => "Cost-effectiveness Analysis of Aldosterone Blockade with Eplerenone in Patients with Heart Failure after Acute Myocardial Infarction in the French Context: The EPHESUS Study"
"description" => "PUYOU DE POUVOURVILLE, G., SOLESSE, A. et BEILLAT, M. (2008). Cost-effectiveness Analysis of Aldosterone Blockade with Eplerenone in Patients with Heart Failure after Acute Myocardial Infarction in the French Context: The EPHESUS Study. <i>Archives of Cardiovascular Diseases</i>, 101(9), pp. 515-521."
"authors" => array:3 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "SOLESSE A."
]
2 => array:1 [
"name" => "BEILLAT M."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "515-521"
"volume" => "101"
"number" => "9"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L’essai EPHESUS a démontré l’efficacité d’éplérénone, un nouveau diurétique antagoniste de l’aldostérone, avec un traitement standard, comparé au traitement standard seul, dans la réduction de la mortalité et du taux de réhospitalisation cardiovasculaires chez des patients insuffisants cardiaques après infarctus aigu du myocarde. Le coût incrémental d’éplérénone par année de vie gagnée comparativement au traitement standard a été calculé en France."
"en" => """
The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) randomized clinical trial demonstrated the efficacy of eplerenone, a new aldosterone antagonist diuretic, with standard treatment versus standard treatment alone in the reduction of cardiovascular mortality and cardiovascular-related hospital readmissions for patients with heart failure after an acute myocardial infarction.We assessed the incremental cost per life-year saved of eplerenone in the French context\n
versus standard treatment.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
52 => Essec\Faculty\Model\Contribution {#2439
#_index: "academ_contributions"
#_id: "891"
#_source: array:18 [
"id" => "891"
"slug" => "cost-effectiveness-analysis-of-the-sapien-3-tavi-valve-compared-with-surgery-in-intermediate-risk-patients"
"yearMonth" => "2019-04"
"year" => "2019"
"title" => "Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients"
"description" => "GOODALL, G., LAMOTTE, M., RAMOS, S., MAUNOURY, F., PEJCHALOVA, B. et DE POUVOURVILLE, G. (2019). Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients. <i>Journal of Medical Economics</i>, 22(4), pp. 289-296."
"authors" => array:6 [
0 => array:3 [
"name" => "RAMOS Sofia"
"bid" => "B00683001"
"slug" => "ramos-sofia"
]
1 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
2 => array:1 [
"name" => "GOODALL G."
]
3 => array:1 [
"name" => "LAMOTTE M."
]
4 => array:1 [
"name" => "MAUNOURY F."
]
5 => array:1 [
"name" => "PEJCHALOVA B."
]
]
"ouvrage" => ""
"keywords" => array:7 [
0 => "Cost-effectiveness"
1 => "I10"
2 => "I39"
3 => "SAPIEN 3"
4 => "TAVI"
5 => "severe aortic stenosis"
6 => "transcatheter aortic valve"
]
"updatedAt" => "2023-03-15 13:14:13"
"publicationUrl" => "https://pubmed.ncbi.nlm.nih.gov/30547704/"
"publicationInfo" => array:3 [
"pages" => "289-296"
"volume" => "22"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'implantation par voie transcatherale de valves aortiques (TAVI) est devenue la technique de référence du traitement des sténoses aortiques sévères. L'étude évalue le coût et les bénéfices de l'utilisation de cette technique chres les patients présentant un risque intermédiaire, dans le contexte français."
"en" => "Transcatheter aortic valve implantation (TAVI) has become the therapy of choice for treating severe aortic stenosis in patients at high-risk for surgery or where it is considered too risky to attempt. We sought to evaluate the potential cost and clinical impact of TAVI in intermediate risk patients from a French collective perspective."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
53 => Essec\Faculty\Model\Contribution {#2440
#_index: "academ_contributions"
#_id: "892"
#_source: array:18 [
"id" => "892"
"slug" => "cost-effectiveness-of-intraperitoneal-chemohyperthermia-in-the-treatment-of-peritoneal-carcinomatosis-from-colorectal-cancer"
"yearMonth" => "2008-05"
"year" => "2008"
"title" => "Cost-effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer"
"description" => "BONASTRE, J., CHEVALIER, J., ELIAS, D., CLASSE, J.M., FERRON, G. et DE POUVOURVILLE, G. (2008). Cost-effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer. <i>Value in Health</i>, 11(3), pp. 347-353."
"authors" => array:6 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BONASTRE J."
]
2 => array:1 [
"name" => "CHEVALIER J."
]
3 => array:1 [
"name" => "ELIAS D."
]
4 => array:1 [
"name" => "CLASSE J.M."
]
5 => array:1 [
"name" => "FERRON G."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2020-12-17 17:55:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "347-353"
"volume" => "11"
"number" => "3"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Etude coût-efficacité de la chimiothérapie hyperthermique intrapéritonéale pour le traitement des carcinomes péritoneaux dans les cancers colo-rectaux en France."
"en" => "Compared to other treatments in oncology, intraperitoneal chemohyperthermia is ocst-effective for the treatment of peritoneal carcinomatosis for patients with colo-rectal cancer."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
54 => Essec\Faculty\Model\Contribution {#2441
#_index: "academ_contributions"
#_id: "12645"
#_source: array:18 [
"id" => "12645"
"slug" => "human-papillomavirus-hpv-vaccine-coverage-rates-vcrs-in-france-a-french-claims-data-study"
"yearMonth" => "2021-08"
"year" => "2021"
"title" => "Human papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study"
"description" => "DALON, F., MAJED, L., BELHASSEN, M., JACOUD, F., BÉRARD, M., LÉVY-BACHELOT, L. ... BALDAUF, J.J. (2021). Human papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study. <i>Vaccine</i>, 39(36), pp. 5129-5137."
"authors" => array:10 [
0 => array:3 [
"name" => "PUYOU de POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "DALON Faustine"
]
2 => array:1 [
"name" => "MAJED Laureen"
]
3 => array:1 [
"name" => "BELHASSEN Manon"
]
4 => array:1 [
"name" => "JACOUD Flore"
]
5 => array:1 [
"name" => "BÉRARD Marjorie"
]
6 => array:1 [
"name" => "LÉVY-BACHELOT Laurie"
]
7 => array:1 [
"name" => "ROUZIER Roman"
]
8 => array:1 [
"name" => "RAUDE Jocelyn"
]
9 => array:1 [
"name" => "BALDAUF Jean-Jacques"
]
]
"ouvrage" => ""
"keywords" => array:5 [
0 => "Human papillomavirus"
1 => "Vaccination coverage rate"
2 => "Claims database"
3 => "Full vaccination"
4 => "Partial vaccination"
]
"updatedAt" => "2023-01-27 01:00:40"
"publicationUrl" => "https://www.sciencedirect.com/science/article/pii/S0264410X21009452?via%3Dihub"
"publicationInfo" => array:3 [
"pages" => "5129-5137"
"volume" => "39"
"number" => "36"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Overall, the HPV VCR substantively increased between 2017 and 2018, which is positive evidence of the resumption of vaccination. Updates in 2022 should confirm these results."
"en" => "Overall, the HPV VCR substantively increased between 2017 and 2018, which is positive evidence of the resumption of vaccination. Updates in 2022 should confirm these results."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
55 => Essec\Faculty\Model\Contribution {#2442
#_index: "academ_contributions"
#_id: "12646"
#_source: array:18 [
"id" => "12646"
"slug" => "eliciting-health-state-utilities-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency-a-vignette-study-in-france"
"yearMonth" => "2021-07"
"year" => "2021"
"title" => "Eliciting Health State Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Vignette Study in France"
"description" => "SMITH, A.B., HANBURY, A., BEITIA ORTIZ DE ZARATE, I., HAMMES, F., PUYOU DE POUVOURVILLE, G. et BUESCH, K. (2021). Eliciting Health State Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Vignette Study in France. <i>Patient Related Outcome Measures</i>, 12, pp. 237-246."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "SMITH Adam B"
]
2 => array:1 [
"name" => "HANBURY Andria"
]
3 => array:1 [
"name" => "BEITIA ORTIZ DE ZARATE Igor"
]
4 => array:1 [
"name" => "HAMMES Florence"
]
5 => array:1 [
"name" => "BUESCH Katharina"
]
]
"ouvrage" => ""
"keywords" => array:4 [
0 => "AADC deficiency"
1 => "standard gamble"
2 => "time trade-off"
3 => "vignettes"
]
"updatedAt" => "2023-01-30 13:35:24"
"publicationUrl" => "https://doi.org/10.2147/PROM.S306228"
"publicationInfo" => array:3 [
"pages" => "237-246"
"volume" => "12"
"number" => ""
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Health-related quality of life (HRQoL) is difficult to measure in rare diseases, especially in paediatric populations, yet capturing HRQoL is critical to evaluating treatment, including the cost-effectiveness of treatments. Given the ultra-rare nature of AADC deficiency indirect elicitation of HRQoL data through proxy caregiver/parent ratings is not feasible. In these circumstances, HRQoL data may be derived through vignette studies using the general population. The aim of the study was to generate health utility values specific for France for AADC deficiency using vignettes."
"en" => "Health-related quality of life (HRQoL) is difficult to measure in rare diseases, especially in paediatric populations, yet capturing HRQoL is critical to evaluating treatment, including the cost-effectiveness of treatments. Given the ultra-rare nature of AADC deficiency indirect elicitation of HRQoL data through proxy caregiver/parent ratings is not feasible. In these circumstances, HRQoL data may be derived through vignette studies using the general population. The aim of the study was to generate health utility values specific for France for AADC deficiency using vignettes."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
56 => Essec\Faculty\Model\Contribution {#2443
#_index: "academ_contributions"
#_id: "12647"
#_source: array:18 [
"id" => "12647"
"slug" => "la-fabrication-du-prix-du-medicament"
"yearMonth" => "2021-06"
"year" => "2021"
"title" => "La fabrication du prix du médicament"
"description" => "PUYOU DE POUVOURVILLE, G. (2021). La fabrication du prix du médicament. Dans: Thomas Barnay, Anne-Laure Sanson, Bruno Ventelou eds. <i>Le système de santé français : aujourd'hui. Enjeux et défis</i>. 1st ed. ESKA."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => "Le système de santé français : aujourd'hui. Enjeux et défis"
"keywords" => []
"updatedAt" => "2023-02-02 15:50:52"
"publicationUrl" => "https://www.decitre.fr/ebooks/le-systeme-de-sante-francais-aujourd-hui-enjeux-et-defis-9782747231862_9782747231862_1.html"
"publicationInfo" => array:3 [
"pages" => ""
"volume" => "1"
"number" => "14"
]
"type" => array:2 [
"fr" => "Chapitres"
"en" => "Book chapters"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => ""
"en" => ""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
57 => Essec\Faculty\Model\Contribution {#2444
#_index: "academ_contributions"
#_id: "12648"
#_source: array:18 [
"id" => "12648"
"slug" => "trente-ans-de-depenses-de-sante-en-france"
"yearMonth" => "2021-09"
"year" => "2021"
"title" => "Trente ans de dépenses de santé en France"
"description" => "PUYOU DE POUVOURVILLE, G. (2021). Trente ans de dépenses de santé en France. Dans: René Demeleumeester, Jean-Calude Henrard, Bernadette Roussille, Patricia Siwek eds. <i>Trente ans d'évolution de la santé en France : À quoi ont servi les politiques de santé ?</i> 1st ed. Boulogne-Billancourt: Berger-Levrault, pp. 255-270."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => "Trente ans d'évolution de la santé en France : À quoi ont servi les politiques de santé ?"
"keywords" => []
"updatedAt" => "2023-02-01 15:14:53"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "255-270"
"volume" => "Les indispensables"
"number" => "4"
]
"type" => array:2 [
"fr" => "Chapitres"
"en" => "Book chapters"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => "France"
"en" => "France"
]
"abstract" => array:2 [
"fr" => ""
"en" => ""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
58 => Essec\Faculty\Model\Contribution {#2445
#_index: "academ_contributions"
#_id: "12649"
#_source: array:18 [
"id" => "12649"
"slug" => "trente-ans-dadministration-et-de-financement-du-systeme-de-soins"
"yearMonth" => "2021-09"
"year" => "2021"
"title" => "Trente ans d’administration et de financement du système de soins"
"description" => "PUYOU DE POUVOURVILLE, G. (2021). Trente ans d’administration et de financement du système de soins. Dans: René Demeleumeester, Jean-Calude-Henrard, Bernadette Roussille, Patricia Siwek eds. <i>Trente ans d'évolution de la santé en France : À quoi ont servi les politiques de santé ?</i> 1st ed. Boulogne-Billancourt: Berger-Levrault, pp. 125-140."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => "Trente ans d'évolution de la santé en France : À quoi ont servi les politiques de santé ?"
"keywords" => []
"updatedAt" => "2023-02-01 15:14:00"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "125-140"
"volume" => "1"
"number" => "2(4)"
]
"type" => array:2 [
"fr" => "Chapitres"
"en" => "Book chapters"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => "France"
"en" => "France"
]
"abstract" => array:2 [
"fr" => ""
"en" => ""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
59 => Essec\Faculty\Model\Contribution {#2446
#_index: "academ_contributions"
#_id: "12650"
#_source: array:18 [
"id" => "12650"
"slug" => "important-drop-in-rate-of-acute-diabetes-complications-in-people-with-type-1-or-type-2-diabetes-after-initiation-of-flash-glucose-monitoring-in-france-the-relief-study"
"yearMonth" => "2021-06"
"year" => "2021"
"title" => "Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study"
"description" => "ROUSSEL, R., RIVELINE, J.P., VICAUT, E., PUYOU DE POUVOURVILLE, G., DETOURNAY, B., EMERY, C. ... GUERCI, B. (2021). Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. <i>Diabetes Care</i>, 44(6), pp. 1368-1376."
"authors" => array:8 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "ROUSSEL Ronan"
]
2 => array:1 [
"name" => "RIVELINE Jean-Pierre"
]
3 => array:1 [
"name" => "VICAUT Eric"
]
4 => array:1 [
"name" => "DETOURNAY Bruno"
]
5 => array:1 [
"name" => "EMERY Corinne"
]
6 => array:1 [
"name" => "LEVRAT-GUILLEN Fleur"
]
7 => array:1 [
"name" => "GUERCI Bruno"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2023-09-22 16:46:53"
"publicationUrl" => "https://doi.org/10.2337/dc20-1690"
"publicationInfo" => array:3 [
"pages" => "1368-1376"
"volume" => "44"
"number" => "6"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => "États-Unis"
"en" => "United States of America"
]
"abstract" => array:2 [
"fr" => "This large retrospective study on hospitalizations for acute diabetes complications shows that a significantly lower incidence of admissions for DKA and for diabetes-related coma is associated with use of flash glucose monitoring. This study has significant implications for patient-centered diabetes care and potentially for long-term health economic outcomes."
"en" => "This large retrospective study on hospitalizations for acute diabetes complications shows that a significantly lower incidence of admissions for DKA and for diabetes-related coma is associated with use of flash glucose monitoring. This study has significant implications for patient-centered diabetes care and potentially for long-term health economic outcomes."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
60 => Essec\Faculty\Model\Contribution {#2447
#_index: "academ_contributions"
#_id: "12651"
#_source: array:18 [
"id" => "12651"
"slug" => "current-challenges-for-assessing-the-long-term-clinical-benefit-of-cancer-immunotherapy-a-multi-stakeholder-perspective"
"yearMonth" => "2020-07"
"year" => "2020"
"title" => "Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective"
"description" => "QUINN, C., GARRISON, L.P., POWNELL, A.K., ATKINS, M.B., PUYOU DE POUVOURVILLE, G., HARRINGTON, K. ... WU, E. (2020). Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. <i>Journal for ImmunoTherapy of Cancer</i>, 8(2), pp. e000648."
"authors" => array:11 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "QUINN Casey"
]
2 => array:1 [
"name" => "GARRISON Louis P"
]
3 => array:1 [
"name" => "POWNELL Anja K"
]
4 => array:1 [
"name" => "ATKINS Michael B"
]
5 => array:1 [
"name" => "HARRINGTON Kevin"
]
6 => array:1 [
"name" => "ASCIERTO Paolo Antonio"
]
7 => array:1 [
"name" => "MCEWAN Phil"
]
8 => array:1 [
"name" => "WAGNER Samuel"
]
9 => array:1 [
"name" => "BORRILL John"
]
10 => array:1 [
"name" => "WU Elise"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2023-01-30 13:36:38"
"publicationUrl" => "http://dx.doi.org/10.1136/jitc-2020-000648"
"publicationInfo" => array:3 [
"pages" => "e000648"
"volume" => "8"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient’s immune system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of action leads to durable responses and prolonged survival in some patients. However, providing robust evidence of the long-term benefits of IOs at health technology assessment (HTA) submission presents several challenges for manufacturers. The aim of this article was to identify, analyze, categorize, and further explore the key challenges that regulators, HTA agencies, and payers commonly encounter when assessing the long-term benefits of IO therapies. Insights were obtained from an international, multi-stakeholder steering committee (SC) and expert panels comprising of payers, economists, and clinicians."
"en" => "Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient’s immune system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of action leads to durable responses and prolonged survival in some patients. However, providing robust evidence of the long-term benefits of IOs at health technology assessment (HTA) submission presents several challenges for manufacturers. The aim of this article was to identify, analyze, categorize, and further explore the key challenges that regulators, HTA agencies, and payers commonly encounter when assessing the long-term benefits of IO therapies. Insights were obtained from an international, multi-stakeholder steering committee (SC) and expert panels comprising of payers, economists, and clinicians."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
61 => Essec\Faculty\Model\Contribution {#2448
#_index: "academ_contributions"
#_id: "12652"
#_source: array:18 [
"id" => "12652"
"slug" => "out%e2%80%90of%e2%80%90pocket-expenditures-in-france-to-manage-psoriasis-in-adult-patients-results-from-an-observational-cross%e2%80%90sectional-non%e2%80%90comparative-multicentre-study"
"yearMonth" => "2021-04"
"year" => "2021"
"title" => "Out‐of‐pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross‐sectional, non‐comparative, multicentre study"
"description" => "RICHARD, M., PAUL, C., PUYOU DE POUVOURVILLE, G., JULLIEN, D., MAHE, E., BACHELEZ, H. ... EZZEDINE, K. (2021). Out‐of‐pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross‐sectional, non‐comparative, multicentre study. <i>Journal of the European Academy of Dermatology and Venereology</i>, 35(4), pp. 912-918."
"authors" => array:14 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "RICHARD M.‐A."
]
2 => array:1 [
"name" => "PAUL C."
]
3 => array:1 [
"name" => "JULLIEN D."
]
4 => array:1 [
"name" => "MAHE E."
]
5 => array:1 [
"name" => "BACHELEZ H."
]
6 => array:1 [
"name" => "SENESCHAL J."
]
7 => array:1 [
"name" => "MISERY L."
]
8 => array:1 [
"name" => "AUBERT R."
]
9 => array:1 [
"name" => "REGUIAI Z."
]
10 => array:1 [
"name" => "SHOURICK J."
]
11 => array:1 [
"name" => "TAIEB C."
]
12 => array:1 [
"name" => "JOLY P."
]
13 => array:1 [
"name" => "EZZEDINE K."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2023-01-30 13:36:18"
"publicationUrl" => "https://doi.org/10.1111/jdv.17000"
"publicationInfo" => array:3 [
"pages" => "912-918"
"volume" => "35"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "In France, in 2019, OOP expenditures to manage psoriasis were on average more than twice as high as the overall mean health-related OOP expenditures estimated by the French Health Agency in 2018. These results should lead health authorities to review certain standards of healthcare reimbursement."
"en" => "In France, in 2019, OOP expenditures to manage psoriasis were on average more than twice as high as the overall mean health-related OOP expenditures estimated by the French Health Agency in 2018. These results should lead health authorities to review certain standards of healthcare reimbursement."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
62 => Essec\Faculty\Model\Contribution {#2449
#_index: "academ_contributions"
#_id: "12838"
#_source: array:18 [
"id" => "12838"
"slug" => "logique-medicale-economique-industrielle-et-politique-dans-la-definition-du-prix-du-medicament"
"yearMonth" => "2021-09"
"year" => "2021"
"title" => "Logique médicale, économique, industrielle et politique dans la définition du « prix » du médicament"
"description" => "PUYOU DE POUVOURVILLE, G. (2021). Logique médicale, économique, industrielle et politique dans la définition du « prix » du médicament. <i>Revue d’Économie Financière</i>, 2021/3(143), pp. 213-229."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2023-03-14 01:00:43"
"publicationUrl" => "https://www.cairn.info/revue-d-economie-financiere-2021-3-page-213.htm"
"publicationInfo" => array:3 [
"pages" => "213-229"
"volume" => "2021/3"
"number" => "143"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "La pandémie du coronavirus a une fois de plus soulevé des controverses mettant en cause la pratique des prix des industriels du médicaments, sujet qui revient régulièrement au gré des innovations thérapeutiques. Les biotechnologies pour le traitement des cancers et des maladies auto-immunes, les traitements innovants de l'hépatite C et maintenant les thérapies géniques et cellulaires ont à la fois ouvert de réels espoirs dans le traitement de ces pathologies et attisé les critiques sur une industrie accusée de réaliser de confortables profits sur la santé. Le but de cet article est pédagogique : il explique le rationnel industriel des modes de fixation du prix des nouveaux médicaments, orienté par la réalisation de profits permettant à la fois de rémunérer des actionnaires et de réinvestir dans le développement de produits nouveaux ; en miroir, de présenter deux idéaux types de « payeurs » européens, la France et le Royaume Uni, dont l'objectif est d'offrir un accès aux traitements innovants à leur population tout en maîtrisant les dépenses de médicaments remboursés et en tentant de trouver un bon équilibre entre la soutenabilité de leurs systèmes de financement et l'encouragement à l'innovation."
"en" => "The coronavirus pandemic has once again raised controversies calling into question the pricing practices of drug manufacturers, a subject that regularly emerges with therapeutic innovations. Biotechnologies for the treatment of cancers and autoimmune diseases, innovative treatments for hepatitis C and now gene and cell therapies have both opened real hopes in the treatment of these pathologies and stoked criticism on an industry. accused of making comfortable profits on health. The purpose of this article is educational: it explains the industrial rationale behind the pricing methods for new drugs, oriented by the achievement of profits allowing both to remunerate shareholders and to reinvest in the development of new products. Mirroring this rationale, to present two models of European “payers”, France and the United Kingdom, whose objective is to offer access to innovative treatments to their population while controlling expenditure on reimbursed drugs and trying to find a good balance between the sustainability of their financing systems and the encouragement of innovation."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
63 => Essec\Faculty\Model\Contribution {#2450
#_index: "academ_contributions"
#_id: "12839"
#_source: array:18 [
"id" => "12839"
"slug" => "cost-effectiveness-of-fractional-flow-reserve-measurement-in-multivessel-coronary-artery-disease-in-belgium-and-in-france"
"yearMonth" => "2011-11"
"year" => "2011"
"title" => "Cost-effectiveness of fractional flow reserve measurement in multivessel coronary artery disease in Belgium and in France"
"description" => "FEARON, W., BORNSCHEIN, B., ARVANDI, M., GOTHE, R., RIOUFOL, G., DE BRUYNE, B. ... SIEBERT, U. (2011). Cost-effectiveness of fractional flow reserve measurement in multivessel coronary artery disease in Belgium and in France. Dans: <i>ISPOR Europe</i>. Value in Health, pp. 251."
"authors" => array:11 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BORNSCHEIN Bernhard"
]
2 => array:1 [
"name" => "ARVANDI Marjan"
]
3 => array:1 [
"name" => "GOTHE Raffaella"
]
4 => array:1 [
"name" => "RIOUFOL Gilles"
]
5 => array:1 [
"name" => "DE BRUYNE Bernard"
]
6 => array:1 [
"name" => "DESMET Wim"
]
7 => array:1 [
"name" => "LEFÈVRE Thierry"
]
8 => array:1 [
"name" => "FEARON William"
]
9 => array:1 [
"name" => "PIJLS Nico"
]
10 => array:1 [
"name" => "SIEBERT Uwe"
]
]
"ouvrage" => "ISPOR Europe"
"keywords" => []
"updatedAt" => "2023-03-15 12:49:25"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "251"
"volume" => "14"
"number" => "7"
]
"type" => array:2 [
"fr" => "Actes d'une conférence"
"en" => "Conference Proceedings"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => ""
"en" => ""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
64 => Essec\Faculty\Model\Contribution {#2451
#_index: "academ_contributions"
#_id: "12840"
#_source: array:18 [
"id" => "12840"
"slug" => "a-discrete-choice-experiment-to-derive-health-utilities-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency-in-france"
"yearMonth" => "2022-01"
"year" => "2022"
"title" => "A Discrete Choice Experiment to Derive Health Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in France"
"description" => "SMITH, A., HANBURY, A., WHITTY, J., BEITIA ORTIZ DE ZARATE, I., PUYOU DE POUVOURVILLE, G., HAMMES, F. et BUESCH, K. (2022). A Discrete Choice Experiment to Derive Health Utilities for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in France. <i>Patient Related Outcome Measures</i>, (13), pp. 21-30."
"authors" => array:7 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "SMITH Adam"
]
2 => array:1 [
"name" => "HANBURY Andria"
]
3 => array:1 [
"name" => "WHITTY Jennifer"
]
4 => array:1 [
"name" => "BEITIA ORTIZ DE ZARATE Igor"
]
5 => array:1 [
"name" => "HAMMES Florence"
]
6 => array:1 [
"name" => "BUESCH Katharina"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "aromatic L-amino acid decarboxylase deficiency,"
1 => "discrete choice experiment -health state utilities"
2 => "health utilities"
]
"updatedAt" => "2023-01-30 13:41:08"
"publicationUrl" => "https://doi.org/10.2147/PROM.S332519"
"publicationInfo" => array:3 [
"pages" => "21-30"
"volume" => ""
"number" => "13"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Purpose: Cost-effectiveness evaluations of interventions require health utility data. However, in medical conditions, such as aromatic L-amino acid decarboxylase (AADC) deficiency, this presents problems due to the rarity of the disease. The study aim therefore was to employ a discrete choice experiment (DCE) to generate health utilities for AADC deficiency."
"en" => "Purpose: Cost-effectiveness evaluations of interventions require health utility data. However, in medical conditions, such as aromatic L-amino acid decarboxylase (AADC) deficiency, this presents problems due to the rarity of the disease. The study aim therefore was to employ a discrete choice experiment (DCE) to generate health utilities for AADC deficiency."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
65 => Essec\Faculty\Model\Contribution {#2452
#_index: "academ_contributions"
#_id: "13245"
#_source: array:18 [
"id" => "13245"
"slug" => "abiraterone-acetate-versus-docetaxel-for-metastatic-castration-resistant-prostate-cancer-a-cohort-study-within-the-french-nationwide-claims-database"
"yearMonth" => "2022-08"
"year" => "2022"
"title" => "Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database"
"description" => "THURIN, N., ROUYER, M., JOVÉ, J., GROSS-GOUPIL, M., HAASER, T., REBILLARD, X. ... BLIN, P. (2022). Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database. <i>Expert Review of Clinical Pharmacology</i>, 15(9), pp. 1139-1145."
"authors" => array:16 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "THURIN Nicolas"
]
2 => array:1 [
"name" => "ROUYER Magali"
]
3 => array:1 [
"name" => "JOVÉ Jérémy"
]
4 => array:1 [
"name" => "GROSS-GOUPIL Marine"
]
5 => array:1 [
"name" => "HAASER Thibaud"
]
6 => array:1 [
"name" => "REBILLARD Xavier"
]
7 => array:1 [
"name" => "SOULIÉ Michel"
]
8 => array:1 [
"name" => "CAPONE Camille"
]
9 => array:1 [
"name" => "BAZIL Marie-Laure"
]
10 => array:1 [
"name" => "MESSAOUD Fatiha"
]
11 => array:1 [
"name" => "LAMARQUE Stéphanie"
]
12 => array:1 [
"name" => "BIGNON Emmanuelle"
]
13 => array:1 [
"name" => "DROZ-PERROTEAU Cécile"
]
14 => array:1 [
"name" => "MOORE Nicholas"
]
15 => array:1 [
"name" => "BLIN Patrick"
]
]
"ouvrage" => ""
"keywords" => array:2 [
0 => "prostate cancer"
1 => "treatment"
]
"updatedAt" => "2023-08-25 09:23:51"
"publicationUrl" => "https://doi.org/10.1080/17512433.2022.2115356"
"publicationInfo" => array:3 [
"pages" => "1139-1145"
"volume" => "15"
"number" => "9"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => "Royaume-Uni"
"en" => "United Kingdom"
]
"abstract" => array:2 [
"fr" => """
The aim of the article is to conduct the direct comparison of abiraterone acetate and docetaxel for first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-life settings.\n
The findings underline the interest of oral abiraterone acetate over intravenous docetaxel as the first-line treatment option in mCRPC.
"""
"en" => """
The aim of the article is to conduct the direct comparison of abiraterone acetate and docetaxel for first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-life settings.\n
The findings underline the interest of oral abiraterone acetate over intravenous docetaxel as the first-line treatment option in mCRPC.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
66 => Essec\Faculty\Model\Contribution {#2453
#_index: "academ_contributions"
#_id: "13248"
#_source: array:18 [
"id" => "13248"
"slug" => "facilitating-more-efficient-negotiations-for-innovative-therapies-a-value-based-negotiation-framework"
"yearMonth" => "2022-05"
"year" => "2022"
"title" => "Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework"
"description" => "WITHALL, A., JOMMI, C., PUYOU DE POUVOURVILLE, G., TAYLOR, D., ANNEMANS, L., SCHOONAERT, L. ... PATRIS, J. (2022). Facilitating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework. <i>International Journal of Technology Assessment in Health Care</i>, 38(1), pp. e23, 1-8."
"authors" => array:8 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "WITHALL Amanda"
]
2 => array:1 [
"name" => "JOMMI Claudio"
]
3 => array:1 [
"name" => "TAYLOR David"
]
4 => array:1 [
"name" => "ANNEMANS Lieven"
]
5 => array:1 [
"name" => "SCHOONAERT Lies"
]
6 => array:1 [
"name" => "HUTCHINGS Adam"
]
7 => array:1 [
"name" => "PATRIS Julien"
]
]
"ouvrage" => ""
"keywords" => array:2 [
0 => "negotiations"
1 => "innovative therapies"
]
"updatedAt" => "2024-10-31 13:51:19"
"publicationUrl" => "https://doi.org/10.1017/S0266462322000095"
"publicationInfo" => array:3 [
"pages" => "e23, 1-8"
"volume" => "38"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => """
An increasing number of innovative therapies (e.g., gene- and cell-based treatments) have been developed in the past 20 years. Despite the significant clinical potential of these therapies, access delays may arise because of differing perspectives of manufacturers and payers regarding issues such as the value of the product, clinical and financial uncertainties, and sustainability.\n
Managed entry agreements (MEAs) can enable access to treatments that would not be reimbursed by conventional methods because of such concerns. However, although MEA typologies exist, there is currently no structured process to come to agreements on MEAs, which can be difficult to decide upon and implement.\n
To facilitate more structured MEA negotiations, we propose a conceptual “value-based negotiation framework” with corresponding application tools.
"""
"en" => """
An increasing number of innovative therapies (e.g., gene- and cell-based treatments) have been developed in the past 20 years. Despite the significant clinical potential of these therapies, access delays may arise because of differing perspectives of manufacturers and payers regarding issues such as the value of the product, clinical and financial uncertainties, and sustainability.\n
Managed entry agreements (MEAs) can enable access to treatments that would not be reimbursed by conventional methods because of such concerns. However, although MEA typologies exist, there is currently no structured process to come to agreements on MEAs, which can be difficult to decide upon and implement.\n
To facilitate more structured MEA negotiations, we propose a conceptual “value-based negotiation framework” with corresponding application tools.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
67 => Essec\Faculty\Model\Contribution {#2454
#_index: "academ_contributions"
#_id: "13246"
#_source: array:18 [
"id" => "13246"
"slug" => "important-decrease-in-hospitalizations-for-acute-diabetes-events-following-freestyle-libre-system-initiation-in-people-with-type-2-diabetes-on-basal-insulin-therapy-in-france"
"yearMonth" => "2023-01"
"year" => "2023"
"title" => "Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre® system initiation in people with type 2 diabetes on basal insulin therapy in France"
"description" => "GUERCI, B., ROUSSEL, R., LEVRAT-GUILLEN, F., DETOURNAY, B., VICAUT, E., PUYOU DE POUVOURVILLE, G. ... RIVELINE, J.P. (2023). Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre® system initiation in people with type 2 diabetes on basal insulin therapy in France. <i>Diabetes Technology & Therapeutics</i>, 25(1), pp. 1-30."
"authors" => array:8 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "GUERCI Bruno"
]
2 => array:1 [
"name" => "ROUSSEL Ronan"
]
3 => array:1 [
"name" => "LEVRAT-GUILLEN Fleur"
]
4 => array:1 [
"name" => "DETOURNAY Bruno"
]
5 => array:1 [
"name" => "VICAUT Eric"
]
6 => array:1 [
"name" => "EMERY Corinne"
]
7 => array:1 [
"name" => "RIVELINE Jean-Pierre"
]
]
"ouvrage" => ""
"keywords" => array:1 [
0 => "diabetes therapy"
]
"updatedAt" => "2023-03-07 15:21:46"
"publicationUrl" => "https://doi.org/10.1089/dia.2022.0271"
"publicationInfo" => array:3 [
"pages" => "1-30"
"volume" => "25"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => "États-Unis"
"en" => "United States of America"
]
"abstract" => array:2 [
"fr" => "Introduction/Aims Initiation of insulin therapy in people withT2DM may be necessary to achieve glycemic targets but is associated with acute diabetes events (ADEs), including severe hypoglycemia (SH) or diabetic ketoacidosis (DKA). We assessed the impact of initiating FreeStyle Libre® glucose monitoring system (FSL) on hospitalizations for ADEs in people with T2DM on basal insulin only regimen +/- non-insulin antidiabetic drugs Methods A retrospective study of the French national SNDS reimbursement claims database (≈66 million French people) identified people with T2DM on basal insulin therapy receiving a first reimbursement of FSL between 01/08/2017 to 31/12/2018. Claims data for the 12 months before, and up to 24 months after FSL initiation, were analyzed. Hospitalizations for ADEs were identified, using ICD-10 codes as main or related diagnosis, for: SH events; DKA events; comas; and hyperglycemia-related admissions. Results 5,933 people with T2DM on basal insulin therapy initiated FSL during the selection period. 78.9% of patients were on basal insulin and other hypoglycemic agents. Amongst the 5,933 patients identified, 2.01% had at least one hospitalization for any ADE in the year before FSL initiation, compared to 0.75% (1 year) and 0.60% (2 years). Reductions in ADEs were driven by 75% fewer DKA admissions, with a 44% reduction in SH admissions. These patterns of reduced ADEs persisted after 2 years, with a further 43% reduction in DKA rates. Conclusions This study emphasizes the value of the FSL system in reducing ADEs in people with T2DM in France not on intensive insulin therapy and initially treated with basal-only insulin therapy."
"en" => "Introduction/Aims Initiation of insulin therapy in people withT2DM may be necessary to achieve glycemic targets but is associated with acute diabetes events (ADEs), including severe hypoglycemia (SH) or diabetic ketoacidosis (DKA). We assessed the impact of initiating FreeStyle Libre® glucose monitoring system (FSL) on hospitalizations for ADEs in people with T2DM on basal insulin only regimen +/- non-insulin antidiabetic drugs Methods A retrospective study of the French national SNDS reimbursement claims database (≈66 million French people) identified people with T2DM on basal insulin therapy receiving a first reimbursement of FSL between 01/08/2017 to 31/12/2018. Claims data for the 12 months before, and up to 24 months after FSL initiation, were analyzed. Hospitalizations for ADEs were identified, using ICD-10 codes as main or related diagnosis, for: SH events; DKA events; comas; and hyperglycemia-related admissions. Results 5,933 people with T2DM on basal insulin therapy initiated FSL during the selection period. 78.9% of patients were on basal insulin and other hypoglycemic agents. Amongst the 5,933 patients identified, 2.01% had at least one hospitalization for any ADE in the year before FSL initiation, compared to 0.75% (1 year) and 0.60% (2 years). Reductions in ADEs were driven by 75% fewer DKA admissions, with a 44% reduction in SH admissions. These patterns of reduced ADEs persisted after 2 years, with a further 43% reduction in DKA rates. Conclusions This study emphasizes the value of the FSL system in reducing ADEs in people with T2DM in France not on intensive insulin therapy and initially treated with basal-only insulin therapy."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
68 => Essec\Faculty\Model\Contribution {#2455
#_index: "academ_contributions"
#_id: "13650"
#_source: array:18 [
"id" => "13650"
"slug" => "population-norms-in-france-with-eq-5d-5l-health-states-value-indexes-and-vas"
"yearMonth" => "2023-12"
"year" => "2023"
"title" => "Population norms in France with EQ-5D-5L: health states, value indexes, and VAS"
"description" => "GAUTIER, L., AZZI, J., SABA, G., BONNELYE, G. et PUYOU DE POUVOURVILLE, G. (2023). Population norms in France with EQ-5D-5L: health states, value indexes, and VAS. <i>European Journal of Health Economics</i>, 24(9), pp. 1517-1530."
"authors" => array:5 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "GAUTIER Laurène"
]
2 => array:1 [
"name" => "AZZI Jessica"
]
3 => array:1 [
"name" => "SABA Grèce"
]
4 => array:1 [
"name" => "BONNELYE Geneviève"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "EQ-5D"
1 => "Health States"
2 => "Quality of life-Population"
]
"updatedAt" => "2024-04-17 11:14:10"
"publicationUrl" => "https://link.springer.com/article/10.1007/s10198-022-01559-2"
"publicationInfo" => array:3 [
"pages" => "1517-1530"
"volume" => "24"
"number" => "9"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Based on the National Health and Wellness Survey, an international, annual, self-administered Internet survey, this study extracted data from France for 2018 involving a sample of 15,000 respondents. Responses to the EQ-5D-5L questionnaire and the Visual Analog Sclae (VAS), together with sociodemographic, health behavior, and disease status were collected. VAS, value indexes, the level sum score and the distribution of levels per dimension were described. Based on a large sample, this study il the first to report EQ-5D-5L population norms for France."
"en" => "Based on the National Health and Wellness Survey, an international, annual, self-administered Internet survey, this study extracted data from France for 2018 involving a sample of 15,000 respondents. Responses to the EQ-5D-5L questionnaire and the Visual Analog Sclae (VAS), together with sociodemographic, health behavior, and disease status were collected. VAS, value indexes, the level sum score and the distribution of levels per dimension were described. Based on a large sample, this study il the first to report EQ-5D-5L population norms for France."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
69 => Essec\Faculty\Model\Contribution {#2456
#_index: "academ_contributions"
#_id: "13651"
#_source: array:18 [
"id" => "13651"
"slug" => "real-world-data-and-evidence-in-health-technology-assessment-when-are-they-complementary-substitutes-or-the-only-sources-of-data-compared-to-clinical-trials"
"yearMonth" => "2023-01"
"year" => "2023"
"title" => "Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials?"
"description" => "PUYOU DE POUVOURVILLE, G., ARMOIRY, X., LAVOREL, A., BILBAULT, P., MAUGENDRE, P., BENSIMON, L. ... VIPREY, M. (2023). Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials? <i>Therapies</i>, 78(1), pp. 81-94."
"authors" => array:19 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "ARMOIRY Xavier"
]
2 => array:1 [
"name" => "LAVOREL Aurélie"
]
3 => array:1 [
"name" => "BILBAULT Pascal"
]
4 => array:1 [
"name" => "MAUGENDRE Philippe"
]
5 => array:1 [
"name" => "BENSIMON Lionel"
]
6 => array:1 [
"name" => "BEZIZ Dan"
]
7 => array:1 [
"name" => "BLIN Patrick"
]
8 => array:1 [
"name" => "BORGET Isabelle"
]
9 => array:1 [
"name" => "BOUÉE Stéphane"
]
10 => array:1 [
"name" => "COLLIGNON Céline"
]
11 => array:1 [
"name" => "DERVAUX Benoît"
]
12 => array:1 [
"name" => "DURAND-ZALESKI Isabelle"
]
13 => array:1 [
"name" => "JULIEN Marc"
]
14 => array:1 [
"name" => "DE LÉONTAING Lucie"
]
15 => array:1 [
"name" => "MAJEED Laureen"
]
16 => array:1 [
"name" => "MARTELLI Nicolas"
]
17 => array:1 [
"name" => "SÉJOURNÉ Thomas"
]
18 => array:1 [
"name" => "VIPREY Marie"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "Real-world data"
1 => "Health technology assessment"
2 => "Decision making"
]
"updatedAt" => "2024-10-31 13:51:19"
"publicationUrl" => "https://doi.org/10.1016/j.therap.2022.11.001"
"publicationInfo" => array:3 [
"pages" => "81-94"
"volume" => "78"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => "France"
"en" => "France"
]
"abstract" => array:2 [
"fr" => "Ateliers de Giens - Travaux de la Table Ronde Données en vie réelle"
"en" => "Within the life-cycle assessment of health technologies, real-world data (RWD) have until now been of secondary importance to clinical trial data. The availability of massive, better quality RWD, particularly with the emergence of connected devices, the improvement of methods for characterizing populations, make it possible to have a better insight into the effects of treatment, sometimes on a national scale the importance of RWD is likely to progress in the eyes of health technology assessors, going from being traditionally complementary to possibly replacing clinical trial data."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
70 => Essec\Faculty\Model\Contribution {#2457
#_index: "academ_contributions"
#_id: "13703"
#_source: array:18 [
"id" => "13703"
"slug" => "across-country-variations-of-real-world-data-and-evidence-for-drugs-a-5-european-country-study"
"yearMonth" => "2023-05"
"year" => "2023"
"title" => "Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study"
"description" => "PUYOU DE POUVOURVILLE, G., CUNNINGHAM, D., FRICKE, F.U., LINDGREN, P. et MANTOVANI, L. (2023). Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study. <i>Value in Health</i>, 26(4), pp. 11-19."
"authors" => array:5 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "CUNNINGHAM David"
]
2 => array:1 [
"name" => "FRICKE Franck-Ulrich"
]
3 => array:1 [
"name" => "LINDGREN Peter"
]
4 => array:1 [
"name" => "MANTOVANI Lorenzo"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "Real-World data"
1 => "Real-world evidence"
2 => "country comparison"
]
"updatedAt" => "2024-10-31 13:51:19"
"publicationUrl" => "https://doi.org/10.1016/j.jval.2023.01.009"
"publicationInfo" => array:3 [
"pages" => "11-19"
"volume" => "26"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "This paper explores the variety of use of real-world data and evidence for the assessment of drugs in five European countries: France, Germany Italy, Sweden and the United Kingdom."
"en" => "This paper explores the variety of use of real-world data and evidence for the assessment of drugs in five European countries: France, Germany Italy, Sweden and the United Kingdom."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
71 => Essec\Faculty\Model\Contribution {#2458
#_index: "academ_contributions"
#_id: "13840"
#_source: array:18 [
"id" => "13840"
"slug" => "a-review-of-data-systems-for-assessing-the-impact-of-hpv-vaccination-in-selected-high-income-countries"
"yearMonth" => "2023-01"
"year" => "2023"
"title" => "A review of data systems for assessing the impact of HPV vaccination in selected high-income countries"
"description" => "WANG, W., KOTHARI, S., KHOURY, H., NICCOLAI, L., GARLAND, S.M., SUNDSTRÖM, K. ... FRANCO, E.L. (2023). A review of data systems for assessing the impact of HPV vaccination in selected high-income countries. <i>Expert Review of Vaccines</i>, 22(1), pp. 161-179."
"authors" => array:10 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:2 [
"name" => "WANG Wei"
"bid" => "VIVIAN"
]
2 => array:1 [
"name" => "KOTHARI Smita"
]
3 => array:1 [
"name" => "KHOURY Hanane"
]
4 => array:1 [
"name" => "NICCOLAI Linda"
]
5 => array:1 [
"name" => "GARLAND Suzanne M."
]
6 => array:1 [
"name" => "SUNDSTRÖM Karin"
]
7 => array:1 [
"name" => "BONANNI Paolo"
]
8 => array:1 [
"name" => "CHEN Ya-Ting"
]
9 => array:1 [
"name" => "FRANCO Eduardo L."
]
]
"ouvrage" => ""
"keywords" => array:10 [
0 => "Cervical cancer"
1 => "cervical screening"
2 => "data systems"
3 => "genital warts"
4 => "human papillomavirus"
5 => "literature review"
6 => "real-world data"
7 => "recurrent respiratory papillomavirus"
8 => "surveillance"
9 => "vaccination"
]
"updatedAt" => "2024-03-20 16:27:08"
"publicationUrl" => "https://doi.org/10.1080/14760584.2023.2162505"
"publicationInfo" => array:3 [
"pages" => "161-179"
"volume" => "22"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => """
The introduction of effective human papillomavirus (HPV) vaccination, screening, and treatment programs has led the World Health Organization to call for the global elimination of cervical cancer. Assessing progress toward this goal is supported through monitoring vaccination coverage and its impact.\n
\n
We performed a targeted review to assess the characteristics of HPV-related data systems from seven high-income countries (HICs) that represented varied approaches, including Australia, Canada, France, Italy, Scotland, Sweden, and the United States (US). Included data systems focused on preventive and early detection measures: HPV vaccination and cervical screening programs, as well as HPV-related disease outcomes. Differences were observed in approach to development of data systems, along with variation in geographical scope and methods of data collection.
"""
"en" => """
The introduction of effective human papillomavirus (HPV) vaccination, screening, and treatment programs has led the World Health Organization to call for the global elimination of cervical cancer. Assessing progress toward this goal is supported through monitoring vaccination coverage and its impact.\n
\n
We performed a targeted review to assess the characteristics of HPV-related data systems from seven high-income countries (HICs) that represented varied approaches, including Australia, Canada, France, Italy, Scotland, Sweden, and the United States (US). Included data systems focused on preventive and early detection measures: HPV vaccination and cervical screening programs, as well as HPV-related disease outcomes. Differences were observed in approach to development of data systems, along with variation in geographical scope and methods of data collection.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
72 => Essec\Faculty\Model\Contribution {#2459
#_index: "academ_contributions"
#_id: "13848"
#_source: array:18 [
"id" => "13848"
"slug" => "the-diffusion-of-health-economics-knowledge-in-europe"
"yearMonth" => "2012-09"
"year" => "2012"
"title" => "The Diffusion of Health Economics Knowledge in Europe"
"description" => "PUYOU DE POUVOURVILLE, G., ULMANN, P., NIXON, J., BOULENGER, S., GLANVILLE, J. et DRUMMOND, M. (2012). The Diffusion of Health Economics Knowledge in Europe. <i>Pharmacoeconomics</i>, 23(2), pp. 113-120."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "ULMANN Philippe"
]
2 => array:1 [
"name" => "NIXON John"
]
3 => array:1 [
"name" => "BOULENGER St??phanie"
]
4 => array:1 [
"name" => "GLANVILLE Julie"
]
5 => array:1 [
"name" => "DRUMMOND Michael"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2023-06-12 10:51:41"
"publicationUrl" => "https://doi.org/10.2165/00019053-200523020-00003"
"publicationInfo" => array:3 [
"pages" => "113-120"
"volume" => "23"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "This paper overviews the EURONHEED (EUROpean Network of Health Economics Evaluation Databases) project. Launched in 2003, this project is funded by the EU. Its aim is to create a network of national and international databases dedicated to health economic evaluation of health services and innovations. Seven centres (France, Germany, Italy, The Netherlands, Spain, Sweden and the UK) are involved covering 17 countries. The network is based on two existing databases, the French CODECS (COnnaissance et Decision en EConomie de la Santé) database, created in 2000 by the French Health Economists Association (Collège des Economistes de la Santé), and the UK NHS-EED (NHS Economic Electronic Database), run by the Centre for Reviews and Dissemination, University of York, York, England."
"en" => "This paper overviews the EURONHEED (EUROpean Network of Health Economics Evaluation Databases) project. Launched in 2003, this project is funded by the EU. Its aim is to create a network of national and international databases dedicated to health economic evaluation of health services and innovations. Seven centres (France, Germany, Italy, The Netherlands, Spain, Sweden and the UK) are involved covering 17 countries. The network is based on two existing databases, the French CODECS (COnnaissance et Decision en EConomie de la Santé) database, created in 2000 by the French Health Economists Association (Collège des Economistes de la Santé), and the UK NHS-EED (NHS Economic Electronic Database), run by the Centre for Reviews and Dissemination, University of York, York, England."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
73 => Essec\Faculty\Model\Contribution {#2460
#_index: "academ_contributions"
#_id: "13851"
#_source: array:18 [
"id" => "13851"
"slug" => "cost-effectiveness-analysis-of-sapien-3-transcatheter-aortic-valve-implantation-procedure-compared-with-surgery-in-patients-with-severe-aortic-stenosis-at-low-risk-of-surgical-mortality-in-france"
"yearMonth" => "2022-04"
"year" => "2022"
"title" => "Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France"
"description" => "GILARD, M., ELTCHANINOFF, H., IUNG, B., LEFÈVRE, T., SPAULDING, C., DUMONTEIL, N. ... SHORE, J. (2022). Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France. <i>Value in Health</i>, 25(4), pp. 605-613."
"authors" => array:12 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "GILARD Martine"
]
2 => array:1 [
"name" => "ELTCHANINOFF Hélène"
]
3 => array:1 [
"name" => "IUNG Bernard"
]
4 => array:1 [
"name" => "LEFÈVRE Thierry"
]
5 => array:1 [
"name" => "SPAULDING Christian"
]
6 => array:1 [
"name" => "DUMONTEIL Nicolas"
]
7 => array:1 [
"name" => "MUTUON Pierre"
]
8 => array:1 [
"name" => "ROUSSEL Christophe"
]
9 => array:1 [
"name" => "CANDOLFI Pascal"
]
10 => array:1 [
"name" => "GREEN Michelle"
]
11 => array:1 [
"name" => "SHORE Judith"
]
]
"ouvrage" => ""
"keywords" => array:6 [
0 => "ortic stenosis"
1 => "cost-effectiveness"
2 => "cost-utility"
3 => "low risk"
4 => "surgical aortic valve replacement"
5 => "transcatheter aortic valve implantation"
]
"updatedAt" => "2023-03-16 01:00:45"
"publicationUrl" => "https://doi.org/10.1016/j.jval.2021.10.003"
"publicationInfo" => array:3 [
"pages" => "605-613"
"volume" => "25"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "The clinical and cost-saving benefits of transcatheter aortic valve implantation (TAVI) over surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis who are at high or intermediate risk of surgical mortality are supported by a growing evidence base. The PARTNER 3 trial (Placement of AoRTic TraNscathetER Valve Trial) demonstrated clinical benefits with SAPIEN 3 TAVI compared with SAVR in selected patients at low risk of surgical mortality. This study uses PARTNER 3 outcomes in combination with a French national hospital claim database to inform a cost-utility model and examine the cost implications of TAVI over SAVR in a low-risk population."
"en" => "The clinical and cost-saving benefits of transcatheter aortic valve implantation (TAVI) over surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis who are at high or intermediate risk of surgical mortality are supported by a growing evidence base. The PARTNER 3 trial (Placement of AoRTic TraNscathetER Valve Trial) demonstrated clinical benefits with SAPIEN 3 TAVI compared with SAVR in selected patients at low risk of surgical mortality. This study uses PARTNER 3 outcomes in combination with a French national hospital claim database to inform a cost-utility model and examine the cost implications of TAVI over SAVR in a low-risk population."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
74 => Essec\Faculty\Model\Contribution {#2461
#_index: "academ_contributions"
#_id: "13856"
#_source: array:18 [
"id" => "13856"
"slug" => "reduced-rate-of-acute-diabetes-events-with-flash-glucose-monitoring-is-sustained-for-2-years-after-initiation-extended-outcomes-from-the-relief-study"
"yearMonth" => "2022-08"
"year" => "2022"
"title" => "Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study"
"description" => "RIVELINE, J.P., ROUSSEL, R., VICAUT, E., PUYOU DE POUVOURVILLE, G., DETOURNAY, B., EMERY, C. ... GUERCI, B. (2022). Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study. <i>Diabetes Technology & Therapeutics</i>, 24(9), pp. 611-618."
"authors" => array:8 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "RIVELINE Jean-Pierre"
]
2 => array:1 [
"name" => "ROUSSEL Ronan"
]
3 => array:1 [
"name" => "VICAUT Eric"
]
4 => array:1 [
"name" => "DETOURNAY Bruno"
]
5 => array:1 [
"name" => "EMERY Corinne"
]
6 => array:1 [
"name" => "LEVRAT-GUILLEN Fleur"
]
7 => array:1 [
"name" => "GUERCI Bruno"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2023-03-15 15:43:51"
"publicationUrl" => "https://doi.org/10.1089/dia.2022.0085"
"publicationInfo" => array:3 [
"pages" => "611-618"
"volume" => "24"
"number" => "9"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => "États-Unis"
"en" => "United States of America"
]
"abstract" => array:2 [
"fr" => """
Background: The RELIEF study has previously shown a fall in the rate of acute diabetes events (ADEs) in people living with type 1 diabetes (PwDT1) or people living with type 2 diabetes (PwDT2) in the 12 months after initiation of flash glucose monitoring (FLASH) in France. The 2-year follow-up has provided new insights on the frequency of ADEs, including severe hypoglycemia and diabetic ketoacidosis (DKA), during use of FLASH.\n
\n
Methods: The RELIEF study included 31,446 PwDT1 and 41,027 PwDT2 with a first delivery of FreeStyle Libre (FSL) between August 1 and December 31, 2017. Hospitalizations for DKA, severe hypoglycemia, diabetes-related coma, and hyperglycemia were recorded for the 12 months before and 24 months after FSL initiation. Persistence of the FSL system use was estimated through a Kaplan–Meier survival curve. Change in usual blood glucose monitoring was estimated through acquisition of blood glucose test strips.\n
\n
Results: In the 2 years after FSL initiation, hospitalizations for ADEs were reduced by 49% and by 48% in PwDT1 or PwDT2, respectively, driven by reductions in DKA. After 2 years, 88% of patients persisted with the system and estimated mean consumption of blood glucose test strips had fallen after 2 years by −82% and by −84% in type 1 diabetes mellitus and type 2 diabetes mellitus, respectively.\n
\n
Conclusion: Use of FSL consistently reduces the rates of hospitalization for ADEs, mainly DKA, 2 years after initiation, confirming this is not a transitory effect. Use of FSL also results in a clear and progressive drop in use of blood glucose test strips over the 2-year period.
"""
"en" => """
Background: The RELIEF study has previously shown a fall in the rate of acute diabetes events (ADEs) in people living with type 1 diabetes (PwDT1) or people living with type 2 diabetes (PwDT2) in the 12 months after initiation of flash glucose monitoring (FLASH) in France. The 2-year follow-up has provided new insights on the frequency of ADEs, including severe hypoglycemia and diabetic ketoacidosis (DKA), during use of FLASH.\n
\n
Methods: The RELIEF study included 31,446 PwDT1 and 41,027 PwDT2 with a first delivery of FreeStyle Libre (FSL) between August 1 and December 31, 2017. Hospitalizations for DKA, severe hypoglycemia, diabetes-related coma, and hyperglycemia were recorded for the 12 months before and 24 months after FSL initiation. Persistence of the FSL system use was estimated through a Kaplan–Meier survival curve. Change in usual blood glucose monitoring was estimated through acquisition of blood glucose test strips.\n
\n
Results: In the 2 years after FSL initiation, hospitalizations for ADEs were reduced by 49% and by 48% in PwDT1 or PwDT2, respectively, driven by reductions in DKA. After 2 years, 88% of patients persisted with the system and estimated mean consumption of blood glucose test strips had fallen after 2 years by −82% and by −84% in type 1 diabetes mellitus and type 2 diabetes mellitus, respectively.\n
\n
Conclusion: Use of FSL consistently reduces the rates of hospitalization for ADEs, mainly DKA, 2 years after initiation, confirming this is not a transitory effect. Use of FSL also results in a clear and progressive drop in use of blood glucose test strips over the 2-year period.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
75 => Essec\Faculty\Model\Contribution {#2462
#_index: "academ_contributions"
#_id: "13922"
#_source: array:18 [
"id" => "13922"
"slug" => "review-and-assessment-of-policy-options-for-improving-access-to-combination-therapies-in-oncology-in-europe"
"yearMonth" => "2023-07"
"year" => "2023"
"title" => "Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe"
"description" => "HENSHALL, C.H., DANKÓ, D., BARHAM, L., ESPÍN, J., FELIX, J., HARNEY, M. ... WILKING, N. (2023). Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe. <i>Applied Health Economics and Policy</i>, 21(4), pp. 537-546."
"authors" => array:12 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "HENSHALL Christopher H."
]
2 => array:1 [
"name" => "DANKÓ Dávid"
]
3 => array:1 [
"name" => "BARHAM Leela"
]
4 => array:1 [
"name" => "ESPÍN Jaime"
]
5 => array:1 [
"name" => "FELIX Jorge"
]
6 => array:1 [
"name" => "HARNEY Mary"
]
7 => array:1 [
"name" => "INDRA Peter"
]
8 => array:1 [
"name" => "MESTRE-FERRANDIZ Jorge"
]
9 => array:1 [
"name" => "SPANDONARO Federico"
]
10 => array:1 [
"name" => "VONČINA Luka"
]
11 => array:1 [
"name" => "WILKING Nils"
]
]
"ouvrage" => ""
"keywords" => array:2 [
0 => "combination therapies"
1 => "oncology"
]
"updatedAt" => "2024-03-18 11:49:16"
"publicationUrl" => "https://link.springer.com/article/10.1007/s40258-023-00795-8"
"publicationInfo" => array:3 [
"pages" => "537-546"
"volume" => "21"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Combinations of on-patent therapies (CTs) are increasingly common in oncology. They cause challenges for funding and affordability, and hence patient access, especially when constituent therapies are owned by different manufacturers. The aim of our study was to develop policy proposals for the assessment, pricing, and funding of CTs and identify which might be relevant in different European countries."
"en" => "Combinations of on-patent therapies (CTs) are increasingly common in oncology. They cause challenges for funding and affordability, and hence patient access, especially when constituent therapies are owned by different manufacturers. The aim of our study was to develop policy proposals for the assessment, pricing, and funding of CTs and identify which might be relevant in different European countries."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
76 => Essec\Faculty\Model\Contribution {#2463
#_index: "academ_contributions"
#_id: "13998"
#_source: array:18 [
"id" => "13998"
"slug" => "data-governance-for-real-world-data-management-a-proposal-for-a-checklist-to-support-decision-making"
"yearMonth" => "2023-04"
"year" => "2023"
"title" => "Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making"
"description" => "SOLÀ-MORALES, O., SIGURÐARDÓTTIR, K., AKEHURST, R., MURPHY, L.A., MESTRE-FERRANDIZ, J., CUNNINGHAM, D. et PUYOU DE POUVOURVILLE, G. (2023). Data Governance for Real-World Data Management: A Proposal for a Checklist to Support Decision Making. <i>Value in Health</i>, 26(4), pp. 32-42."
"authors" => array:7 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "SOLÀ-MORALES Oriol"
]
2 => array:1 [
"name" => "SIGURÐARDÓTTIR Katla"
]
3 => array:1 [
"name" => "AKEHURST Ron"
]
4 => array:1 [
"name" => "MURPHY Linda A."
]
5 => array:1 [
"name" => "MESTRE-FERRANDIZ Jorge"
]
6 => array:1 [
"name" => "CUNNINGHAM David"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "data governance"
1 => "real-world data"
2 => "real-world evidence"
]
"updatedAt" => "2023-05-25 01:00:41"
"publicationUrl" => "https://doi.org/10.1016/j.jval.2023.02.012"
"publicationInfo" => array:3 [
"pages" => "32-42"
"volume" => "26"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Real-world data (RWD) and real-world evidence (RWE) can provide extensive information on healthcare for use in health technology assessment and decision making. Nevertheless, there is a lack of consensus surrounding the appropriate data governance (DG) practices for RWD/RWE. Data sharing is also a large concern, especially considering evolving data protection regulations. Our objective is to propose recommendations for international standards of evaluating the acceptability of RWD governance practices."
"en" => "Real-world data (RWD) and real-world evidence (RWE) can provide extensive information on healthcare for use in health technology assessment and decision making. Nevertheless, there is a lack of consensus surrounding the appropriate data governance (DG) practices for RWD/RWE. Data sharing is also a large concern, especially considering evolving data protection regulations. Our objective is to propose recommendations for international standards of evaluating the acceptability of RWD governance practices."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
77 => Essec\Faculty\Model\Contribution {#2464
#_index: "academ_contributions"
#_id: "14048"
#_source: array:18 [
"id" => "14048"
"slug" => "reduced-acute-diabetes-events-after-freestyle-libre-system-initiation-in-people-65-years-or-older-with-type-2-diabetes-on-intensive-insulin-therapy-in-france"
"yearMonth" => "2023-05"
"year" => "2023"
"title" => "Reduced Acute Diabetes Events After FreeStyle Libre System Initiation in People 65 Years or Older with Type 2 Diabetes on Intensive Insulin Therapy in France"
"description" => "GUERCI, B., LEVRAT-GUILLEN, F., VICAUT, E., PUYOU DE POUVOURVILLE, G., DETOURNAY, B., EMERY, C. et RIVELINE, J.P. (2023). Reduced Acute Diabetes Events After FreeStyle Libre System Initiation in People 65 Years or Older with Type 2 Diabetes on Intensive Insulin Therapy in France. <i>Diabetes Technology & Therapeutics</i>, 25(6), pp. 384-394."
"authors" => array:7 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "GUERCI Bruno"
]
2 => array:1 [
"name" => "LEVRAT-GUILLEN Fleur"
]
3 => array:1 [
"name" => "VICAUT Eric"
]
4 => array:1 [
"name" => "DETOURNAY Bruno"
]
5 => array:1 [
"name" => "EMERY Corinne"
]
6 => array:1 [
"name" => "RIVELINE Jean-Pierre"
]
]
"ouvrage" => ""
"keywords" => array:1 [
0 => "diabetes therapy"
]
"updatedAt" => "2023-06-13 16:55:06"
"publicationUrl" => "https://doi.org/10.1089/dia.2023.0034"
"publicationInfo" => array:3 [
"pages" => "384-394"
"volume" => "25"
"number" => "6"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => "États-Unis"
"en" => "United States of America"
]
"abstract" => array:2 [
"fr" => "Older people with type 2 diabetes (T2DM) on insulin are at increased risk of hypoglycemia and associated morbidity. Management of T2DM in older people must optimize glycemic control, while minimizing risks for hypoglycemia and diabetic ketoacidosis (DKA). In France, the FreeStyle Libre® (FSL) system has been reimbursed since June 2017 for T2DM on intensive insulin therapy. We assessed the impact of starting FSL on hospitalizations for acute diabetes events (ADEs) in people ≥65 years old, with T2DM on intensive insulin therapy."
"en" => "Older people with type 2 diabetes (T2DM) on insulin are at increased risk of hypoglycemia and associated morbidity. Management of T2DM in older people must optimize glycemic control, while minimizing risks for hypoglycemia and diabetic ketoacidosis (DKA). In France, the FreeStyle Libre® (FSL) system has been reimbursed since June 2017 for T2DM on intensive insulin therapy. We assessed the impact of starting FSL on hospitalizations for acute diabetes events (ADEs) in people ≥65 years old, with T2DM on intensive insulin therapy."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
78 => Essec\Faculty\Model\Contribution {#2465
#_index: "academ_contributions"
#_id: "14046"
#_source: array:18 [
"id" => "14046"
"slug" => "how-are-health-technology-assessment-bodies-responding-to-the-assessment-challenges-posed-by-cell-and-gene-therapy"
"yearMonth" => "2023-05"
"year" => "2023"
"title" => "How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?"
"description" => "DRUMMOND, M., CIANI, O., FORNARO, G., JOMMI, C., DIETRICH, E.S., ESPIN, J. ... PUYOU DE POUVOURVILLE, G. (2023). How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? <i>BMC Health Services Research</i>, 23(484)."
"authors" => array:8 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "DRUMMOND Michael"
]
2 => array:1 [
"name" => "CIANI Oriana"
]
3 => array:1 [
"name" => "FORNARO Giulia"
]
4 => array:1 [
"name" => "JOMMI Claudio"
]
5 => array:1 [
"name" => "DIETRICH Eva Susanne"
]
6 => array:1 [
"name" => "ESPIN Jaime"
]
7 => array:1 [
"name" => "MOSSMAN Jean"
]
]
"ouvrage" => ""
"keywords" => array:5 [
0 => "Cost-efectiveness analysis"
1 => "Advanced therapy medicinal products"
2 => "Health technology assessment"
3 => "Managed entry agreements"
4 => "Reimbursement"
]
"updatedAt" => "2023-06-13 16:23:34"
"publicationUrl" => "https://doi.org/10.1186/s12913-023-09494-5"
"publicationInfo" => array:3 [
"pages" => ""
"volume" => "23"
"number" => "484"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "The aims of this research were to provide a better understanding of the specific evidence needs for assessment of clinical and cost-effectiveness of cell and gene therapies, and to explore the extent that the relevant categories of evidence are considered in health technology assessment (HTA) processes. Methods: A targeted literature review was conducted to identify the specific categories of evidence relevant to the assessment of these therapies. Forty-six HTA reports for 9 products in 10 cell and gene therapy indications across 8 jurisdictions were analysed to determine the extent to which various items of evidence were considered. Results: The items to which the HTA bodies reacted positively were: treatment was for a rare disease or serious condition, lack of alternative therapies, evidence indicating substantial health gains, and when alternative payment models could be agreed. The items to which they reacted negatively were: use of unvalidated surrogate endpoints, single arm trials without an adequately matched alternative therapy, inadequate reporting of adverse consequences and risks, short length of follow-up in clinical trials, extrapolating to long-term outcomes, and uncertainty around the economic estimates. Conclusions: The consideration by HTA bodies of evidence relating to the particular features of cell and gene therapies is variable. Several suggestions are made for addressing the assessment challenges posed by these therapies. Jurisdictions conducting HTAs of these therapies can consider whether these suggestions could be incorporated within their existing approach through strengthening deliberative decision-making or performing additional analyses."
"en" => "The aims of this research were to provide a better understanding of the specific evidence needs for assessment of clinical and cost-effectiveness of cell and gene therapies, and to explore the extent that the relevant categories of evidence are considered in health technology assessment (HTA) processes. Methods: A targeted literature review was conducted to identify the specific categories of evidence relevant to the assessment of these therapies. Forty-six HTA reports for 9 products in 10 cell and gene therapy indications across 8 jurisdictions were analysed to determine the extent to which various items of evidence were considered. Results: The items to which the HTA bodies reacted positively were: treatment was for a rare disease or serious condition, lack of alternative therapies, evidence indicating substantial health gains, and when alternative payment models could be agreed. The items to which they reacted negatively were: use of unvalidated surrogate endpoints, single arm trials without an adequately matched alternative therapy, inadequate reporting of adverse consequences and risks, short length of follow-up in clinical trials, extrapolating to long-term outcomes, and uncertainty around the economic estimates. Conclusions: The consideration by HTA bodies of evidence relating to the particular features of cell and gene therapies is variable. Several suggestions are made for addressing the assessment challenges posed by these therapies. Jurisdictions conducting HTAs of these therapies can consider whether these suggestions could be incorporated within their existing approach through strengthening deliberative decision-making or performing additional analyses."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
79 => Essec\Faculty\Model\Contribution {#2466
#_index: "academ_contributions"
#_id: "14050"
#_source: array:18 [
"id" => "14050"
"slug" => "using-real-world-data-in-the-health-technology-assessment-of-pharmaceuticals-strengths-difficulties-and-a-pragmatic-way-forward"
"yearMonth" => "2023-04"
"year" => "2023"
"title" => "Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward"
"description" => "AKEHURST, R., MURPHY, L.A., SOLÀ-MORALES, O., CUNNINGHAM, D., MESTRE-FERRANDIZ, J. et PUYOU DE POUVOURVILLE, G. (2023). Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward. <i>Value in Health</i>, 26(4), pp. 11-19."
"authors" => array:6 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "AKEHURST Ron"
]
2 => array:1 [
"name" => "MURPHY Linda A."
]
3 => array:1 [
"name" => "SOLÀ-MORALES Oriol"
]
4 => array:1 [
"name" => "CUNNINGHAM David"
]
5 => array:1 [
"name" => "MESTRE-FERRANDIZ Jorge"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2023-06-13 17:28:09"
"publicationUrl" => "https://doi.org/10.1016/j.jval.2023.01.010"
"publicationInfo" => array:3 [
"pages" => "11-19"
"volume" => "26"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "In the past decade, there have been increasing calls for greater use of real-world evidence (RWE) and data (RWD), with the explicit goal of enabling faster provision of effective medicines to patients in need. The push for decision makers to accept RWE is especially noticeable in the pursuit of regulatory approval, but RWE, particularly when used to estimate the relative effectiveness of interventions, is not always readily accepted by agencies responsible for reimbursement and pricing of new pharmaceuticals and, to a varying degree, is not accepted across jurisdictions. This lack of trust hampers the use of RWE despite a very large and growing literature base on the principles of how RWE should be used."
"en" => "In the past decade, there have been increasing calls for greater use of real-world evidence (RWE) and data (RWD), with the explicit goal of enabling faster provision of effective medicines to patients in need. The push for decision makers to accept RWE is especially noticeable in the pursuit of regulatory approval, but RWE, particularly when used to estimate the relative effectiveness of interventions, is not always readily accepted by agencies responsible for reimbursement and pricing of new pharmaceuticals and, to a varying degree, is not accepted across jurisdictions. This lack of trust hampers the use of RWE despite a very large and growing literature base on the principles of how RWE should be used."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
80 => Essec\Faculty\Model\Contribution {#2467
#_index: "academ_contributions"
#_id: "14055"
#_source: array:18 [
"id" => "14055"
"slug" => "structure-and-content-of-a-taxonomy-to-support-the-use-of-real-world-evidence-by-health-technology-assessment-practitioners-and-healthcare-decision-makers"
"yearMonth" => "2023-04"
"year" => "2023"
"title" => "Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers"
"description" => "MURPHY, L.A., AKEHURST, R., SOLÀ-MORALES, O., CUNNINGHAM, D., MESTRE-FERRANDIZ, J., FRANKLIN, M. et PUYOU DE POUVOURVILLE, G. (2023). Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers. <i>Value in Health</i>, 26(4), pp. 20-31."
"authors" => array:7 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "MURPHY Linda A."
]
2 => array:1 [
"name" => "AKEHURST Ron"
]
3 => array:1 [
"name" => "SOLÀ-MORALES Oriol"
]
4 => array:1 [
"name" => "CUNNINGHAM David"
]
5 => array:1 [
"name" => "MESTRE-FERRANDIZ Jorge"
]
6 => array:1 [
"name" => "FRANKLIN Matthew"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "health technology assessment"
1 => "real-world data"
2 => "real-world evidence"
]
"updatedAt" => "2023-06-21 16:59:12"
"publicationUrl" => "https://doi.org/10.1016/j.jval.2023.01.007"
"publicationInfo" => array:3 [
"pages" => "20-31"
"volume" => "26"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "This is one of a series of articles that consider the barriers to optimal use of real-world evidence (RWE) in health technology assessment and how to overcome them. The work was performed as part of EUreccA 2025, in particular with the RWE workstream embodied within that collaboration. Elsewhere in this issue we described the reasoning and process that led us to develop practical tools to support RWE use, including this taxonomy and explained the methods used to do so. The taxonomy classifies questions that are typically addressed using real-world data in health technology assessment and the data sources typically used to address these questions. In this article, we describe the taxonomy itself. For as many of the pairings as possible, we have provided links to advice and methods on how to address the associated question using those data. We have also provided links to examples of RWE use in practical decision making to answer the questions posed. Our work is not complete, but we believe it is sufficient to demonstrate the value of such a taxonomy and information source if it is completed and curated as a “wiki” by the community that would use it."
"en" => "This is one of a series of articles that consider the barriers to optimal use of real-world evidence (RWE) in health technology assessment and how to overcome them. The work was performed as part of EUreccA 2025, in particular with the RWE workstream embodied within that collaboration. Elsewhere in this issue we described the reasoning and process that led us to develop practical tools to support RWE use, including this taxonomy and explained the methods used to do so. The taxonomy classifies questions that are typically addressed using real-world data in health technology assessment and the data sources typically used to address these questions. In this article, we describe the taxonomy itself. For as many of the pairings as possible, we have provided links to advice and methods on how to address the associated question using those data. We have also provided links to examples of RWE use in practical decision making to answer the questions posed. Our work is not complete, but we believe it is sufficient to demonstrate the value of such a taxonomy and information source if it is completed and curated as a “wiki” by the community that would use it."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
81 => Essec\Faculty\Model\Contribution {#2468
#_index: "academ_contributions"
#_id: "14056"
#_source: array:18 [
"id" => "14056"
"slug" => "use-of-ibrutinib-in-real-life-settings-in-france-results-from-a-retrospective-observational-study-using-the-snds-database-osiris"
"yearMonth" => "2022-11"
"year" => "2022"
"title" => "Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database (OSIRIS)"
"description" => "CHOQUET, S., DESLANDES, M., MACHER, N., PUYOU DE POUVOURVILLE, G., MARCHAL, C., BELHASSEN, M. ... LEVY, V. (2022). Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database (OSIRIS). Dans: American Society of Hematology Conference."
"authors" => array:8 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "CHOQUET Sylvain"
]
2 => array:1 [
"name" => "DESLANDES Marine"
]
3 => array:1 [
"name" => "MACHER Nahid"
]
4 => array:1 [
"name" => "MARCHAL Clarisse"
]
5 => array:1 [
"name" => "BELHASSEN Manon"
]
6 => array:1 [
"name" => "JACOUD Flore"
]
7 => array:1 [
"name" => "LEVY Vincent"
]
]
"ouvrage" => "American Society of Hematology Conference"
"keywords" => []
"updatedAt" => "2023-06-26 10:59:48"
"publicationUrl" => "https://doi.org/10.1182/blood-2022-162213"
"publicationInfo" => array:3 [
"pages" => "9898-9899"
"volume" => "140"
"number" => "Supplement 1"
]
"type" => array:2 [
"fr" => "Communications dans une conférence"
"en" => "Presentations at an Academic or Professional conference"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Ibrutinib is a Bruton's Tyrosine Kinase Inhibitor indicated in the treatment of several B-cell malignancies: Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Waldenström Macroglobulinemia (WM). The number and the characteristics of patients treated by Ibrutinib in France in real life settings are unknown and need to be determined, as well as treatment pattern in real-life settings."
"en" => "Ibrutinib is a Bruton's Tyrosine Kinase Inhibitor indicated in the treatment of several B-cell malignancies: Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Waldenström Macroglobulinemia (WM). The number and the characteristics of patients treated by Ibrutinib in France in real life settings are unknown and need to be determined, as well as treatment pattern in real-life settings."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
82 => Essec\Faculty\Model\Contribution {#2469
#_index: "academ_contributions"
#_id: "14057"
#_source: array:18 [
"id" => "14057"
"slug" => "p45-internal-external-and-cross-validation-of-the-deduce-model-a-cost-utility-tool-using-patient-level-microsimulation-to-evaluate-sensor-based-glucose-monitoring-systems-in-type-1-and-type-2-diabe"
"yearMonth" => "2022-11"
"year" => "2022"
"title" => "P45 Internal, External, and Cross-Validation of the DEDUCE Model, a Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes"
"description" => "COAQUIRA CASTRO, J., PUYOU DE POUVOURVILLE, G., GREENBERG, D., HARRIS, S., JENDLE, J., SHAW, J. ... SZAFRANSKI, K. (2022). P45 Internal, External, and Cross-Validation of the DEDUCE Model, a Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes. Dans: ISPOR Europe 2022. Vienna & Virtual."
"authors" => array:8 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "COAQUIRA CASTRO J"
]
2 => array:1 [
"name" => "GREENBERG D"
]
3 => array:1 [
"name" => "HARRIS S"
]
4 => array:1 [
"name" => "JENDLE J"
]
5 => array:1 [
"name" => "SHAW JE"
]
6 => array:1 [
"name" => "LEVRAT GUILLEN F"
]
7 => array:1 [
"name" => "SZAFRANSKI K"
]
]
"ouvrage" => "ISPOR Europe 2022"
"keywords" => []
"updatedAt" => "2023-06-26 11:16:44"
"publicationUrl" => "https://doi.org/10.1016/j.jval.2022.09.057"
"publicationInfo" => array:3 [
"pages" => "S11"
"volume" => "25"
"number" => "12"
]
"type" => array:2 [
"fr" => "Communications dans une conférence"
"en" => "Presentations at an Academic or Professional conference"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "For health care decision-makers, the use of computer simulation models requires transparency, precision and accuracy. Systematic comparisons of diabetes models, per Mount Hood Challenges, have shown significant variability in results between models. We developed and validated a new cost-effectiveness model (the DEtermination of Diabetes Utilities, Costs, and Effects [DEDUCE] model) in both type 1 and 2 diabetes mellitus (T1DM, T2DM) to evaluate sensor-based glucose monitoring."
"en" => "For health care decision-makers, the use of computer simulation models requires transparency, precision and accuracy. Systematic comparisons of diabetes models, per Mount Hood Challenges, have shown significant variability in results between models. We developed and validated a new cost-effectiveness model (the DEtermination of Diabetes Utilities, Costs, and Effects [DEDUCE] model) in both type 1 and 2 diabetes mellitus (T1DM, T2DM) to evaluate sensor-based glucose monitoring."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
83 => Essec\Faculty\Model\Contribution {#2470
#_index: "academ_contributions"
#_id: "14058"
#_source: array:18 [
"id" => "14058"
"slug" => "msr23-health-economic-evaluations-alongside-new-clinical-trial-designs-results-of-an-international-expert-panel-workshop"
"yearMonth" => "2022-11"
"year" => "2022"
"title" => "MSR23 Health Economic Evaluations Alongside New Clinical Trial Designs – Results of an International Expert Panel Workshop"
"description" => "MOLNAR, A., STÖRZEL, M., MUCHADEYI, M., BAIRD, R., IMAZ-IGLESIA, I., NAGY, B. ... SCHLANDER, M. (2022). MSR23 Health Economic Evaluations Alongside New Clinical Trial Designs – Results of an International Expert Panel Workshop. Dans: ISPOR Europe 2022. Vienna & Virtual."
"authors" => array:10 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "MOLNAR A"
]
2 => array:1 [
"name" => "STÖRZEL M"
]
3 => array:1 [
"name" => "MUCHADEYI M"
]
4 => array:1 [
"name" => "BAIRD R"
]
5 => array:1 [
"name" => "IMAZ-IGLESIA I"
]
6 => array:1 [
"name" => "NAGY B"
]
7 => array:1 [
"name" => "POSTMA MJ"
]
8 => array:1 [
"name" => "RETEL V"
]
9 => array:1 [
"name" => "SCHLANDER M"
]
]
"ouvrage" => "ISPOR Europe 2022"
"keywords" => []
"updatedAt" => "2023-06-26 11:21:08"
"publicationUrl" => "https://doi.org/10.1016/j.jval.2022.09.1755"
"publicationInfo" => array:3 [
"pages" => "S354"
"volume" => "25"
"number" => "12"
]
"type" => array:2 [
"fr" => "Communications dans une conférence"
"en" => "Presentations at an Academic or Professional conference"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Cancer research is rapidly evolving with the proliferation of molecular targeted therapies. New types of adaptive, basket, and umbrella trials came to fore to assess innovative treatments tied to the existence of selected biomarkers rather than histological site. There is a lack of sound methodological guidance on conducting health economic evaluations alongside new trial designs. This study aims to investigate 1) how clinical evidence from such trials can be used in economic analyses, and 2) how HTA can respond to the paradigm shift in cancer research and development."
"en" => "Cancer research is rapidly evolving with the proliferation of molecular targeted therapies. New types of adaptive, basket, and umbrella trials came to fore to assess innovative treatments tied to the existence of selected biomarkers rather than histological site. There is a lack of sound methodological guidance on conducting health economic evaluations alongside new trial designs. This study aims to investigate 1) how clinical evidence from such trials can be used in economic analyses, and 2) how HTA can respond to the paradigm shift in cancer research and development."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
84 => Essec\Faculty\Model\Contribution {#2471
#_index: "academ_contributions"
#_id: "14061"
#_source: array:18 [
"id" => "14061"
"slug" => "posb405-data-governance-for-rwd-e-management-optimising-its-use-in-hta-and-decision-making"
"yearMonth" => "2022-11"
"year" => "2022"
"title" => "POSB405 Data Governance for Rwd/E Management: Optimising Its Use in HTA and Decision-Making"
"description" => "SIGURÐARDÓTTIR, K., SOLA-MORALES, O., MURPHY, L., CORRY, S., MESTRE-FERRANDIZ, J., CUNNINGHAM, D. ... PUYOU DE POUVOURVILLE, G. (2022). POSB405 Data Governance for Rwd/E Management: Optimising Its Use in HTA and Decision-Making. Dans: Virtual ISPOR Europe 2021 Meeting."
"authors" => array:8 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "SIGURÐARDÓTTIR K"
]
2 => array:1 [
"name" => "SOLA-MORALES O"
]
3 => array:1 [
"name" => "MURPHY LA"
]
4 => array:1 [
"name" => "CORRY S"
]
5 => array:1 [
"name" => "MESTRE-FERRANDIZ J"
]
6 => array:1 [
"name" => "CUNNINGHAM D"
]
7 => array:1 [
"name" => "AKEHURST R"
]
]
"ouvrage" => "Virtual ISPOR Europe 2021 Meeting"
"keywords" => []
"updatedAt" => "2023-06-26 16:08:04"
"publicationUrl" => "https://doi.org/10.1016/j.jval.2021.11.1268"
"publicationInfo" => array:3 [
"pages" => "S260"
"volume" => "25"
"number" => "1"
]
"type" => array:2 [
"fr" => "Communications dans une conférence"
"en" => "Presentations at an Academic or Professional conference"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Real-World Data (RWD) and Real-World Evidence (RWE) can provide extensive information on health care to use in HTA and regulatory decision-making. However, there is a lack of consensus surrounding the appropriate data governance practices for RWD/E. Data sharing is also a large concern, especially considering novel data protection regulations (GDPR). Our objective is to propose recommendations for international standards of evaluating the acceptability of RWD governance practices. These could benefit all RWD users, such as public/private researchers, data managers and regulatory/HTA assessment bodies."
"en" => "Real-World Data (RWD) and Real-World Evidence (RWE) can provide extensive information on health care to use in HTA and regulatory decision-making. However, there is a lack of consensus surrounding the appropriate data governance practices for RWD/E. Data sharing is also a large concern, especially considering novel data protection regulations (GDPR). Our objective is to propose recommendations for international standards of evaluating the acceptability of RWD governance practices. These could benefit all RWD users, such as public/private researchers, data managers and regulatory/HTA assessment bodies."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
85 => Essec\Faculty\Model\Contribution {#2472
#_index: "academ_contributions"
#_id: "14062"
#_source: array:18 [
"id" => "14062"
"slug" => "facilitating-corrected-more-efficient-negotiations-for-innovative-therapies-a-value-based-negotiation-framework"
"yearMonth" => "2022-03"
"year" => "2022"
"title" => "Facilitating [corrected] More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework"
"description" => "WHITTAL, A., JOMMI, C., PUYOU DE POUVOURVILLE, G., TAYLOR, D., ANNEMANS, L., SCHOONAERT, L. ... PATRIS, J. (2022). Facilitating [corrected] More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework. International Journal of Technology Assessment in Health Care."
"authors" => array:9 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "WHITTAL Amanda"
]
2 => array:1 [
"name" => "JOMMI Claudio"
]
3 => array:1 [
"name" => "TAYLOR David"
]
4 => array:1 [
"name" => "ANNEMANS Lieven"
]
5 => array:1 [
"name" => "SCHOONAERT Lies"
]
6 => array:1 [
"name" => "VERMEERSCH Sebastian"
]
7 => array:1 [
"name" => "HUTCHINGS Adam"
]
8 => array:1 [
"name" => "PATRIS Julien"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2023-06-26 11:37:33"
"publicationUrl" => "https://pubmed.ncbi.nlm.nih.gov/35274602/"
"publicationInfo" => array:3 [
"pages" => "e23"
"volume" => "38"
"number" => "1"
]
"type" => array:2 [
"fr" => "Autre"
"en" => "Other"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => """
Results: The framework aims to (i) systematically identify and prioritize manufacturer and payer concerns about a new treatment, and (ii) select a mutually acceptable combination of MEA terms that can best address priority concerns, with the lowest possible implementation burden.\n
\n
Conclusions: The proposed framework will be tested in practice, and is a step toward supporting payers and manufacturers to engage in more structured, transparent negotiations to balance the needs of both sides, and enabling quicker, more transparent MEA negotiations and patient access to innovative products.
"""
"en" => """
Results: The framework aims to (i) systematically identify and prioritize manufacturer and payer concerns about a new treatment, and (ii) select a mutually acceptable combination of MEA terms that can best address priority concerns, with the lowest possible implementation burden.\n
\n
Conclusions: The proposed framework will be tested in practice, and is a step toward supporting payers and manufacturers to engage in more structured, transparent negotiations to balance the needs of both sides, and enabling quicker, more transparent MEA negotiations and patient access to innovative products.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
86 => Essec\Faculty\Model\Contribution {#2473
#_index: "academ_contributions"
#_id: "14065"
#_source: array:18 [
"id" => "14065"
"slug" => "quality-of-life-in-ssc-ild-patients-understanding-the-impact-of-the-ild-and-the-needs-of-the-ssc-ild-patients-and-their-need-for-caregivers-in-france"
"yearMonth" => "2022-02"
"year" => "2022"
"title" => "Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France"
"description" => "ALLANORE, Y., CONSTANS, J., GODARD, D., PUYOU DE POUVOURVILLE, G., BOUEE, S., JEANBAT, V. ... HACHULLA, E. (2022). Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. <i>Journal of Scleroderma and Related Disorders</i>, 7(1), pp. 49-56."
"authors" => array:10 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "ALLANORE Yannick"
]
2 => array:1 [
"name" => "CONSTANS Joel"
]
3 => array:1 [
"name" => "GODARD Dominique"
]
4 => array:1 [
"name" => "BOUEE Stephane"
]
5 => array:1 [
"name" => "JEANBAT Viviane"
]
6 => array:1 [
"name" => "TEISSIER Clement"
]
7 => array:1 [
"name" => "LE LAY Katell"
]
8 => array:1 [
"name" => "CHOLLET Julien"
]
9 => array:1 [
"name" => "HACHULLA Eric"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2024-10-31 13:51:19"
"publicationUrl" => "https://doi.org/10.1177/23971983211013979"
"publicationInfo" => array:3 [
"pages" => "49-56"
"volume" => "7"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "The objectives of this study were to describe the impact of systemic sclerosis associated interstitial lung disease, on quality of life, to estimate the correlation between quality of life and severity of lung disease and to assess the impact of interstitial lung disease on caregivers."
"en" => "The objectives of this study were to describe the impact of systemic sclerosis associated interstitial lung disease, on quality of life, to estimate the correlation between quality of life and severity of lung disease and to assess the impact of interstitial lung disease on caregivers."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
87 => Essec\Faculty\Model\Contribution {#2474
#_index: "academ_contributions"
#_id: "14068"
#_source: array:18 [
"id" => "14068"
"slug" => "use-of-complementary-and-alternative-medicines-by-patients-with-psoriasis-results-from-a-study-with-2562-patients"
"yearMonth" => "2021-03"
"year" => "2021"
"title" => "Use of Complementary and Alternative Medicines by Patients with Psoriasis: Results from a Study with 2562 Patients"
"description" => "MISERY, L., SHOURICK, J., SÉNÉSCHAL, J., PAUL, C., PUYOU DE POUVOURVILLE, G., JULLIEN, D. ... RICHARD, M.A. (2021). Use of Complementary and Alternative Medicines by Patients with Psoriasis: Results from a Study with 2562 Patients. <i>American Journal of Clinical Dermatology</i>, 22(2), pp. 285-287."
"authors" => array:15 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "MISERY Laurent"
]
2 => array:1 [
"name" => "SHOURICK Jason"
]
3 => array:1 [
"name" => "SÉNÉSCHAL Julien"
]
4 => array:1 [
"name" => "PAUL Carle"
]
5 => array:1 [
"name" => "JULLIEN Denis"
]
6 => array:1 [
"name" => "MAHÉ Emmanuel"
]
7 => array:1 [
"name" => "BACHELEZ Hervé"
]
8 => array:1 [
"name" => "AUBERT Roberte"
]
9 => array:1 [
"name" => "JOLY Pascal"
]
10 => array:1 [
"name" => "HÉAS Stéphane"
]
11 => array:1 [
"name" => "REGUIAI Ziad"
]
12 => array:1 [
"name" => "EZZEDINE Khaled"
]
13 => array:1 [
"name" => "TAIEB Charles"
]
14 => array:1 [
"name" => "RICHARD Marie-Aleth"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2023-06-23 11:20:57"
"publicationUrl" => "https://doi.org/10.1007/s40257-021-00587-7"
"publicationInfo" => array:3 [
"pages" => "285-287"
"volume" => "22"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => ""
"en" => ""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
88 => Essec\Faculty\Model\Contribution {#2475
#_index: "academ_contributions"
#_id: "14075"
#_source: array:18 [
"id" => "14075"
"slug" => "psoriasis-frequency-and-reasons-for-absenteeism-results-from-a-study-on-1609-active-patients"
"yearMonth" => "2021-04"
"year" => "2021"
"title" => "Psoriasis: frequency and reasons for absenteeism results from a study on 1609 active patients"
"description" => "JULLIEN, D., PAUL, C., SHOURICK, J., SÉNÉSCHAL, J., PUYOU DE POUVOURVILLE, G., MISERY, L. ... RICHARD, M.A. (2021). Psoriasis: frequency and reasons for absenteeism results from a study on 1609 active patients. <i>Journal of the European Academy of Dermatology and Venereology</i>, 35(4), pp. e301-e303."
"authors" => array:15 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "JULLIEN D."
]
2 => array:1 [
"name" => "PAUL C."
]
3 => array:1 [
"name" => "SHOURICK J."
]
4 => array:1 [
"name" => "SÉNÉSCHAL J."
]
5 => array:1 [
"name" => "MISERY L."
]
6 => array:1 [
"name" => "MAHÉ E."
]
7 => array:1 [
"name" => "BACHELEZ H."
]
8 => array:1 [
"name" => "AUBERT R."
]
9 => array:1 [
"name" => "JOLY P."
]
10 => array:1 [
"name" => "HÉAS S."
]
11 => array:1 [
"name" => "REGUIAI Z."
]
12 => array:1 [
"name" => "EZZEDINE K."
]
13 => array:1 [
"name" => "TAIEB C."
]
14 => array:1 [
"name" => "RICHARD M.A."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2023-06-26 16:34:34"
"publicationUrl" => "https://onlinelibrary.wiley.com/doi/10.1111/jdv.17056"
"publicationInfo" => array:3 [
"pages" => "e301-e303"
"volume" => "35"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => ""
"en" => ""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
89 => Essec\Faculty\Model\Contribution {#2476
#_index: "academ_contributions"
#_id: "14090"
#_source: array:18 [
"id" => "14090"
"slug" => "budget-impact-analysis-of-expanding-gliflozin-coverage-in-the-ckd-population-a-french-perspective"
"yearMonth" => "2023-06"
"year" => "2023"
"title" => "Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective"
"description" => "PUYOU DE POUVOURVILLE, G., ROSSIGNOL, P., BOUSSAHOUA, M., CHEVALIER, J., GABB, P.D., POULNAIS, R. ... GARCIA SANCHEZ, J.J. (2023). Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective. <i>Advances in Therapy</i>, 40, pp. 3751-3769."
"authors" => array:10 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "ROSSIGNOL Patrick"
]
2 => array:1 [
"name" => "BOUSSAHOUA Meriem"
]
3 => array:1 [
"name" => "CHEVALIER Julie"
]
4 => array:1 [
"name" => "GABB Peter D."
]
5 => array:1 [
"name" => "POULNAIS Roch"
]
6 => array:1 [
"name" => "VERBOUX Dorian"
]
7 => array:1 [
"name" => "RAO Naveen"
]
8 => array:1 [
"name" => "SÖRSTADIUS Elisabeth"
]
9 => array:1 [
"name" => "GARCIA SANCHEZ Juan Jose"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2024-10-31 13:51:19"
"publicationUrl" => "https://doi.org/10.1007/s12325-023-02574-2"
"publicationInfo" => array:3 [
"pages" => "3751-3769"
"volume" => "40"
"number" => null
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Gliflozins have historically been indicated for type 2 diabetes in France. However, their efficacy has recently been demonstrated in heart failure and chronic kidney disease (CKD), with positive recommendations by Haute Autorité de Santé for gliflozin therapies in these indications. The study objective was to investigate the 5-year budget impact associated with the introduction of gliflozins in addition to standard therapy in people with CKD and elevated albuminuria, regardless of diabetes status, from the perspective of the French healthcare system."
"en" => "Gliflozins have historically been indicated for type 2 diabetes in France. However, their efficacy has recently been demonstrated in heart failure and chronic kidney disease (CKD), with positive recommendations by Haute Autorité de Santé for gliflozin therapies in these indications. The study objective was to investigate the 5-year budget impact associated with the introduction of gliflozins in addition to standard therapy in people with CKD and elevated albuminuria, regardless of diabetes status, from the perspective of the French healthcare system."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
90 => Essec\Faculty\Model\Contribution {#2477
#_index: "academ_contributions"
#_id: "14611"
#_source: array:18 [
"id" => "14611"
"slug" => "epidemiology-of-myasthenia-gravis-in-france-a-retrospective-claims-database-study-stamina"
"yearMonth" => "2024-03"
"year" => "2024"
"title" => "Epidemiology of myasthenia gravis in France: A retrospective claims database study (STAMINA)"
"description" => "SALORT-CAMPANA, E., LAFORET, P., PUYOU DE POUVOURVILLE, G., CROCHARD, A., CHOLLET, G., NEVORET, C. ... TARD, C. (2024). Epidemiology of myasthenia gravis in France: A retrospective claims database study (STAMINA). <i>Revue Neurologique</i>, 180(3), pp. 202-210."
"authors" => array:9 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "SALORT-CAMPANA E."
]
2 => array:1 [
"name" => "LAFORET P."
]
3 => array:1 [
"name" => "CROCHARD A."
]
4 => array:1 [
"name" => "CHOLLET G."
]
5 => array:1 [
"name" => "NEVORET C."
]
6 => array:1 [
"name" => "EMERY C."
]
7 => array:1 [
"name" => "BOUÉE S."
]
8 => array:1 [
"name" => "TARD C."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2024-03-18 12:12:37"
"publicationUrl" => "https://doi.org/10.1016/j.neurol.2023.09.004"
"publicationInfo" => array:3 [
"pages" => "202-210"
"volume" => "180"
"number" => "3"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "The objectives of this observational study were to report the incidence and prevalence of myasthenia gravis (MG) in France, describe patients’ characteristics and treatment patterns, and estimate mortality."
"en" => "The objectives of this observational study were to report the incidence and prevalence of myasthenia gravis (MG) in France, describe patients’ characteristics and treatment patterns, and estimate mortality."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
91 => Essec\Faculty\Model\Contribution {#2478
#_index: "academ_contributions"
#_id: "14649"
#_source: array:18 [
"id" => "14649"
"slug" => "respiratory-syncytial-virus-related-hospital-stays-in-adults-in-france-from-2012-to-2021-a-national-hospital-database-study"
"yearMonth" => "2024-04"
"year" => "2024"
"title" => "Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study"
"description" => "LOUBET, P., FERNANDES, J., PUYOU DE POUVOURVILLE, G., SOSNOWIEZ, K., ELONG, A., GUILMET, C. ... CHAKRA, C.N.A. (2024). Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study. <i>Journal of Clinical Virology</i>, 171, pp. 105635."
"authors" => array:11 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Loubet Paul"
]
2 => array:1 [
"name" => "Fernandes Jérôme"
]
3 => array:1 [
"name" => "Sosnowiez Katia"
]
4 => array:1 [
"name" => "Elong Anne"
]
5 => array:1 [
"name" => "Guilmet Caroline"
]
6 => array:1 [
"name" => "Omichessan Hanane"
]
7 => array:1 [
"name" => "Bureau Isabelle"
]
8 => array:1 [
"name" => "Fagnani Francis"
]
9 => array:1 [
"name" => "Emery Corinne"
]
10 => array:1 [
"name" => "Chakra Claire Nour Abou"
]
]
"ouvrage" => ""
"keywords" => array:4 [
0 => "Respiratory syncytial virus"
1 => "Hospitalization"
2 => "Epidemiology"
3 => "France"
]
"updatedAt" => "2024-10-31 13:51:19"
"publicationUrl" => "https://doi.org/10.1016/j.jcv.2023.105635"
"publicationInfo" => array:3 [
"pages" => "105635"
"volume" => "171"
"number" => null
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => "Pays-Bas"
"en" => "Netherlands"
]
"abstract" => array:2 [
"fr" => """
Respiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTI) that may lead to hospitalization or death. The present study aimed to assess the burden of RSV infections in hospitalized adults.\n
RSV-related hospitalizations were identified from the nationwide hospital claims database in France (PMSI) from 2012 to 2021 using ICD-10 codes J12.1, J20.5, J21.0 or B97.4, and outcomes assessment focused on 2016–2020. In-hospital outcomes included length of stay, need for intensive care (ICU) and in-hospital all-cause mortality. Post-discharge outcomes included 30-day readmission for decompensation, 90-day RSV-related readmission, and 30 and 60-day in-hospital mortality.\n
A cumulated number of 17 483 RSV-related stays were identified representing a rate of 72.0 cases per million stays. The outcomes assessment included 12,987 patients: 55.8 % were females and the mean age was 74.1 ± 16.4 years, with 57 % ≥ 75 years. Most of patients (78.6 %) had at least one comorbidity, mainly chronic respiratory (56.3 %) and cardiovascular diseases (41.3 %), or diabetes (23.5 %). A co-infection was found in 22.4 %, primarily bacterial (12 %). The mean length of stay was 12.3 ± 13.1 days. Overall, 10.9 % were admitted to an ICU and in-hospital mortality was 7.3 %. In-hospital outcomes were higher in cases of co-infection. Among 12 033 patients alive at discharge from the index stay, 6.5 % were readmitted with RSV within 90 days, 8.1 % for decompensation within 30 days, and 5.6 % died within 60-day.\n
This study demonstrated the high burden of RSV infections in older adults and those with chronic conditions, and the need for preventive strategies.
"""
"en" => """
Respiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTI) that may lead to hospitalization or death. The present study aimed to assess the burden of RSV infections in hospitalized adults.\n
RSV-related hospitalizations were identified from the nationwide hospital claims database in France (PMSI) from 2012 to 2021 using ICD-10 codes J12.1, J20.5, J21.0 or B97.4, and outcomes assessment focused on 2016–2020. In-hospital outcomes included length of stay, need for intensive care (ICU) and in-hospital all-cause mortality. Post-discharge outcomes included 30-day readmission for decompensation, 90-day RSV-related readmission, and 30 and 60-day in-hospital mortality.\n
A cumulated number of 17 483 RSV-related stays were identified representing a rate of 72.0 cases per million stays. The outcomes assessment included 12,987 patients: 55.8 % were females and the mean age was 74.1 ± 16.4 years, with 57 % ≥ 75 years. Most of patients (78.6 %) had at least one comorbidity, mainly chronic respiratory (56.3 %) and cardiovascular diseases (41.3 %), or diabetes (23.5 %). A co-infection was found in 22.4 %, primarily bacterial (12 %). The mean length of stay was 12.3 ± 13.1 days. Overall, 10.9 % were admitted to an ICU and in-hospital mortality was 7.3 %. In-hospital outcomes were higher in cases of co-infection. Among 12 033 patients alive at discharge from the index stay, 6.5 % were readmitted with RSV within 90 days, 8.1 % for decompensation within 30 days, and 5.6 % died within 60-day.\n
This study demonstrated the high burden of RSV infections in older adults and those with chronic conditions, and the need for preventive strategies.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
92 => Essec\Faculty\Model\Contribution {#2479
#_index: "academ_contributions"
#_id: "14752"
#_source: array:18 [
"id" => "14752"
"slug" => "the-determination-of-diabetes-utilities-costs-and-effects-model-a-cost-utility-tool-using-patient-level-microsimulation-to-evaluate-sensor-based-glucose-monitoring-systems-in-type-1-and-type-2-diab"
"yearMonth" => "2024-02"
"year" => "2024"
"title" => "The Determination of Diabetes Utilities, Costs, and Effects Model, A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation"
"description" => "SZAFRANSKI, K., PUYOU DE POUVOURVILLE, G., GREENBERG, D., HARRIS, S., JENDLE, J., SHAW, J.E. ... LEVRAT-GUILLEN, F. (2024). The Determination of Diabetes Utilities, Costs, and Effects Model, A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation. <i>Value in Health</i>, In press, pp. 8."
"authors" => array:9 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Szafranski Kirk"
]
2 => array:1 [
"name" => "Greenberg Dan"
]
3 => array:1 [
"name" => "Harris Stewart"
]
4 => array:1 [
"name" => "Jendle Johan"
]
5 => array:1 [
"name" => "Shaw Jonathan E."
]
6 => array:1 [
"name" => "Castro JeanPierre Coaquira"
]
7 => array:1 [
"name" => "Poon Yeesha"
]
8 => array:1 [
"name" => "Levrat-Guillen Fleur"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "DEDUCE model"
1 => "patient-level microsimulation"
2 => "sensor-based glucose monitoring systems"
]
"updatedAt" => "2024-10-31 13:51:19"
"publicationUrl" => "https://doi.org/10.1016/j.jval.2024.01.010"
"publicationInfo" => array:3 [
"pages" => "8"
"volume" => "In press"
"number" => null
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => """
Existing cost-effectiveness models in diabetes are useful, but they are not suitable for all health technology assessment (HTA) agencies. The Determination of Diabetes Utilities, Costs, and Effects (DEDUCE) model was developed to better meet the needs of those HTA agencies.\n
To assess the accuracy and validity of the DEDUCE model in type 1 and type 2 diabetes.\n
DEDUCE predicts diabetes-related complications well when compared with previously validated cost-effectiveness models.\n
DEDUCE is suitable to assess the cost-effectiveness of diabetes technologies for HTA submissions.
"""
"en" => """
Existing cost-effectiveness models in diabetes are useful, but they are not suitable for all health technology assessment (HTA) agencies. The Determination of Diabetes Utilities, Costs, and Effects (DEDUCE) model was developed to better meet the needs of those HTA agencies.\n
To assess the accuracy and validity of the DEDUCE model in type 1 and type 2 diabetes.\n
DEDUCE predicts diabetes-related complications well when compared with previously validated cost-effectiveness models.\n
DEDUCE is suitable to assess the cost-effectiveness of diabetes technologies for HTA submissions.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
93 => Essec\Faculty\Model\Contribution {#2480
#_index: "academ_contributions"
#_id: "14782"
#_source: array:18 [
"id" => "14782"
"slug" => "les-cellules-car-t-prix-efficience-et-soutenabilite-en-france"
"yearMonth" => "2024-04"
"year" => "2024"
"title" => "Les cellules CAR-T : prix, efficience et soutenabilité en France"
"description" => "PUYOU DE POUVOURVILLE, G. (2024). Les cellules CAR-T : prix, efficience et soutenabilité en France. <i>Bulletin de l'Académie Nationale de Médecine</i>, In press."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => array:4 [
0 => "Car-T cells"
1 => "price"
2 => "cost-efficency"
3 => "sustainability"
]
"updatedAt" => "2024-04-24 11:07:17"
"publicationUrl" => "https://doi.org/10.1016/j.banm.2024.01.020"
"publicationInfo" => array:3 [
"pages" => ""
"volume" => "In press"
"number" => ""
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "La soutenabilité des dépenses pour les cellules CAR-T dans le futur est fonction de l’efficacité des mécanismes de fixation des prix en France, remises et contrats à la performance fondée sur des données en vie réelle. Les coûts de production vont baisser, mais l’émergence d’acteurs privés à but non lucratif aurait un impact majeur sur les prix. Les pertes de brevet attendues de médicaments à fort impact budgétaire vont dégager des marges de manœuvre pour le payeur public en France."
"en" => "The sustainability of spending on CAR-T cells in the future depends on the effectiveness of pricing mechanisms in France, discounts and performance-based contracts based on real-life data. Production costs will fall, but the emergence of private, non-profit players would have a major impact on prices. The expected patent losses for drugs with a strong budgetary impact will generate major savings for the French public payer."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
94 => Essec\Faculty\Model\Contribution {#2481
#_index: "academ_contributions"
#_id: "14815"
#_source: array:18 [
"id" => "14815"
"slug" => "medico-economic-evaluation-of-health-products-in-the-context-of-the-social-security-financing-act-for-2012"
"yearMonth" => "2013-07"
"year" => "2013"
"title" => "Medico-economic Evaluation of Health Products in the Context of the Social Security Financing Act for 2012"
"description" => "DERVAUX, B., BASEILHAC, E., FAGON, J.Y., AMEYE, V., ANGOT, P., AUDRY, A. ... SUN, A. (2013). Medico-economic Evaluation of Health Products in the Context of the Social Security Financing Act for 2012. <i>Therapies</i>, 68(4), pp. 259-263."
"authors" => array:23 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Dervaux Benoît"
]
2 => array:1 [
"name" => "Baseilhac Eric"
]
3 => array:1 [
"name" => "Fagon Jean-Yves"
]
4 => array:1 [
"name" => "Ameye Véronique"
]
5 => array:1 [
"name" => "Angot Pierre"
]
6 => array:1 [
"name" => "Audry Antoine"
]
7 => array:1 [
"name" => "Becquemont Laurent"
]
8 => array:1 [
"name" => "Borel Thomas"
]
9 => array:1 [
"name" => "Cazeneuve Béatrice"
]
10 => array:1 [
"name" => "Courtois Jocelyn"
]
11 => array:1 [
"name" => "Detournay Bruno"
]
12 => array:1 [
"name" => "Favre Pascal"
]
13 => array:1 [
"name" => "Granger Muriel"
]
14 => array:1 [
"name" => "Josseran Anne"
]
15 => array:1 [
"name" => "Lassale Catherine"
]
16 => array:1 [
"name" => "Louvet Olivier"
]
17 => array:1 [
"name" => "Pinson Jean"
]
18 => array:1 [
"name" => "Rochaix Lise"
]
19 => array:1 [
"name" => "Rumeau-Pichon Catherine"
]
20 => array:1 [
"name" => "de Saab Rima"
]
21 => array:1 [
"name" => "Schwarzinger Mickaël"
]
22 => array:1 [
"name" => "Sun Aristide"
]
]
"ouvrage" => ""
"keywords" => array:1 [
0 => "Social Security Financing Act for 2012"
]
"updatedAt" => "2024-05-29 01:01:19"
"publicationUrl" => "https://doi.org/10.2515/therapie/2013045"
"publicationInfo" => array:3 [
"pages" => "259-263"
"volume" => "68"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => "France"
"en" => "France"
]
"abstract" => array:2 [
"fr" => "The participants in round table 6 of the Giens Workshops 2012 drafted recommendations based on the collective interpretation of important elements of the decree concerning the medico-economic evaluation of health products published a few days earlier (02 October 2012). The medico-economic evaluation (MEE), becomes an additional determinant for fixing the prices of health products by the Health products economic committee (Comité économique des produits de santé, CEPS) via the hierarchisation of treatment strategies, and thus modifies the market access conditions."
"en" => "The participants in round table 6 of the Giens Workshops 2012 drafted recommendations based on the collective interpretation of important elements of the decree concerning the medico-economic evaluation of health products published a few days earlier (02 October 2012). The medico-economic evaluation (MEE), becomes an additional determinant for fixing the prices of health products by the Health products economic committee (Comité économique des produits de santé, CEPS) via the hierarchisation of treatment strategies, and thus modifies the market access conditions."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
95 => Essec\Faculty\Model\Contribution {#2482
#_index: "academ_contributions"
#_id: "14817"
#_source: array:18 [
"id" => "14817"
"slug" => "health-related-quality-of-life-in-patients-with-community-acquired-pneumococcal-pneumonia-in-france"
"yearMonth" => "2018-12"
"year" => "2018"
"title" => "Health related quality of life in patients with community-acquired pneumococcal pneumonia in France"
"description" => "ANDRADE, L.F., SABA, G., RICARD, J.D., MESSIKA, J., GAILLAT, J., BONNIN, P. ... PUYOU DE POUVOURVILLE, G. (2018). Health related quality of life in patients with community-acquired pneumococcal pneumonia in France. <i>Health and Quality of Life Outcomes</i>, 16(1)."
"authors" => array:12 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Andrade Luiz Flavio"
]
2 => array:1 [
"name" => "Saba Grèce"
]
3 => array:1 [
"name" => "Ricard Jean-Damien"
]
4 => array:1 [
"name" => "Messika Jonathan"
]
5 => array:1 [
"name" => "Gaillat Jacques"
]
6 => array:1 [
"name" => "Bonnin Pierre"
]
7 => array:1 [
"name" => "Chidiac Christian"
]
8 => array:1 [
"name" => "Illes Hajnal-Gabriela"
]
9 => array:1 [
"name" => "Laurichesse Henri"
]
10 => array:1 [
"name" => "Detournay Bruno"
]
11 => array:1 [
"name" => "Petitpretz Patrick"
]
]
"ouvrage" => ""
"keywords" => array:6 [
0 => "Community Acquired Pneumococcal Pneumonia"
1 => "CAP"
2 => "EQ-5D"
3 => "Pneumonia"
4 => "Quality of life"
5 => "Tobit model"
]
"updatedAt" => "2024-05-28 16:16:05"
"publicationUrl" => "https://doi.org/10.1186/s12955-018-0854-6"
"publicationInfo" => array:3 [
"pages" => ""
"volume" => "16"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Community Acquired Pneumococcal Pneumonia is a lung infection that causes serious health problems and can lead to complications and death. The aim of this study was to observe and analyze health related quality of life after a hospital episode for patients with community acquired pneumococcal pneumonia in France."
"en" => "Community Acquired Pneumococcal Pneumonia is a lung infection that causes serious health problems and can lead to complications and death. The aim of this study was to observe and analyze health related quality of life after a hospital episode for patients with community acquired pneumococcal pneumonia in France."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
96 => Essec\Faculty\Model\Contribution {#2483
#_index: "academ_contributions"
#_id: "14820"
#_source: array:18 [
"id" => "14820"
"slug" => "effectiveness-of-montelukast-on-asthma-control-in-infants-methodology-of-a-french-claims-data-study"
"yearMonth" => "2015-12"
"year" => "2015"
"title" => "Effectiveness of Montelukast on asthma control in infants: methodology of a French claims data study"
"description" => "BELHASSEN, M., PUYOU DE POUVOURVILLE, G., LAFOREST, L., BROUARD, J., DE BLIC, J., FAUROUX, B. ... VAN GANSE, E. (2015). Effectiveness of Montelukast on asthma control in infants: methodology of a French claims data study. <i>BMC Pulmonary Medicine</i>, 15(Art. 51)."
"authors" => array:10 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Belhassen Manon"
]
2 => array:1 [
"name" => "Laforest Laurent"
]
3 => array:1 [
"name" => "Brouard Jacques"
]
4 => array:1 [
"name" => "de Blic Jacques"
]
5 => array:1 [
"name" => "Fauroux Brigitte"
]
6 => array:1 [
"name" => "Laigle Valérie"
]
7 => array:1 [
"name" => "Chanut-Vogel Céline"
]
8 => array:1 [
"name" => "Lamezec Liliane"
]
9 => array:1 [
"name" => "Van Ganse Eric"
]
]
"ouvrage" => ""
"keywords" => array:9 [
0 => "Asthma"
1 => "Therapy"
2 => "Control"
3 => "Exacerbation"
4 => "Infants"
5 => "Effectiveness"
6 => "Claims data"
7 => "Cohort study"
8 => "Pilot study"
]
"updatedAt" => "2024-10-31 13:51:19"
"publicationUrl" => "https://doi.org/10.1186/s12890-015-0047-6"
"publicationInfo" => array:3 [
"pages" => null
"volume" => "15"
"number" => "Art. 51"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "This pilot study, conducted on a 1/97th representative sample of French claims data, prepared a project to assess the effectiveness of Montelukast (MTL-4) as add-on therapy for asthma in infants (6–24 months) compared to inhaled corticosteroids (ICS), based on real-world data. Due to the very recent opening of French claims data for effectiveness research, and the complex structure of this data source, we first tested the feasibility of identifying infants with asthma and outcome criteria, and the ability to perform relevant comparisons."
"en" => "This pilot study, conducted on a 1/97th representative sample of French claims data, prepared a project to assess the effectiveness of Montelukast (MTL-4) as add-on therapy for asthma in infants (6–24 months) compared to inhaled corticosteroids (ICS), based on real-world data. Due to the very recent opening of French claims data for effectiveness research, and the complex structure of this data source, we first tested the feasibility of identifying infants with asthma and outcome criteria, and the ability to perform relevant comparisons."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
97 => Essec\Faculty\Model\Contribution {#2484
#_index: "academ_contributions"
#_id: "14836"
#_source: array:18 [
"id" => "14836"
"slug" => "public-health-impact-and-cost-effectiveness-analysis-of-4-component-meningococcal-serotype-b-vaccination-for-infants-in-france"
"yearMonth" => "2024-05"
"year" => "2024"
"title" => "Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France"
"description" => "PUYOU DE POUVOURVILLE, G., BREAU-BRUNEL, M., LONCLE-PROVOT, V., BECK, E., GAUGAIN, L., NACHBAUR, G. et PRIBIL, C. (2024). Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France. <i>PharmacoEconomics - Open</i>, In press."
"authors" => array:7 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Breau-Brunel Manon"
]
2 => array:1 [
"name" => "Loncle-Provot Véronique"
]
3 => array:1 [
"name" => "Beck Ekkehard"
]
4 => array:1 [
"name" => "Gaugain Loïg"
]
5 => array:1 [
"name" => "Nachbaur Gaëlle"
]
6 => array:1 [
"name" => "Pribil Céline"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "meningococcal serogroup B (MenB)"
1 => "meningococcal disease (IMD)"
2 => "cost-effectiveness of infant vaccination"
]
"updatedAt" => "2024-10-31 13:51:19"
"publicationUrl" => "https://doi.org/10.1007/s41669-024-00488-5"
"publicationInfo" => array:3 [
"pages" => null
"volume" => "In press"
"number" => null
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Background and Objectives In France, meningococcal serogroup B (MenB) is the most common serogroup causing invasive meningococcal disease (IMD) in infants and young children. Our objective was to illustrate the impact of model choices on health outcomes and the cost-effectiveness of infant vaccination with the multicomponent meningococcal serogroup B vaccine (4CMenB) versus no vaccine in France. Methods A previously published dynamic transmission-based cost-effectiveness model was adapted for the French context using updated, French-specific demographic, epidemiological, and cost data. IMD incidence and long-term sequelae were derived through analysis of French healthcare and surveillance databases. A collective perspective over a 100-year time horizon was adopted, with a discount rate of 2.5%, reduced to 1.5% after the first 30 years. Deterministic and probabilistic sensitivity and scenario analyses were performed. Results In the base case analysis, infant vaccination with 4CMenB avoided 3101 MenB IMD cases in infants aged < 1 year (− 54%) and 6845 cases in all age groups (− 21%). The estimated incremental cost-effectiveness ratio was €316,272/qualityadjusted life-year (QALY) but was highly sensitive to the types of sequelae included, MenB incidence, vaccine effectiveness parameters, and consideration of life-expectancy in IMD survivors (range: €65,272/QALY to €493,218/QALY). Conclusions Using economic models compliant with French methodology guidelines, 4CMenB does not seem cost-effective; however, results are sensitive to model choices and 4CMenB immunization is an effective strategy to prevent MenB IMD cases and to improve quality of life and economic burden associated with MenB IMD treatment, especially with regard to long-term sequelae."
"en" => "Background and Objectives In France, meningococcal serogroup B (MenB) is the most common serogroup causing invasive meningococcal disease (IMD) in infants and young children. Our objective was to illustrate the impact of model choices on health outcomes and the cost-effectiveness of infant vaccination with the multicomponent meningococcal serogroup B vaccine (4CMenB) versus no vaccine in France. Methods A previously published dynamic transmission-based cost-effectiveness model was adapted for the French context using updated, French-specific demographic, epidemiological, and cost data. IMD incidence and long-term sequelae were derived through analysis of French healthcare and surveillance databases. A collective perspective over a 100-year time horizon was adopted, with a discount rate of 2.5%, reduced to 1.5% after the first 30 years. Deterministic and probabilistic sensitivity and scenario analyses were performed. Results In the base case analysis, infant vaccination with 4CMenB avoided 3101 MenB IMD cases in infants aged < 1 year (− 54%) and 6845 cases in all age groups (− 21%). The estimated incremental cost-effectiveness ratio was €316,272/qualityadjusted life-year (QALY) but was highly sensitive to the types of sequelae included, MenB incidence, vaccine effectiveness parameters, and consideration of life-expectancy in IMD survivors (range: €65,272/QALY to €493,218/QALY). Conclusions Using economic models compliant with French methodology guidelines, 4CMenB does not seem cost-effective; however, results are sensitive to model choices and 4CMenB immunization is an effective strategy to prevent MenB IMD cases and to improve quality of life and economic burden associated with MenB IMD treatment, especially with regard to long-term sequelae."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
98 => Essec\Faculty\Model\Contribution {#2485
#_index: "academ_contributions"
#_id: "14857"
#_source: array:18 [
"id" => "14857"
"slug" => "human-papillomavirus-hpv-vaccination-coverage-among-french-adolescents-a-claims-data-study"
"yearMonth" => "2024-06"
"year" => "2024"
"title" => "Human Papillomavirus (HPV) vaccination coverage among French adolescents: A claims data study"
"description" => "PUYOU DE POUVOURVILLE, G., GUYOT, E., FARGE, G., BELHASSEN, M., BÉRARD, M., JACOUD, F. ... BALDAUF, J.J. (2024). Human Papillomavirus (HPV) vaccination coverage among French adolescents: A claims data study. <i>Vaccine</i>, In press."
"authors" => array:8 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Guyot E."
]
2 => array:1 [
"name" => "Farge G."
]
3 => array:1 [
"name" => "Belhassen M."
]
4 => array:1 [
"name" => "Bérard M."
]
5 => array:1 [
"name" => "Jacoud F."
]
6 => array:1 [
"name" => "Bensimon L."
]
7 => array:1 [
"name" => "Baldauf J.J."
]
]
"ouvrage" => ""
"keywords" => array:5 [
0 => "Human papillomavirus"
1 => "Vaccination coverage rate"
2 => "Claims database"
3 => "Full vaccination"
4 => "Partial vaccination"
]
"updatedAt" => "2024-10-31 13:51:19"
"publicationUrl" => "https://doi.org/10.1016/j.vaccine.2024.06.007"
"publicationInfo" => array:3 [
"pages" => null
"volume" => "In press"
"number" => null
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "The French cancer control strategy 2021–2030 aims to achieve 80 % human papillomavirus (HPV) vaccination coverage. Since 2021, HPV vaccination is also recommended for boys aged 11–14 years, with a catch-up vaccination recommended for unvaccinated adolescents aged ≤19 years. The PAPILLON study used claims data to monitor the evolution of HPV Vaccination Coverage Rate (VCR) in the French population."
"en" => "The French cancer control strategy 2021–2030 aims to achieve 80 % human papillomavirus (HPV) vaccination coverage. Since 2021, HPV vaccination is also recommended for boys aged 11–14 years, with a catch-up vaccination recommended for unvaccinated adolescents aged ≤19 years. The PAPILLON study used claims data to monitor the evolution of HPV Vaccination Coverage Rate (VCR) in the French population."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
99 => Essec\Faculty\Model\Contribution {#2486
#_index: "academ_contributions"
#_id: "14993"
#_source: array:18 [
"id" => "14993"
"slug" => "a-budget-impact-analysis-of-a-digital-monitoring-solution-in-patients-treated-with-oral-anticancer-agents-a-medico-economic-analysis-of-the-randomized-phase-3-capri-trial"
"yearMonth" => "2024-06"
"year" => "2024"
"title" => "A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial"
"description" => "MINVIELLE, E., LELEU, H., MASSETI, M., FERREIRA, A., PUYOU DE POUVOURVILLE, G., PALMA, M.D. et SCOTTÉ, F. (2024). A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial. <i>European Journal of Health Economics</i>, In press."
"authors" => array:7 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Minvielle Etienne"
]
2 => array:1 [
"name" => "Leleu Henri"
]
3 => array:1 [
"name" => "Masseti Marc"
]
4 => array:1 [
"name" => "Ferreira Arlindo"
]
5 => array:1 [
"name" => "Palma Mario Di"
]
6 => array:1 [
"name" => "Scotté Florian"
]
]
"ouvrage" => ""
"keywords" => array:2 [
0 => "medical resource utilization and costs"
1 => "CAPRI trial"
]
"updatedAt" => "2024-07-24 01:01:26"
"publicationUrl" => "https://link.springer.com/article/10.1007/s10198-024-01702-1"
"publicationInfo" => array:3 [
"pages" => ""
"volume" => "In press"
"number" => ""
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Remote patient monitoring (RPM) has demonstrated numerous benefits in cancer care, including improved quality of life, overall survival, and reduced medical resource use. This study presents a budget impact analysis of a nurse navigator-led RPM program, based on the CAPRI trial, from the perspective of the French national health insurance (NHI). The study aimed to assess the impact of the program on medical resource utilization and costs."
"en" => "Remote patient monitoring (RPM) has demonstrated numerous benefits in cancer care, including improved quality of life, overall survival, and reduced medical resource use. This study presents a budget impact analysis of a nurse navigator-led RPM program, based on the CAPRI trial, from the perspective of the French national health insurance (NHI). The study aimed to assess the impact of the program on medical resource utilization and costs."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
100 => Essec\Faculty\Model\Contribution {#2487
#_index: "academ_contributions"
#_id: "15001"
#_source: array:18 [
"id" => "15001"
"slug" => "reduced-rate-of-hospitalizations-for-acute-diabetes-events-before-and-after-freestyle-libre-system-initiation-in-some-people-with-type-2-diabetes-on-insulin-secretagogue-oral-drug-therapy-withou"
"yearMonth" => "2024-07"
"year" => "2024"
"title" => "Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre® System Initiation in Some People With Type 2 Diabetes on Insulin-Secretagogue Oral Drug Therapy Without Insulin in France"
"description" => "RIVELINE, J.P., LEVRAT-GUILLEN, F., DETOURNAY, B., VICAUT, E., PUYOU DE POUVOURVILLE, G., EMERY, C. et GUERCI, B. (2024). Reduced Rate of Hospitalizations for Acute Diabetes Events Before and After FreeStyle Libre® System Initiation in Some People With Type 2 Diabetes on Insulin-Secretagogue Oral Drug Therapy Without Insulin in France. <i>Diabetes Technology & Therapeutics</i>, In press."
"authors" => array:7 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Riveline Jean-Pierre"
]
2 => array:1 [
"name" => "Levrat-Guillen Fleur"
]
3 => array:1 [
"name" => "Detournay Bruno"
]
4 => array:1 [
"name" => "Vicaut Eric"
]
5 => array:1 [
"name" => "Emery Corinne"
]
6 => array:1 [
"name" => "Guerci Bruno"
]
]
"ouvrage" => ""
"keywords" => array:7 [
0 => "FreeStyle Libre"
1 => "acute diabetes events"
2 => "continuous glucose monitoring"
3 => "flash glucose monitoring"
4 => "insulin-secretagogues"
5 => "noninsulin therapy"
6 => "type 2 diabetes"
]
"updatedAt" => "2024-07-29 14:25:42"
"publicationUrl" => "https://doi.org/10.1089/dia.2024.0171"
"publicationInfo" => array:3 [
"pages" => ""
"volume" => "In press"
"number" => ""
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => "États-Unis"
"en" => "United States of America"
]
"abstract" => array:2 [
"fr" => "Glycemic management in people with type 2 diabetes mellitus (T2DM) on insulin-secretagogue regimens without insulin is of importance, as this group still represents a significant proportion of patients. Risks for acute diabetes events (ADEs), including diabetic ketoacidosis (DKA) or hypoglycemia, using insulin-secretagogue drugs are well established. Few studies have suggested that continuous glucose monitoring (CGM) could be useful for monitoring glucose dynamics associated with the use of such therapies. To document this point an exploratory analysis was conducted in a group of individuals with noninsulin treated T2DM in France who are managed with oral insulin-secretagogues and initiating the FreeStyle Libre® system (FSL). Methods: A retrospective study of the French national SNDS reimbursement claims database (≈66 million French people) was conducted to identify people with T2DM on oral insulin-secretagogues and receiving a first reimbursement of FSL between August 1, 2017 and December 31, 2018. The analysis included data for the 12 months before and up to 24 months after FSL initiation. Hospitalizations for diabetes-related acute events were identified using ICD-10 codes as main or related diagnosis, for: hypoglycemic events; DKA events; comas; and hyperglycemia-related admissions."
"en" => "Glycemic management in people with type 2 diabetes mellitus (T2DM) on insulin-secretagogue regimens without insulin is of importance, as this group still represents a significant proportion of patients. Risks for acute diabetes events (ADEs), including diabetic ketoacidosis (DKA) or hypoglycemia, using insulin-secretagogue drugs are well established. Few studies have suggested that continuous glucose monitoring (CGM) could be useful for monitoring glucose dynamics associated with the use of such therapies. To document this point an exploratory analysis was conducted in a group of individuals with noninsulin treated T2DM in France who are managed with oral insulin-secretagogues and initiating the FreeStyle Libre® system (FSL). Methods: A retrospective study of the French national SNDS reimbursement claims database (≈66 million French people) was conducted to identify people with T2DM on oral insulin-secretagogues and receiving a first reimbursement of FSL between August 1, 2017 and December 31, 2018. The analysis included data for the 12 months before and up to 24 months after FSL initiation. Hospitalizations for diabetes-related acute events were identified using ICD-10 codes as main or related diagnosis, for: hypoglycemic events; DKA events; comas; and hyperglycemia-related admissions."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
101 => Essec\Faculty\Model\Contribution {#2488
#_index: "academ_contributions"
#_id: "10169"
#_source: array:18 [
"id" => "10169"
"slug" => "calcitonin-determination-in-patients-with-nodular-thyroid-disease"
"yearMonth" => "2007-02"
"year" => "2007"
"title" => "Calcitonin determination in patients with nodular thyroid disease."
"description" => "DE POUVOURVILLE, G., BORGET, I. et SCHLUMBERGER, M. (2007). Calcitonin determination in patients with nodular thyroid disease. <i>The Journal of Clinical Endocrinology & Metabolism</i>, 92(2), pp. 425-427."
"authors" => array:3 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BORGET Isabelle"
]
2 => array:1 [
"name" => "SCHLUMBERGER Martin"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "screening"
1 => "cost-effectiveness"
2 => "nodular thyroid disease."
]
"updatedAt" => "2021-07-13 14:31:28"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "425-427"
"volume" => "92"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'article étudie la pertinence clinique et économique du dosage de la calcitonine dans le dépistage des nodules thyroïdiens."
"en" => "The article studies the clinical and economic relevance of the dosage of calciton to screen patients with thyroid nodules."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
102 => Essec\Faculty\Model\Contribution {#2489
#_index: "academ_contributions"
#_id: "10177"
#_source: array:18 [
"id" => "10177"
"slug" => "cost-of-radiofrequency-ablation-in-the-treatment-of-hepatic-malignancies"
"yearMonth" => "2007-12"
"year" => "2007"
"title" => "Cost of radiofrequency ablation in the treatment of hepatic malignancies"
"description" => "DE POUVOURVILLE, G., BONASTRE, J., DE BAÈRE, T., ELIAS, D. et SERGE, E. (2007). Cost of radiofrequency ablation in the treatment of hepatic malignancies. <i>Gastroentérologie Clinique et Biologique</i>, 31, pp. 828-835."
"authors" => array:5 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BONASTRE Julia"
]
2 => array:1 [
"name" => "DE BAÈRE Thierry"
]
3 => array:1 [
"name" => "ELIAS Dominique"
]
4 => array:1 [
"name" => "SERGE Evrard"
]
]
"ouvrage" => ""
"keywords" => array:4 [
0 => "cost"
1 => "hepatic malignancies"
2 => "radiofrequency"
3 => "France"
]
"updatedAt" => "2021-07-13 14:31:28"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "828-835"
"volume" => "31"
"number" => null
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'étude réalisée a estimé le coût de la mise en oeuvre d'un traitement des tumeurs hépatiques par radiofréquence dans le contexte hospitalier français."
"en" => "The cost of hepatic malignancies by radiofrequency was estimated in the French hospital context."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
103 => Essec\Faculty\Model\Contribution {#2490
#_index: "academ_contributions"
#_id: "10188"
#_source: array:18 [
"id" => "10188"
"slug" => "evaluation-du-cout-de-la-prise-en-charge-ambulatoire-des-patients-apres-avc-resultats-dune-enquete-postale-aupres-des-patients-du-registre-des-avc-de-dijon"
"yearMonth" => "2007-03"
"year" => "2007"
"title" => "Evaluation du coût de la prise en charge ambulatoire des patients après AVC: résultats d'une enquête postale auprès des patients du registre des AVC de Dijon."
"description" => "DE POUVOURVILLE, G. et SPIELER, J.F. (2007). Evaluation du coût de la prise en charge ambulatoire des patients après AVC: résultats d'une enquête postale auprès des patients du registre des AVC de Dijon. <i>La Presse Médicale</i>, 36(3), pp. 399-403."
"authors" => array:2 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "SPIELER Jean-François"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "cost"
1 => "ambulatory care"
2 => "stroke."
]
"updatedAt" => "2021-07-13 14:31:29"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "399-403"
"volume" => "36"
"number" => "3"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Le coût de la prise en charge en ambulatoire des séquelles del 'accident vasculaore cérébral à distance de l'évènement intiial est estimé sur cinq ans à partir des données du registre de Dijon (France)."
"en" => "The ambulatory cost of the management of post-stroke patients is estimated over five years using the Dijon (France) Registry."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
104 => Essec\Faculty\Model\Contribution {#2491
#_index: "academ_contributions"
#_id: "10192"
#_source: array:18 [
"id" => "10192"
"slug" => "gravite-des-patients-et-surcouts-dans-les-hopitaux-de-reference"
"yearMonth" => "2007-05"
"year" => "2007"
"title" => "Gravité des patients et surcoüts dans les hôpitaux de référence"
"description" => "DE POUVOURVILLE, G., HALLAIS, C., CZERNICHOW, P., LE VAILLANT, M. et FROMENT, L. (2007). Gravité des patients et surcoüts dans les hôpitaux de référence. <i>Journal d'Economie Médicale</i>, 25(3), pp. 177-187."
"authors" => array:5 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "HALLAIS Corinne"
]
2 => array:1 [
"name" => "CZERNICHOW Pierre"
]
3 => array:1 [
"name" => "LE VAILLANT Marc"
]
4 => array:1 [
"name" => "FROMENT L"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "cost"
1 => "severity"
2 => "teaching hospitals"
]
"updatedAt" => "2021-07-13 14:31:29"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "177-187"
"volume" => "25"
"number" => "3"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'article démontre que les établissements hospitalo-universitaires prennent en charge des patients plus lourdes et donc plus coûteux. Ces surcoûts doivent être pris en compte dans les tarifs hospitaliers."
"en" => "The paper demonstrates that teaching hospitalsadmit more severe and costly patients than community hospitals. Extra- costs should be taken intop account in propsective rates per DRG."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
105 => Essec\Faculty\Model\Contribution {#2492
#_index: "academ_contributions"
#_id: "10193"
#_source: array:18 [
"id" => "10193"
"slug" => "health-related-quality-of-life-an-economists-perspective"
"yearMonth" => "2007-12"
"year" => "2007"
"title" => "Health-related quality of life- an economist's perspective"
"description" => "DE POUVOURVILLE, G., BORGET, I. et SCHLUMBERGER, M. (2007). Health-related quality of life- an economist's perspective. <i>Nature Clinical Practice Endocrinology & Metabolism</i>, 3, pp. 786-787."
"authors" => array:3 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BORGET Isabelle"
]
2 => array:1 [
"name" => "SCHLUMBERGER Martin"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "quality of life"
1 => "evaluation"
2 => "health technology"
]
"updatedAt" => "2021-07-13 14:31:29"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "786-787"
"volume" => "3"
"number" => null
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "La mesure de la qualité de vie liée à des états de santé est devenue un standard dans l'évaluation des actoins de santé. L'article en présente les fondements économiques théoriques."
"en" => "Measuring health-related quality of life is now a standard in the assessment of new medical technologies. The article presents the underlying economic prionciples."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
106 => Essec\Faculty\Model\Contribution {#2493
#_index: "academ_contributions"
#_id: "10194"
#_source: array:18 [
"id" => "10194"
"slug" => "impact-du-choix-dune-therapie-anti-agregante-dans-larteriopathie-des-membres-inferieurs-etude-cout-efficacite-et-impact-economique"
"yearMonth" => "2007-02"
"year" => "2007"
"title" => "Impact du choix d'une thérapie anti-agrégante dans l'artériopathie des membres inférieurs: étude coût-efficacité et impact économique"
"description" => "DE POUVOURVILLE, G. et PRIOLLET, P. (2007). Impact du choix d'une thérapie anti-agrégante dans l'artériopathie des membres inférieurs: étude coût-efficacité et impact économique. <i>Journal des Maladies Vasculaires</i>, 32(1), pp. 8-14."
"authors" => array:2 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "PRIOLLET Pierre"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "cost-effectiveness"
1 => "prophylaxis"
2 => "arteriopathy"
]
"updatedAt" => "2021-07-13 14:31:29"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "8-14"
"volume" => "32"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'utulisation du clopidogrel dans la prévention des complications cardio- et cérébro-vasculaires chez les patients artéritiques est coût-efficace en France."
"en" => "Clopidogrel is cost-effective in the prevention of cardio- and cerebro-vascular events for patients with lower imb arteriopathy."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
107 => Essec\Faculty\Model\Contribution {#2494
#_index: "academ_contributions"
#_id: "10196"
#_source: array:18 [
"id" => "10196"
"slug" => "implications-of-learning-effects-for-hospital-costs-of-new-technologies-the-case-of-intensity-modulated-radiation-therapy"
"yearMonth" => "2007-04"
"year" => "2007"
"title" => "Implications of learning effects for hospital costs of new technologies: the case of intensity modulated radiation therapy"
"description" => "BONASTRE, J., CHEVALIER, J., GÉRARD, J.P., LEFKOPOULOS, D. et DE POUVOURVILLE, G. (2007). Implications of learning effects for hospital costs of new technologies: the case of intensity modulated radiation therapy. <i>International Journal of Technology Assessment in Health Care</i>, 23(2), pp. 248-254."
"authors" => array:5 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BONASTRE Julia"
]
2 => array:1 [
"name" => "CHEVALIER Julie"
]
3 => array:1 [
"name" => "GÉRARD Jean-Pierre"
]
4 => array:1 [
"name" => "LEFKOPOULOS Dimitri"
]
]
"ouvrage" => ""
"keywords" => array:4 [
0 => "innovation"
1 => "leraning curve"
2 => "cost"
3 => "hospital"
]
"updatedAt" => "2021-07-13 14:31:29"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "248-254"
"volume" => "23"
"number" => "2"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'article a estimé la courbe d'apprentissage d'une nouvelle technologie médicale, la radiothérpaie à modulation d'intensité, sur le coût unitaire de la technqiue. Les implications des résultats en termes de financement des innovations sont discutées."
"en" => "The learning curve for intensity modulation raduiation therpay and its impact on costs has been estimated in France. Implications interms of payment for inovative technologies are discussed."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
108 => Essec\Faculty\Model\Contribution {#2495
#_index: "academ_contributions"
#_id: "10203"
#_source: array:18 [
"id" => "10203"
"slug" => "la-recherche-en-medecine-generale-en-france-etat-es-lieux"
"yearMonth" => "2007-06"
"year" => "2007"
"title" => "La recherche en médecine générale en France: état es lieux"
"description" => "DE POUVOURVILLE, G. (2007). La recherche en médecine générale en France: état es lieux. <i>La Revue du Practicien</i>, 57(11), pp. 1200-1202."
"authors" => array:1 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => array:3 [
0 => "primary care"
1 => "general practice"
2 => "research"
]
"updatedAt" => "2021-07-13 14:31:29"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "1200-1202"
"volume" => "57"
"number" => "11"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Cet article évalue les thèmes abordés et les recense les équipes de recherche en médecine générale en France et en anakyse les forces et les faiblesses."
"en" => "This pper reviews research issues and identifies general practice reserach teams in France, and assesses strength and weaknesses."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
109 => Essec\Faculty\Model\Contribution {#2496
#_index: "academ_contributions"
#_id: "10215"
#_source: array:18 [
"id" => "10215"
"slug" => "reformer-la-gouvernance-de-lhopital-mission-impossible"
"yearMonth" => "2007-04"
"year" => "2007"
"title" => "Réformer la gouvernance de l'hôpital: mission impossible?"
"description" => "DE POUVOURVILLE, G. (2007). Réformer la gouvernance de l'hôpital: mission impossible? <i>La Presse Médicale</i>, 36(4), pp. 636-637."
"authors" => array:1 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => ""
"keywords" => array:2 [
0 => "governance"
1 => "public hospitals"
]
"updatedAt" => "2021-07-13 14:31:29"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "636-637"
"volume" => "36"
"number" => "4"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue professionnelle"
"en" => "Professional journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "La réfomre Hôpital 2007 prévoit une refonte majeure de la gouvernance des hôpitaux publis en France. Les obstacles à cette réforme sont étudiées."
"en" => "In 2007, a major reform has been immplemented in France to change the governance of public hospitals. The article identifies the main resistances to change."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
110 => Essec\Faculty\Model\Contribution {#2497
#_index: "academ_contributions"
#_id: "10218"
#_source: array:18 [
"id" => "10218"
"slug" => "sick-leave-for-follow-up-control-in-thyroid-cancer-patients-comparison-between-stimulation-with-thyrogen-and-thyroid-hormone-withdrawal"
"yearMonth" => "2007-05"
"year" => "2007"
"title" => "Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal"
"description" => "DE POUVOURVILLE, G., BORGET, I., CORONE, C., NOCAUDIE, M. et ALLYN, M. (2007). Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. <i>European Journal of Endocrinology</i>, 156(5), pp. 531-538."
"authors" => array:5 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BORGET Isabelle"
]
2 => array:1 [
"name" => "CORONE Carine"
]
3 => array:1 [
"name" => "NOCAUDIE Marie"
]
4 => array:1 [
"name" => "ALLYN Mark"
]
]
"ouvrage" => ""
"keywords" => array:2 [
0 => "productivity"
1 => "thyroid cancer."
]
"updatedAt" => "2021-07-13 14:31:29"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => "531-538"
"volume" => "156"
"number" => "5"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'utulisation du TSH recombinant humain Thyrogen au cours des examens de contrôle des patients traités pour un cancer de la thyroïde diminue significativement le nombre et la durée des arrêts de travail, par rapport à la méthode traditionnelle de sevrage de l'hormone thyroïdienne."
"en" => "The prescription of the recombinant human TSH, Thyrogen, during the follow-up controls for patients treated for thyroid cancer significantly reduces the number and the duration of sikleave days when compared to traditional thyroid hormone withdrawal."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
111 => Essec\Faculty\Model\Contribution {#2498
#_index: "academ_contributions"
#_id: "10225"
#_source: array:18 [
"id" => "10225"
"slug" => "the-cost-of-treating-high-blood-pressure-in-france"
"yearMonth" => "2007-05"
"year" => "2007"
"title" => "The cost of treating high blood pressure in France"
"description" => "DE POUVOURVILLE, G., TIBI-LÉVY, Y., BAMBERGER, M. et WESTTERLOPPE, J. (2007). The cost of treating high blood pressure in France. <i>European Journal of Health Economics</i>."
"authors" => array:4 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "TIBI-LÉVY Yaël"
]
2 => array:1 [
"name" => "BAMBERGER Marion"
]
3 => array:1 [
"name" => "WESTTERLOPPE Jérémie"
]
]
"ouvrage" => ""
"keywords" => array:2 [
0 => "cost"
1 => "high blood pressure"
]
"updatedAt" => "2021-07-13 14:31:30"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => null
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Le coût de la prise en charge de l'hypertension artérielle en médecine générale en France est estimé sur tois ans à partir d'une étude rétriospective d'une cohorte de 28 000 patients."
"en" => "A retropsecitve cohort of 28,000 patients treated for high blood pressure by general practitioners was used to estimate the cost of treatment."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
112 => Essec\Faculty\Model\Contribution {#2499
#_index: "academ_contributions"
#_id: "10874"
#_source: array:18 [
"id" => "10874"
"slug" => "the-contribution-of-real-world-evidence-to-cost-effectiveness-analysis-case-study-of-dabigatran-etexilate-in-france"
"yearMonth" => "2020-02"
"year" => "2020"
"title" => "The Contribution of Real-World Evidence to Cost-Effectiveness Analysis: Case Study of Dabigatran Etexilate in France"
"description" => "DE POUVOURVILLE, G., BLIN, P. et KARAM, P. (2020). The Contribution of Real-World Evidence to Cost-Effectiveness Analysis: Case Study of Dabigatran Etexilate in France. <i>European Journal of Health Economics</i>, 21, pp. 235-249."
"authors" => array:3 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BLIN P."
]
2 => array:1 [
"name" => "KARAM P."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-09-24 10:33:27"
"publicationUrl" => "https://link.springer.com/article/10.1007/s10198-019-01123-5"
"publicationInfo" => array:3 [
"pages" => "235-249"
"volume" => "21"
"number" => null
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "The goal of this study was to assess the differences between an ex ante and an ex post cost-effectiveness analysis of Dabigatran etexilate vs VKAs for the prevention of thromboembolic events in non-valvular atrial fibrillation patients and to draw lessons on the design and use of real-world data for decision making. Methods The same model was used to calculate the cost-effectiveness ratio using two sets of parameters. One set included the efficacy and safety outcomes data from RE-LY, the pivotal trial comparing Dabigatran to warfarin; cost data came from an ex ante publication. Outcomes data for the second set came from real-world data studies. Cost data were a mix of real-world data and other sources. Two treatment strategies were compared: treatment initiation by either Dabigatran or VKAs, followed by either VKAs or Dabigatran. A crude comparison of results was performed; the impact of data differences was then assessed. Probabilistic sensitivity results of the two analyses were compared. Results With real-world evidence, Dabigatran at both dosages was more effective for the prevention of ischemic strokes, intra-cranial haemorrhages, with less major extra-cranial haemorrhages and a similar risk of myocardial infarction. Using clinical trial data, Dabigatran150 mg (resp. Dabigatran110 mg) as a first-line treatment vs VKAs yielded an ICER of € 8077/QALY (resp. € 13,116/QALY). Real-world evidence scenarios were cost-saving and more effective for both dosages. Conclusion The reassessment of outcomes and cost data had an impact on results, improving the efficiency of Dabigatran. We identify methodological issues which should be discussed if post-launch RWE based cost-effectiveness data become a standard in HTA decision making."
"en" => "The goal of this study was to assess the differences between an ex ante and an ex post cost-effectiveness analysis of Dabigatran etexilate vs VKAs for the prevention of thromboembolic events in non-valvular atrial fibrillation patients and to draw lessons on the design and use of real-world data for decision making. Methods The same model was used to calculate the cost-effectiveness ratio using two sets of parameters. One set included the efficacy and safety outcomes data from RE-LY, the pivotal trial comparing Dabigatran to warfarin; cost data came from an ex ante publication. Outcomes data for the second set came from real-world data studies. Cost data were a mix of real-world data and other sources. Two treatment strategies were compared: treatment initiation by either Dabigatran or VKAs, followed by either VKAs or Dabigatran. A crude comparison of results was performed; the impact of data differences was then assessed. Probabilistic sensitivity results of the two analyses were compared. Results With real-world evidence, Dabigatran at both dosages was more effective for the prevention of ischemic strokes, intra-cranial haemorrhages, with less major extra-cranial haemorrhages and a similar risk of myocardial infarction. Using clinical trial data, Dabigatran150 mg (resp. Dabigatran110 mg) as a first-line treatment vs VKAs yielded an ICER of € 8077/QALY (resp. € 13,116/QALY). Real-world evidence scenarios were cost-saving and more effective for both dosages. Conclusion The reassessment of outcomes and cost data had an impact on results, improving the efficiency of Dabigatran. We identify methodological issues which should be discussed if post-launch RWE based cost-effectiveness data become a standard in HTA decision making."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
113 => Essec\Faculty\Model\Contribution {#2500
#_index: "academ_contributions"
#_id: "10875"
#_source: array:18 [
"id" => "10875"
"slug" => "a-french-value-set-for-the-eq%e2%80%905d%e2%80%905l"
"yearMonth" => "2020-01"
"year" => "2020"
"title" => "A French Value Set for the EQ‐5D‐5L"
"description" => "ANDRADE, L.F., LUDWIG, K., RAMOS GONI, J.M., OPPE, M. et DE POUVOURVILLE, G. (2020). A French Value Set for the EQ‐5D‐5L. <i>Pharmacoeconomics</i>, 38(1), pp. 1-13."
"authors" => array:5 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "ANDRADE L. F."
]
2 => array:1 [
"name" => "LUDWIG K."
]
3 => array:1 [
"name" => "RAMOS GONI J. M."
]
4 => array:1 [
"name" => "OPPE M."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-09-28 15:26:02"
"publicationUrl" => "https://doi.org/10.1007/s40273-019-00876-4"
"publicationInfo" => array:3 [
"pages" => "1-13"
"volume" => "38"
"number" => "1"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "The objective of this study was to develop a French value set for the EQ-5D-5L, for academic and clinical research, and for regulatory requirements for price-setting of drugs and medical devices. Method This study used the standardized valuation protocol developed by EuroQol, using computer-assisted personal interview software. A representative sample of 1048 French residents were interviewed by a market research company, under the supervision of the research team. Health states were valued using composite time trade-off and a discrete choice experiment. Modeling was used to create values for the 3125 possible health states. The composite time trade-off data were modeled using a Tobit model with censored observations at −1 and correcting for heteroscedasticity. A conditional logit model was used for the discrete choice results, and both models were combined using a hybrid model. An adjusted hybrid model was tested to correct for imbalance in the sample on age and sex compared with the general population. A comparison with the 3-level (3L) value set was performed. Results The adjusted model was preferred to comply with the representativeness of the general population. It provided a value set for which all coefficients were logically consistent. Values ranged from − 0.525 to 1. The distribution of values presented a shift towards higher values versus the 3L value set. Ranking of dimensions changed. Pain and discomfort and mobility were the dimensions with the highest potential for disutility compared with mobility and self-care for the 3L instrument. Conclusions This study provides a value set based on societal preferences of the French population, using an improved descriptive instrument of health-related quality-of-life health states. It will contribute to improve the quality of cost-effectiveness analysis in the French context and help stimulate disease-specific quality-of-life references for academic-, institutional-, and industry-promoted studies."
"en" => "The objective of this study was to develop a French value set for the EQ-5D-5L, for academic and clinical research, and for regulatory requirements for price-setting of drugs and medical devices. Method This study used the standardized valuation protocol developed by EuroQol, using computer-assisted personal interview software. A representative sample of 1048 French residents were interviewed by a market research company, under the supervision of the research team. Health states were valued using composite time trade-off and a discrete choice experiment. Modeling was used to create values for the 3125 possible health states. The composite time trade-off data were modeled using a Tobit model with censored observations at −1 and correcting for heteroscedasticity. A conditional logit model was used for the discrete choice results, and both models were combined using a hybrid model. An adjusted hybrid model was tested to correct for imbalance in the sample on age and sex compared with the general population. A comparison with the 3-level (3L) value set was performed. Results The adjusted model was preferred to comply with the representativeness of the general population. It provided a value set for which all coefficients were logically consistent. Values ranged from − 0.525 to 1. The distribution of values presented a shift towards higher values versus the 3L value set. Ranking of dimensions changed. Pain and discomfort and mobility were the dimensions with the highest potential for disutility compared with mobility and self-care for the 3L instrument. Conclusions This study provides a value set based on societal preferences of the French population, using an improved descriptive instrument of health-related quality-of-life health states. It will contribute to improve the quality of cost-effectiveness analysis in the French context and help stimulate disease-specific quality-of-life references for academic-, institutional-, and industry-promoted studies."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
114 => Essec\Faculty\Model\Contribution {#2501
#_index: "academ_contributions"
#_id: "10877"
#_source: array:18 [
"id" => "10877"
"slug" => "le-cout-hospitalier-des-evenements-cerebro-vasculaires-associes-a-une-fibrillation-atriale-en-france"
"yearMonth" => "2019-12"
"year" => "2019"
"title" => "Le coût hospitalier des événements cérébro-vasculaires associés à une fibrillation atriale en France"
"description" => "DE POUVOURVILLE, G. et KARAM, P. (2019). Le coût hospitalier des événements cérébro-vasculaires associés à une fibrillation atriale en France. <i>Journal de Gestion et d'Économie de la Santé</i>, 37(5), pp. 399-409."
"authors" => array:2 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "KARAM P."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-09-24 10:33:27"
"publicationUrl" => "https://www.researchgate.net/publication/339623644_Le_cout_hospitalier_des_evenements_cerebro-vasculaires_associes_a_une_fibrillation_atriale_en_France"
"publicationInfo" => array:3 [
"pages" => "399-409"
"volume" => "37"
"number" => "5"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Hospital Cost of cerebro-vascular events associated with atrial fibrillation in France Objective : Patients with atrial fibrillation are at risk of ischemic and haemorrhagic strokes. The goal of this study was to assess the hospital cost of such events in the French context. Methods : An extraction from the National Discharge Abstract Database (PMSI) was performed for year 2014. Selected patients were patients who had experienced an ischemic or haemorrhagic stroke and with a related diagnosis of atrial fibrillation. Patients who had experienced a hospital admission for atrial fibrillation in the two preceding years were also included. Consecutive admissions in acute care, rehabilitation centres and information on admissions to nursing homes was collected during the next twelve months after the initial event date. Results : Average one year cost for an ischemic stroke for a patient with atrial fibrillation was € 14,789 and € 15,736 for a haemorrhagic stroke. Rehabilitation costs were respectively 40% and 34% of the total cost. Costs for patients with no handicap, a moderate handicap or totally dependent were respectively € 7,277, € 30,293 and € 15,736 for an ischemic stroke ; after a haemorrhagic stroke, costs were respectively € 9,628, € 33,610 and € 22,559. One year mortality was respectively 26% and 46%. Conclusion : Results confirm the importance of cost of events after the initial event. They allow to populate cost-effectiveness analyses of their prevention for patients with atrial fibrillation."
"en" => "Hospital Cost of cerebro-vascular events associated with atrial fibrillation in France Objective : Patients with atrial fibrillation are at risk of ischemic and haemorrhagic strokes. The goal of this study was to assess the hospital cost of such events in the French context. Methods : An extraction from the National Discharge Abstract Database (PMSI) was performed for year 2014. Selected patients were patients who had experienced an ischemic or haemorrhagic stroke and with a related diagnosis of atrial fibrillation. Patients who had experienced a hospital admission for atrial fibrillation in the two preceding years were also included. Consecutive admissions in acute care, rehabilitation centres and information on admissions to nursing homes was collected during the next twelve months after the initial event date. Results : Average one year cost for an ischemic stroke for a patient with atrial fibrillation was € 14,789 and € 15,736 for a haemorrhagic stroke. Rehabilitation costs were respectively 40% and 34% of the total cost. Costs for patients with no handicap, a moderate handicap or totally dependent were respectively € 7,277, € 30,293 and € 15,736 for an ischemic stroke ; after a haemorrhagic stroke, costs were respectively € 9,628, € 33,610 and € 22,559. One year mortality was respectively 26% and 46%. Conclusion : Results confirm the importance of cost of events after the initial event. They allow to populate cost-effectiveness analyses of their prevention for patients with atrial fibrillation."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
115 => Essec\Faculty\Model\Contribution {#2502
#_index: "academ_contributions"
#_id: "11460"
#_source: array:18 [
"id" => "11460"
"slug" => "value-of-a-qaly-for-france-a-new-approach-to-propose-acceptable-reference-values"
"yearMonth" => "2020-08"
"year" => "2020"
"title" => "Value of a QALY for France: A New Approach to Propose Acceptable Reference Values"
"description" => "TÉHARD, B., DETOURNAY, B., BORGET, I., ROZE, S. et PUYOU DE POUVOURVILLE, G. (2020). Value of a QALY for France: A New Approach to Propose Acceptable Reference Values. <i>Value in Health</i>, 23(8), pp. 985-993."
"authors" => array:5 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "TÉHARD Bertrand"
]
2 => array:1 [
"name" => "DETOURNAY Bruno"
]
3 => array:1 [
"name" => "BORGET Isabelle"
]
4 => array:1 [
"name" => "ROZE Stéphane"
]
]
"ouvrage" => ""
"keywords" => array:6 [
0 => "drug pricing"
1 => "cost-effectiveness"
2 => "France"
3 => "health-economic assessment"
4 => "incremental cost-effectiveness ratio"
5 => "preference-based value"
]
"updatedAt" => "2021-09-28 15:23:06"
"publicationUrl" => "https://doi.org/10.1016/j.jval.2020.04.001"
"publicationInfo" => array:3 [
"pages" => "985-993"
"volume" => "23"
"number" => "8"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "France has included health economic assessment (HEA) as an official criterion for innovative drug pricing since 2013. Until now, no cost-effectiveness threshold (CET) has been officially proposed to qualify incremental cost-effectiveness ratios (ICERs). Although the French health authorities have publicly expressed the need for such reference values, previous initiatives to determine these have failed. The study aims to propose a locally adapted method for estimating a preference-based value for a quality-adjusted life-year (QALY) based on a rational approach to public policy choices in France."
"en" => "France has included health economic assessment (HEA) as an official criterion for innovative drug pricing since 2013. Until now, no cost-effectiveness threshold (CET) has been officially proposed to qualify incremental cost-effectiveness ratios (ICERs). Although the French health authorities have publicly expressed the need for such reference values, previous initiatives to determine these have failed. The study aims to propose a locally adapted method for estimating a preference-based value for a quality-adjusted life-year (QALY) based on a rational approach to public policy choices in France."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
116 => Essec\Faculty\Model\Contribution {#2503
#_index: "academ_contributions"
#_id: "7751"
#_source: array:18 [
"id" => "7751"
"slug" => "the-globalization-of-managerial-innovation-in-health-care"
"yearMonth" => "2008-12"
"year" => "2008"
"title" => "The Globalization of Managerial Innovation in Health Care"
"description" => "KIMBERLY, J., PUYOU DE POUVOURVILLE, G. et D'AUNNO, T. [Eds] (2008). <i>The Globalization of Managerial Innovation in Health Care</i>. Cambridge University Press, 379 pages."
"authors" => array:3 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "KIMBERLY J."
]
2 => array:1 [
"name" => "D'AUNNO T."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-09-06 16:57:04"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => null
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Direction d'ouvrage"
"en" => "Book editor"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "In 1983, the first patient classification system to be used on a national basis, the Diagnosis Relate Groups (DRGs), was adopted as part of the Prospective Payment System in the United States. This system caught the attention of health policy makers in other countries, and a number of them began to implement similar approaches. What motivated them to adopt these systems? What similarities and differences were there among their experiences in implementing these systems? What can we learn about introducing change into national health systems by comparing their experiences? The Globalization of Managerial Innovation in Health Care answers these and other questions by examining patient classification systems in fifteen different countries throughout the world. The result is a remarkable collection of case studies of how change can be introduced effectively into national health systems as well as a careful synthesis of what can be learned from them."
"en" => "In 1983, the first patient classification system to be used on a national basis, the Diagnosis Relate Groups (DRGs), was adopted as part of the Prospective Payment System in the United States. This system caught the attention of health policy makers in other countries, and a number of them began to implement similar approaches. What motivated them to adopt these systems? What similarities and differences were there among their experiences in implementing these systems? What can we learn about introducing change into national health systems by comparing their experiences? The Globalization of Managerial Innovation in Health Care answers these and other questions by examining patient classification systems in fifteen different countries throughout the world. The result is a remarkable collection of case studies of how change can be introduced effectively into national health systems as well as a careful synthesis of what can be learned from them."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
117 => Essec\Faculty\Model\Contribution {#2504
#_index: "academ_contributions"
#_id: "7768"
#_source: array:18 [
"id" => "7768"
"slug" => "traite-deconomie-et-de-gestion-de-la-sante"
"yearMonth" => "2009-06"
"year" => "2009"
"title" => "Traité d'économie et de gestion de la santé"
"description" => "BRAS, P.L., PUYOU DE POUVOURVILLE, G. et TABUTEAU, D. [Eds] (2009). <i>Traité d'économie et de gestion de la santé</i>. Presses de Sciences Po, 564 pages."
"authors" => array:3 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "BRAS P.-L."
]
2 => array:1 [
"name" => "TABUTEAU D."
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2021-09-06 16:57:04"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => null
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Direction d'ouvrage"
"en" => "Book editor"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "L'actualité des questions économiques en matière de santé, le développement des politiques de santé, la multiplication des organismes de gestion, d'évaluation ou de contrôle du système, l'expansion des systèmes de gestion des informations et des dépenses de santé, la succession des réformes, l’émergence d’une Europe de la santé rendent indispensable un ouvrage répondant aux attentes des étudiants, des professionnels de santé, des gestionnnaires d’institutions de santé et des cadres des administrations sanitaires."
"en" => "L'actualité des questions économiques en matière de santé, le développement des politiques de santé, la multiplication des organismes de gestion, d'évaluation ou de contrôle du système, l'expansion des systèmes de gestion des informations et des dépenses de santé, la succession des réformes, l’émergence d’une Europe de la santé rendent indispensable un ouvrage répondant aux attentes des étudiants, des professionnels de santé, des gestionnnaires d’institutions de santé et des cadres des administrations sanitaires."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
118 => Essec\Faculty\Model\Contribution {#2505
#_index: "academ_contributions"
#_id: "8552"
#_source: array:18 [
"id" => "8552"
"slug" => "26th-scientific-plenary-meeting-of-the-euroqol-group"
"yearMonth" => "2009-10"
"year" => "2009"
"title" => "26th Scientific Plenary Meeting of the EuroQol Group"
"description" => "PUYOU DE POUVOURVILLE, G. (2009). 26th Scientific Plenary Meeting of the EuroQol Group. EuroQol Group, Pays-Bas."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => "26th Scientific Plenary Meeting of the EuroQol Group Proceedings"
"keywords" => []
"updatedAt" => "2021-07-13 14:31:15"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => null
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Editeur d'actes de conférence"
"en" => "Conference proceedings editor"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Presentation of the method and results of a survey on a representative sample of the French population, using Time-Trade Off to value health states using the EuroQol-5D questionnaire, with the purpose of performing cost-per-Quality Adjusted Life Years in the French context."
"en" => "Presentation of the method and results of a survey on a representative sample of the French population, using Time-Trade Off to value health states using the EuroQol-5D questionnaire, with the purpose of performing cost-per-Quality Adjusted Life Years in the French context."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
119 => Essec\Faculty\Model\Contribution {#2506
#_index: "academ_contributions"
#_id: "4780"
#_source: array:18 [
"id" => "4780"
"slug" => "le-territoire-dans-la-regulation-du-systeme-de-sante"
"yearMonth" => "2016-04"
"year" => "2016"
"title" => "Le territoire dans la régulation du système de santé"
"description" => "PUYOU DE POUVOURVILLE, G. (2016). Le territoire dans la régulation du système de santé. Dans: <i>Management hospitalier et territoire: les nouveaux défis</i>. Presses des Mines."
"authors" => array:1 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
]
"ouvrage" => "Management hospitalier et territoire: les nouveaux défis"
"keywords" => []
"updatedAt" => "2021-07-13 14:31:06"
"publicationUrl" => null
"publicationInfo" => array:3 [
"pages" => null
"volume" => null
"number" => null
]
"type" => array:2 [
"fr" => "Actes d'une conférence"
"en" => "Conference Proceedings"
]
"support_type" => array:2 [
"fr" => "Editeur"
"en" => "Publisher"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "La notion de territoire joue en rôle central dans la planification des services de santé. L'objet de ce texte est de resituer cette notion dans le contexte de l'organisation des marchés locaux de soins, en montrant que le territoire a une géométrie variable en fonction des différents services."
"en" => "The notion of territories has a central role in health services capacity planning in France. The aim of the article is to discuss this notion and especially to show that it has different geometry as a function of the role of different services in local health care markets."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
120 => Essec\Faculty\Model\Contribution {#2507
#_index: "academ_contributions"
#_id: "15233"
#_source: array:18 [
"id" => "15233"
"slug" => "guiding-principles-for-evaluating-vaccines-in-joint-health-technology-assessment-in-the-european-union-preparing-for-the-european-unions-regulation-on-health-technology-assessment-for-vaccin"
"yearMonth" => "2024-10"
"year" => "2024"
"title" => "Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the European Union: Preparing for the European Union’s Regulation on Health Technology Assessment for Vaccines"
"description" => "LARGERON, N., D’AGOSTINO, P., CHAPMAN, R., DANKO, D., ESKOLA, J., GODFROID, P. ... BECK, E. (2024). Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the European Union: Preparing for the European Union’s Regulation on Health Technology Assessment for Vaccines. <i>Value in Health</i>, 27(10), pp. 1318-1327."
"authors" => array:17 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Largeron Nathalie"
]
2 => array:1 [
"name" => "D’Agostino Paolo"
]
3 => array:1 [
"name" => "Chapman Ruth"
]
4 => array:1 [
"name" => "Danko David"
]
5 => array:1 [
"name" => "Eskola Juhani"
]
6 => array:1 [
"name" => "Godfroid Philippe"
]
7 => array:1 [
"name" => "Feldmajer Gyorgyi"
]
8 => array:1 [
"name" => "Hanley Riona"
]
9 => array:1 [
"name" => "Postma Maarten"
]
10 => array:1 [
"name" => "Puig-Barberà Joan"
]
11 => array:1 [
"name" => "Schaible Kassandra"
]
12 => array:1 [
"name" => "Sabale Ugne"
]
13 => array:1 [
"name" => "Schmitt Joe"
]
14 => array:1 [
"name" => "de Waure Chiara"
]
15 => array:1 [
"name" => "Vicere Anna"
]
16 => array:1 [
"name" => "Beck Ekkehard"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2024-10-01 01:01:37"
"publicationUrl" => "https://doi.org/10.1016/j.jval.2024.06.011"
"publicationInfo" => array:3 [
"pages" => "1318-1327"
"volume" => "27"
"number" => "10"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Given the significance of vaccines for public health, there is an urgency to develop standardized and vaccine-specific methodologies and processes for use in the EU joint HTA framework. The proposed guiding principles could support the effective implementation of the EU Regulation on HTA for vaccines and have the potential to ensure consistent, transparent, and timely access to new vaccines in the EU."
"en" => "Given the significance of vaccines for public health, there is an urgency to develop standardized and vaccine-specific methodologies and processes for use in the EU joint HTA framework. The proposed guiding principles could support the effective implementation of the EU Regulation on HTA for vaccines and have the potential to ensure consistent, transparent, and timely access to new vaccines in the EU."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
121 => Essec\Faculty\Model\Contribution {#2508
#_index: "academ_contributions"
#_id: "15246"
#_source: array:18 [
"id" => "15246"
"slug" => "a-retrospective-observational-study-of-ibrutinib-in-chronic-lymphocytic-leukaemia-in-a-real-life-setting-in-france-using-the-national-claims-database-osiris"
"yearMonth" => "2024-08"
"year" => "2024"
"title" => "A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)"
"description" => "CHOQUET, S., MARCHAL, C., DEYGAS, F., DESLANDES, M., MACHER, N., PUYOU DE POUVOURVILLE, G. et LEVY, V. (2024). A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS). <i>Annals of Hematology</i>, 103(8), pp. 2969-2981."
"authors" => array:7 [
0 => array:3 [
"name" => "PUYOU DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Choquet Sylvain"
]
2 => array:1 [
"name" => "Marchal Clarisse"
]
3 => array:1 [
"name" => "Deygas Floriane"
]
4 => array:1 [
"name" => "Deslandes Marine"
]
5 => array:1 [
"name" => "Macher Nahid"
]
6 => array:1 [
"name" => "Levy Vincent"
]
]
"ouvrage" => ""
"keywords" => []
"updatedAt" => "2024-09-30 17:30:33"
"publicationUrl" => "https://doi.org/10.1007/s00277-024-05859-w"
"publicationInfo" => array:3 [
"pages" => "2969-2981"
"volume" => "103"
"number" => "8"
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => "Ibrutinib is a Bruton’s tyrosine kinase inhibitor indicated for the first-line treatment and relapse of chronic lymphocytic leukaemia (CLL), Waldenström’s macroglobulinemia (WM) and mantle cell lymphoma (MCL). This study aimed to describe the characteristics of CLL patients treated with ibrutinib and its effectiveness, safety, and treatment pattern in real life."
"en" => "Ibrutinib is a Bruton’s tyrosine kinase inhibitor indicated for the first-line treatment and relapse of chronic lymphocytic leukaemia (CLL), Waldenström’s macroglobulinemia (WM) and mantle cell lymphoma (MCL). This study aimed to describe the characteristics of CLL patients treated with ibrutinib and its effectiveness, safety, and treatment pattern in real life."
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2024-11-21T18:21:43.000Z"
]
+lang: "en"
+"_type": "_doc"
+"_score": 4.700139
+"parent": null
}
]
"avatar" => "https://faculty.essec.edu/wp-content/uploads/avatars/B00072308.jpg"
"contributionCounts" => 122
"personalLinks" => array:2 [
0 => "<a href="https://orcid.org/0000-0002-5941-6823" target="_blank">ORCID</a>"
1 => "<a href="https://scholar.google.com/citations?user=w_ysIu8AAAAJ" target="_blank">Google scholar</a>"
]
"docTitle" => "Gérard DE POUVOURVILLE"
"docSubtitle" => "Emeritus Professor"
"docDescription" => "Department: Economics<br>Campus de Cergy"
"docType" => "cv"
"docPreview" => "<img src="https://faculty.essec.edu/wp-content/uploads/avatars/B00072308.jpg"><span><span>Gérard DE POUVOURVILLE</span><span>B00072308</span></span>"
"academ_cv_info" => ""
]
#_index: "academ_cv"
+lang: "en"
+"_type": "_doc"
+"_score": 5.0369525
+"parent": null
}